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Five peptidylarginine deiminases (PADIs), regulating diverse aspects of 
human physiology, catalyse the post-translational modification citrullination in 
mammals. Deregulation of citrullination underlies the development of diverse 
pathologies and PADI4 is of particular medical interest in autoimmune 
diseases and in cancer. PADI activation is understood biochemically at the 
level of the crystal structure where allosteric calcium ion binding drives an 
extensive conformational change and the nucleophilic cysteine relocates 
approximately 5-10 Å. The critical open question for the field is how this 
activation can occur in cells. The calcium concentrations required to drive the 
conformational change in vitro are supraphysiological by two orders of 
magnitude and little is understood mechanistically about how cellular 
signalling events enable PADI enzyme activation. As such, the biological 
activation and therefore the deregulation of PADIs in diseases have 
remained enigmatic. This PhD set out to understand the physiological 
activation and regulation of the PADI4 enzyme.  
 
First, I identified a surprising origin of the mammalian PADI enzyme family as 
deriving from an ancient horizontal gene transfer event from cyanobacteria. A 
variety of maximum likelihood and Bayesian phylogenetic methods as well as 
non-parametric protein sequence analyses revealed that animal PADIs did 
not derive from the last universal common ancestor by conventional vertical 
descent and instead represent an ancient horizontal acquisition. The 
cyanobacterial PADI is shown to be active with a more stringent calcium 
dependency than the mammalian counterpart. This has particular interest as 
to how mechanisms for physiological activation of the human enzyme may 
have evolved and provides a rare example of HGT into the human lineage. 
 
Then, tractable conditions were established for comparing resting PADI4 to 
activated PADI4 across a variety of cell systems relevant to innate immunity 
and pluripotency. Emphasis was placed on identifying cellular stimuli that 




the levels of PADI4 protein may be stringently controlled and independent 
from the activating stimulus. In this model system, PADI4 was shown to be 
activated by canonical Wnt signalling – downstream of recombinant Wnt3a, 
short-term GSK3β inhibition and chemical Wnt agonism. PADI4 inhibition 
reduced Wnt-driven transcription in a reporter assay. A role for PADI4 in Wnt 
signalling would be important for roles in haematopoetic stem cells, in 
neutrophils, in the establishment of pluripotency and its overexpression in 
cancer. Future work will be required to confirm these exciting effects in a 
physiologically relevant context. 
  
Next, work was undertaken to screen a vast library of peptide molecules to 
find candidates that bind with high affinity to different PADI4 conformations, 
using the RaPID system, performed in collaboration with Dr Walport and Prof 
Suga. First, the active calcium-soaked conformation of PADI4 was targeted 
to find active site inhibitors. Second, the active site was covalently blocked to 
identify possible activating peptides. Biochemical and cell biological assays 
revealed different peptides that bound tightly to both conformations of PADI4 
(low nM binding affinity) and a biotinylated peptide was characterized for 
pulldown from lysates. Different peptides were shown both to inhibit and 
activate PADI4 with efficacy in vitro and in live cells. A toolkit of PADI4 
specific cyclic peptide reagents can therefore be taken forward to address 
new biological questions. The activator in particular represents the first such 
cyclic peptide epigenetic activator. 
 
Finally, conditions for the cellular activation of PADI4 were used in high-
resolution proteomic analysis of PADI4 after affinity pulldown. Conditions 
were optimized to pulldown PADI4 using the new biotinylated cyclic peptide 
reagent developed in Chapter 5 and a commercial antibody. An irreversible 
inhibitor was used to distinguish allosteric interactors from substrates. Mass 
spectrometry showed that a number of proteins with established calcium-
binding functions (EF-hand containing proteins), including calmodulin, were 
enriched for allosteric binding to the inactive conformation of PADI4. The 
vii 
 
interaction, which was enriched in the absence of calcium, was confirmed by 
reciprocal pulldown of calmodulin. In vitro experiments showed that 
recombinant calmodulin activates PADI4 at a reduced calcium concentration. 
Putative calmodulin binding sites were identified on PADI4 using 
bioinformatic analysis. These can be readily mutated by site-directed 
mutagenesis and PADI4 variants introduced into cells for future validation of 
the effect in cells. This work represents clear progress towards 







Most people are familiar with the idea of DNA as the genetic code for 
creating life. What is less well known, is the way in which this genetic 
information is converted into instructions for the cell. Triplets of DNA bases, 
called codons, code for just 20 amino acids, which are connected together in 
long strings to make proteins. After proteins have been made, however, they 
can be further modified in the cell in a controlled way. These are called post-
translational modifications and are a fundamental way for cells to send and 
receive signals and control activity. 
 
This study examines the role of the PADI enzymes, and in particular PADI4. 
PADI4 can be found in white blood cells and in stem cells. This enzyme is 
responsible for turning arginine (one of the coded amino acids) into citrulline 
(one of the modifications made to existing proteins in real time). What has 
been observed is that excessive citrullination is present in various disease 
contexts. In particular, the over-expression of PADI proteins (and therefore 
the over-production of citrullinated proteins) is implicated in many diseases 
including Rheumatoid Arthritis, Multiple Sclerosis, and some cancers. 
Several experiments have shown that PADIs can be activated using calcium 
in vitro, but this process requires far more calcium than is present in live 
cells. How the process is switched on and why it goes wrong in disease 
contexts is therefore poorly understood. 
 
This research explores the regulation of PADI4 from several angles and 
using diverse methodologies:  
 
Chapter 3 demonstrates that the gene, which codes for the PADI enzyme, 
originated in ancient bacteria and not in vertebrates as was previously 
thought. Instead of being inherited from parent to offspring over billions of 
years, the gene instead jumped from bacteria into early marine ancestors of 
animals (this explains its absence from the genome of many eukaryotes such 
as plants, yeast, or amoeba). By cloning the ancient gene and synthesizing 
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the protein in bacteria, I show that the cyanobacterial PADI is active, but with 
a more stringent calcium dependency than the mammalian enzyme. This has 
particularly interesting implications for how mechanisms for the activation of 
the human enzyme may have evolved. 
 
In Chapter 4, I set up conditions in a variety of cell systems so that PADI4 
can be activated– including in white blood cells, stem cells, and a cancer cell 
line. I showed that PADI4 was activated by a broader, biologically significant 
cell signaling pathway (called Wnt signalling) in one of these cell systems. 
 
Chapter 5 describes a collaboration I initiated with a former colleague to 
target PADI4 to be able to modify its activity with cyclic peptides. It uses 
novel screening techniques to identify new synthetic cyclic peptide molecules 
that can inhibit PADI4, extract it from cells, or activate it. These molecules 
will provide a toolkit of reagents that can help enable the precise role of 
PADI4 in biological settings to be studied. 
 
In Chapter 6, I use high-resolution mass spectrometry to try to find other 
proteins that bind with PADI4 in cells and which may differ between resting 
and activated PADI4. I generated a dataset of regulatory candidates that 
provide a platform for elucidating the physiological activation of PADI4 in 
cells. I then tested one of the most promising of these candidates showing 
that a calcium-binding protein called calmodulin interacts with PADI4 and 
activates the enzyme at lower calcium in vitro. This can be explored in more 
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Chapter 1: Introduction 
 
1.1 Epigenetic landscape 
C.H. Waddington’s picture of an epigenetic landscape is one of the most 
famous visual metaphors in biology1. A totipotent cell, drawn as a ball at the 
top of a hill, rolls down an increasingly restricted choice of grooves to a point 
of terminal differentiation, when it comes to rest at the end of the valley1. 
Waddington’s elegant definition of the field of epigenetics – the study of “the 
causal interactions between genes and their products which bring the 
phenotype into being” – has made way for a modern (and in some ways quite 
clumsy) definition that stresses heritability outside of sequence changes in 
Deoxyribonucleic acid (DNA) and removes the emphasis on a mechanistic 
understanding that might link genes to their products1-3. 
 
Two remarkable experiments have transformed our conceptual 
understanding of cell specification by defying gravity in Waddington’s 
metaphor. Taken together, they also reveal the importance of his original 
definition of epigenetics as a natural mode of progression in the field from 
genetics, as one that addresses the central question as to how a cell can 
exhibit such phenotypic diversity from the same genetic information. The first 
of these remarkable experiments was in 1958, when John Gurdon 
successfully cloned a frog4. The experiment, behind the cartoonish quality, 
answers a profound “epigenetic” question. In transferring the genetic content 
of a differentiated somatic cell (its nucleus) to an unfertilized egg and in so 
doing creating a viable frog, it showed that the differentiated cell’s DNA 
contains all the information required to produce any cell in the cloned frog- no 
theoretical barriers exist or loss of information occurs during the process of 
differentiation4. In 2006, a second classic experiment (Takahashi and 
Yamanaka) stretched the logic of the first to surprising and almost absurd 
simplicity5. On provision of just four proteins, somatic cells were 
reprogrammed into pluripotent stem cells, with the capacity to redifferentiate 




showed that the subsequent causal interactions of merely four gene products 
on a differentiated cell’s genes are sufficient to reprogram the cell 
completely. From this, it is perhaps not altogether surprising that somatic 
cells can be converted directly into another somatic cell state without 
returning to pluripotency: more recently four gene products (Brn2, Ascl1, 
Myt1l, Ngn2) convert T cells directly into functional neurons in just a few 
days6. 
 
Two further discoveries set the scene by placing the enzymes that form the 
study of this thesis, the tissue-restricted and stringently regulated peptidyl 
arginine deiminases (PADIs or PADs), at the two extremes of Waddington’s 
landscape. On the one hand, PADI4 is highly expressed in terminally 
differentiated granulocytes (marbles resting in the valley); its activity is then 
switched on in neutrophil extracellular trap formation (NET formation or 
NETosis), a cell death program used as an innate immune defence 
mechanism by neutrophils in response to certain infectious agents7,8. On the 
other hand, PADI4 is expressed and its activity switched on in the Yamanaka 
experiment, during the process of reprogramming somatic cells to induced 
pluripotent stem cells (marbles defying gravity and traversing back to the top 
of Waddington’s hill)9. 
 
1.2 From genetics to post translational modifications 
Efforts to put a number to the human gene products contained in the genome 
have been debated extensively; the number has gradually reduced even 
since the publication of the draft sequence of the human genome10. This 
number is beginning to settle on something close to 42000, with just under 
half of those being protein-coding genes11,12. Of course, further diversity and 
complexity is achieved in other ways than possessing more and more genes 
(Figure 1.1). This includes post-transcriptional mechanisms such as splicing 
where segments of genes can be aggregated combinatorially to produce 
alternative isoforms before translation (Figure 1.1). It also extends to post-
translational mechanisms, such as the huge variety of chemical modifications 
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of individual amino acids (post-translational modifications or PTMs) added to 
protein sequences after they have been translated, which thereby expand the 
genetic code (Figure 1.1). Many gene products code for proteins that 
catalyze the addition of PTMs to other proteins, but also catalyse PTMs to 
DNA, Ribonucleic acid (RNA) and gene regulatory proteins (such as histone 
tails or transcription factors) that can affect subsequent expression. PTMs 
provide a crucial “epigenetic” link (once again to use Waddington’s sense of 
the term) to explain the interactions between genes and their products in 
both directions.  
 
Figure 1.1: From genes to the complete proteome. Schematic depicting ways that 
diversity and complexity of the proteome can be increased by post-transcriptional and post-
translational mechanisms. 
    
1.3 PTMs and signalling 
The variety and ubiquity of PTMs across the proteome has emerged as 
improvements in mass spectrometry have simplified their detection. Most 
amino acid residues can be modified in multiple ways (dependent in part on 
the flexibility of their chemistry) and multiple PTMs are more abundant than 
coded amino acid residues13. In tandem, a huge number of enzymatic 
reactions have been shown to catalyse these modifications, which creates a 




proteins with amenable tryptic digestion fragments (classically histone 
proteins), PTMs have been relatively simpler to detect; the exquisite 
decoration of histone tails has been shown to provide an intriguing basis for 
gene regulation14-16. PTMs acting on the same amino acid can be 
competitive and antagonistic, neighbouring marks can occur with increased 
frequency or be mutually exclusively, and PTMs taken together therefore 
result in a huge regulatory framework15,16. 
 
As these chemical modifications can be introduced or removed dynamically 
on fully folded and active proteins, PTMs thereby provide an obvious 
conceptual mechanism for fine-tuned regulation and cellular control in real 
time13. PTMs, for example, regulate protein stability and rapid and controlled 
degradation, protein sub cellular localization (trafficking, nuclear/cytoplasm 
shuttling), control of binding interactions (recruitment or disruption of a 
interaction partner), control of enzyme activity (on/off, up/down), control of a 
protein substrate, and structural integrity (such as the construction of 
collagen fibrils or myelin development)13,17-22. It is therefore hardly surprising 
that much of the temporal and spatial information required for cell signalling 
is transmitted through PTMs. 
 
In terms of the biological significance of these effects, complicated and 
abstract environmental signals are commonly transmitted through PTM 
cascades. The end point may be the stability or activity of a genetic effector 
that has consequent influence on gene expression. Some classic examples 
in the literature are metabolic/energy sensing (e.g. the mTOR system which 
senses amino acid availability)23, low oxygen sensing (e.g. the Hypoxia 
Inducible Factor (HIF) system which is mediated through oxygen-dependent 
hydroxylations and the proteasome)24, nitric oxide gas signalling (the NOS 
system)25, heat-independent mechanisms to detect time (e.g. circadian 
rhythms mediated through phosphorylation feedback loops)26-28, mechanical 
cues and stresses (e.g. the YAP/TAZ signalling pathway)29, or spatially 
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resolved signals across and between different cells (e.g. the Wnt signalling 
pathway)30. 
 
1.3.1 PTMs and signal transduction: the Wnt example 
Of these, perhaps the most classic effect of PTMs is in orchestrating 
signalling cascades (best studied, but by no means exclusive to 
phosphorylation)31. One PTM increases (or decreases) the activity of enzyme 
A; this enzyme A then modifies a second enzyme B affecting its activity. This 
can continue in complicated cascades of enzymes which might for example 
carry signals from the outside of a cell to the nucleus, rapidly transmit or 
amplify signals, or allow interconnectivity between different signalling 
pathways. Another classic effect of PTMs is in regulating protein stability 
(best characterized, but by no means exclusive to ubiquitination)32,33. 
Individual proteins that are tagged with the ubiquitin mark (through Lys48-
linked chains) can be targeted for rapid and highly selective degradation by 
increased affinity to components of the proteasome32,33. The two systems 
(ubiquitination and phosphorylation) show widespread interconnectivity34. An 
illustrative example is the simplified picture of the mechanism of degradation 
of beta-catenin (β-catenin) in the Wnt signalling pathway30,35,36. The E3 
ubiquitin ligase β-TrCP1 can utilize the transcription factor β-catenin as a 
substrate for ubiquitination30,35,36. This is mediated by interacting with a short 
N-terminal motif on β-catenin if it has been multiply phosphorylated30,35,36. 
This short motif is phosphorylated by two different kinases, firstly by the 
priming kinase Casein kinase 1 (CK1) and secondly by Glycogen synthase 
kinase 3 (GSK3)30,35,36. GSK3 only uses the singly phosphorylated N-terminal 
motif as a substrate, catalyzing the second and third phosphorylations30,35,36. 
If left unphosphorylated, however, β-catenin is stabilized, translocates to the 
nucleus and drives a transcriptional programme30,35,36. The requirement for 
two kinases integrates a specific signal between the highly promiscuous and 
constitutively active GSK3 and a context dependent and more specific 
second kinase30,35,36. β-catenin is rapidly turned-over at resting state, but if a 




proteasome), then the transcriptional effects of β-catenin become switched 
on30,35,36. This is a typical cell-signalling paradigm (a signal is transmitted by 
temporarily pausing the continuous degradation of a transcription factor, in 
this case by disrupting a constitutive enzymatic activity). Other similar 
signalling paradigms have been observed throughout biology, such as the 
HIF system used in detecting hypoxia24. This discovery won the Nobel Prize 
in Physiology or Medicine in 2019 – the press announcement (7th October 
2019) was made in the week this thesis was submitted. 
 
1.4 Citrullination 
Citrullination is a PTM made to peptidyl arginine, where the side chain 
primary ketimine (=N-H) is replaced with a ketone (=O) functional group37. 
The replacement of the nitrogen with oxygen results in a small mass 
difference (0.98 Da) and small change in sterics, but reverts both the positive 
electrostatic charge of arginine to the overall neutral (and ∂- negative) charge 
of citrulline as well as two of arginine’s five hydrogen bond donor sites to 
acceptors (Figure 1.2)37.  
 
 
Figure 1.2: Comparison of the chemical structure of L-arginine with L-citrulline. 
Hydrogen bond donor sites are numbered and labelled in red with hydrogen bond acceptor 
sites in blue. 
 
The free amino acid L-citrulline was first isolated in 1914 from watermelon 
juice38, with precedent in nature in several enzymatic processes. Firstly, it is 
a product of deimination by free arginine deiminases (ADI) as part of arginine 
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catabolism and in arginine and proline metabolism (this biosynthetic pathway 
is distributed in some, but not all, bacteria)39. Secondly it is produced by 
ornithine transcarbamylase (OTC) as an intermediate product in the urea 
cycle, where it is subsequently converted back to arginine in two steps by 
argininosuccinate synthase (ASS) and argininosuccinate lyase (ASL)40,41. 
Thirdly citrulline is a byproduct of nitric oxide synthases in nitric oxide 
signalling42-44. Lastly it is generated by dimethylarginine 
dimethylaminohydrolase (DDAH), that removes dimethyl arginine from 
degraded methylated proteins; free dimethylarginine otherwise inhibits nitric 
oxide synthases in nitric oxide signalling45,46. These processes are 
summarized in Figures 1.3 and 1.4. 
 
Figure 1.3: Overview of arginine catabolic pathways in bacteria. The first few steps of 
six major arginine catabolic pathways that are found in bacteria are shown. Intermediates 
are labelled in black and the corresponding enzymes labelled in red italics above the single 
reaction arrows in black. Two black reaction arrows denote that several enzymatic steps 
lead to the eventual product of the pathway, which are abbreviated for clarity. The reactions 
catalysed by Arginine deiminase (ADI) and by Agmatine deiminase (AgD) enzymes are 






Figure 1.4: Overview of the urea cycle with a focus on citrulline. The urea cycle and 
related reactions are shown with reactions denoted by single black arrows. The 
corresponding enzymes are labelled in red italics beside each reaction. Symmetric dimethyl 
arginine (ADMA) and monomethyl arginine amino acids inhibit the activity of nitric oxide 
synthases, but are converted to citrulline by Dimethyl-arginine Dimethyl-aminohydrolase 
(DDAH). 
 
Citrulline was first found in a protein context as early as 1930 when the 
chemical structure of the free amino acid was also assigned47-49. Citrulline 
was subsequently identified by Rogers et al. in hair follicle protein 
hydrolysates where it was found to be highly abundant50,51 and in 1971, it 
was revealed to be a component of myelin by Moscarello and Wood52. In 
1977, the enzyme responsible for the citrulline content in hair follicles was 
partially purified and the calcium-dependent post translational enzymatic 
conversion of arginine to citrulline was first clearly demonstrated in vitro53. In 
1981, the citrullinating enzyme was fully purified from rats, further 
characterized, and named peptidyl arginine deiminase (PADI or PAD)54. 
Since then, several studies have revealed there to be 5 PADI paralogues in 
humans (named PADI1, PADI2, PADI3, PADI4 and PADI6 – PADI5 was 
shown to be the same as PADI4) and many roles for citrullination have been 
identified in different tissue contexts55. PADIs are reported to be distributed 
only in higher eukaryotes, and are widely distributed only in vertebrates; fish 
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possess a single PADI, with five paralogues in mammals55-57. This is 
discussed further in the short introduction to Chapter 3. 
 
The process of citrullination refers specifically to the post-translational 
conversion of arginine to citrulline in protein substrates (Figure 1.5). 
Predominantly, citrullination has been described as the catalytic activity of 
the PADIs, but has two other known precedents in the literature. In the first, 
the reaction is catalyzed by a modified free agmatine deiminase (agmatine is 
decarboxylated arginine) identified in the bacteria responsible for 
periodontitis Porphyrmonas gingivalis (referred to throughout as pPAD) 
(Figure 1.3)58. The second is catalyzed by a modified free arginine deiminase 
identified in Giardia lamblia (referred to throughout as gADI) where it has a 
role in its primitive immune system59 (Figure 1.3). These other enzymes 
(pPAD and gADI) show different substrate preferences to PADIs, are not 
calcium dependent, and possess very divergent protein sequences59-64. A 
“decitrullination” reaction, the reverse catalytic process of citrullination, has 
not been identified to date.  
 
Figure 1.5 Citrullination reaction catalyzed by the PADI enzymes. PADIs catalyze the 
conversion of peptidyl arginine residues into peptidyl citrulline using water with equimolar 
release of ammonia. Calcium ions are required for the formation of the active conformation 
of PADIs by allosteric binding to the enzyme, but do not take part directly in catalysis. 
 
All citrullinating enzymes (and several other enzymes) make use of the same 
pentein protein fold61,65-68 (Figure 1.6). This is highly divergent in terms of 
amino acid similarity among members, but the active site triad (Cys- His- 




containing enzymes catalyse hydroxylation, dihydroxylase and 
aminohydrolyse reactions and have a wide range of substrates. Although 
most members show a preference for free amino acids, PADIs, the extended 
Giardia lamblia gADI, and Porphyrmonas gingivalis pPAD show tolerance for 




Figure 1.6 The catalytic PAD_C domain possesses a pentein fold: A: Crystal structure 
of ribosome anti-association factor eIF6 (1G61, cyan) showing the pentein fold which 
comprises five αββαβ subdomains around a fivefold axis of pseudosymmetry. B: Crystal 
structure of human PADI4 (1WD9) shows the three domains PAD_N (cornflower blue), 
PAD_M (orange), PAD_C (forest green) in a view which rotates the structure to show the 
same orientation of the pentein fold contained in the catalytic PAD_C domain showing the 
same pentagonal fivefold pseudosymmetry and subdomain structure but with additional 
conserved inserted regions. Calcium ions are shown as magenta spheres. 
 
PADI enzymatic activity is stringently regulated70,71. Allosteric binding of up to 
six calcium ions structures the active site for catalysis (Figure 1.7, Figure 
4.1)70,71. This is discussed in more detail in the introduction to Chapter 4. The 
proposed mechanism for the PADIs makes use of a nucleophilic cysteine to 
form a tetrahedral S-alkylthiouronium adduct intermediate72-76. The 
intermediate collapses and ammonia is released. Subsequently, water, 
activated by the core His residue, then attacks as a nucleophile and 
regenerates the tetrahedral S-alkylthiouronium intermediate. This time, the 
core cysteine thiolate is eliminated to leave peptidyl citrulline. Interestingly 
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while PADI1-3 and PADI4 are thought to use a reverse protonation 
mechanism (with a narrow optimal pH window that can support a 
deprotonated core cysteine, and a protonated core histidine), PADI2 is 
instead proposed to use a substrate-assisted mechanism (where the 
positively charged guanidinium substrate improves the cysteine nucleophile 
by lowering its pKa). These conclusions are supported by various pH-
dependent inactivation, kinetic, mutagenesis, pH rate profile, solvent isotope 
effect, and solvent viscosity effect studies72-76.  
 
 
Figure 1.7: Structure of the PADI active site with and without allosteric calcium 
binding. The structure of PADIs in low calcium is called the apo-form, whereas the fully 
calcium coordinated enzyme conformation is called the holo-form. The crystal structure of 
the active conformation of PADI2 is shown in dark grey (4N2C) and the inactive 
conformation is shown in white (4N20). These two structures were superposed in Chimera 
using MatchMaker to align the structures with the Needleman-Wunsch algorithm according 
to the BLOSUM-62 matrix. The figure denotes the apo-form of PADI2 (light grey) 
superimposed on the holo-form of PADI2 (dark grey) showing the active site. The 
nucleophilic cysteine C645 is shown in blue which moves 9.89 Å into the active site in the 
active holo enzyme conformer. Conversely a “gatekeeper” arginine R347 (magenta) located 
within the active site in the apo (inactive) conformer leaves the active site in the active 
conformation to allow substrate binding. The other two residues in the catalytic triad (D473, 
red and H471, green) do not differ greatly in their position in the active site between inactive 






1.5 Properties of arginine 
As an amino acid residue, the intrinsic chemical properties of arginine make 
its modifications particularly biologically interesting. Arginine is protonated 
and positively charged at physiological pH (as such it is a poor nucleophile). 
It possesses five hydrogen bond donors that can be used to interact with 
polar groups. This is characterized by the formation of arginine salt bridges 
with phosphate groups (found for example in nucleic acids or 
phosphoproteins) which are twice as strong as those formed by lysine37. In 
addition, arginine has a long and flexible side chain, which aids interactions. 
It is therefore unsurprising that arginines are one of the key amino acid 
residues for mediating protein interactions to negatively charged nucleic 
acids and RNA and are over-represented at protein interfaces (unlike lysine, 
aspartate or glutamate)77-80. The abundance of arginine modifications in 
histones is also of considerable importance. More specialized consequences 
of modifications to arginine derive from specific contexts such as their 
abundance in nuclear localization signals81, in serine protease inhibitors82, or 
in liquid-liquid phase separation through interactions with tyrosine83. 
 
1.6 Specific cell biological consequences of citrullination 
Many direct effects of citrullination on proteins have been identified in line 
with the functions expected for modifications to arginine. This includes 
regulating protein and nucleic acid interactions9,84,85, altering sub-cellular 
localization86-88, modifying properties of protein structure9,89-91, and most 
recently in modulating liquid-liquid phase separations83,91. A handful of 
specific examples of more specialized modifications of arginine are 





Figure 1.8: Some specific cell biological consequences of citrullination. A schematic 
depicting some of the cell biological consequences of citrullination that are focused on in 
more detail below. 
 
1.6.1 Epigenetic regulation and crosstalk with arginine methylation 
PTMs made to arginine that have been discovered to date, in addition to 
citrullination, include three distinct methylation marks: monomethylation, 
asymmetric dimethylation and symmetric dimethylation, as well as less 
canonical modifications such as arginine phosphorylation, ADP-ribosylation, 
methylglyoxal adduct formation and recently C-5 hydroxylation92-96.  
 
The prevalence of arginine methylation appears to be comparable to that of 
phosphorylation/ubiquitination, but only nine PRMTs have been identified (as 
compared with hundreds of identified kinases/ubiquitin ligases and 
approximately 40 lysine methyltransferases)97,98. Possessing both forward 
and reverse reactions has elevated the importance of certain PTMs such as 
lysine acetylation and methylation in the literature as it is assuming this more 
clearly implies a dynamic role. As such, the first call to fame for citrullination 
was over the hypothesis that it might either act as an arginine demethylase 
(or at least antagonize arginine methylation) and might therefore be able to 
elevate arginine methylation to the same level. This hypothesis for 
citrullination was strengthened by the realization that methylated arginine 
residues overlap with citrullination sites: arginines 2, 17, and 26 in histone H3 
are substrates for methylation by CARM199-102 and arginine 3 in histone H4 is 
methylated by PRMT17,103-105. Indeed, citrullination is found to be 




crosstalk have been identified between these marks and the importance of 
antagonistic marks (such as citrullination) are of clear regulatory importance 
(for example Sharma et al. for Pol II)106. 
 
However, although the citrullination mark has been shown to be antagonistic 
to methylation107, PADIs do not appear to act directly on methylated arginine 
in physiological contexts (and in any case do not recover arginine) and show 
clear independent roles from merely acting in opposition to arginine 
methylation103,108. There is continued interest in the possibility of a true 
arginine demethylase. Although some candidate arginine demethylases 
show activity on peptides in vitro, biological significance has yet to be 
demonstrated109,110. Additionally, there is also capacity for nucleosome 
turnover to account for a dynamic quality to arginine methylation– in the 
absence of a decitrullinase or arginine demethylase dynamic methylation and 
citrullination states could still readily occur111. The caveat of course is that 
lysine methylation was also once thought to be irreversible and its dynamic 
nature rationalized similarly until the discovery of LSD1/KDM1A112-114. 
 
1.6.2 Cellular localisation  
GSK3β is an important cellular kinase with pools in various cellular 
compartments115. Complicated nuclear import mechanisms appear to 
regulate its cellular location along with possible mechanisms to retain a 
cytoplasmic pool115. An interesting study identified a classical monopartite 
type nuclear localization signal (NLS) in GSK3β where repeated basic (lysine 
and arginine) residues are located87. Accordingly, Δ9-GSK3β-HA was found 
to be at 40% lower levels than wild-type GSK3β-HA in the nucleus)87,116. 
Subsequently PADI4 was found to citrullinate the N-terminus of GSK3β 
directly (R3, R5) increasing its nuclear localization (R->K point mutants were 
no longer regulated)87. PADI4 depletion reduced nuclear localization of 
GSK3β; stable expression of PADI4 increased nuclear GSK3β, whereas 
catalytically inactive PADI4 showed no effect87. In a recent study, the protein 
complex mTORC1 was also found to regulate the nuclear localization of 
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GSK3β, presumably through a separate mechanism as it similarly affected 
the GSK3α isozyme that has a truncated N-terminus116. In cells grown in 
serum, GSK3β is increasingly retained in the cytoplasm, but in serum 
withdrawal conditions but the nuclear level of endogenous GSK3 
increased116. These observations have not been fully explained. 
 
In a different mechanism, citrullination affected the nuclear localization of the 
p65 subunit of nuclear factor κB (NF-κB p65) by increasing its interaction with 
a nuclear importin88. PADI4 was shown to interact with and citrullinate four 
arginines in the N-terminal RelA homology domain of NF-κB p65 in 
neutrophils88. This caused increased binding of importin a3 to p65 (with no 
effect observed to R->K point mutants of p65)88. This was correlated with 
increased nuclear import of p65, and in turn drove increased expression of 
inflammatory cytokines IL-1β and tumour necrosis factor alpha (TNFα)88. 
PADI4 was thereby shown to affect the transcriptional activity of nuclear 
factor κB (NF-κB) driven by lipopolysaccharides (LPS)88. In another example, 
citrullination of nucleophosmin (NPM1) at Arg197 by PADI4 was shown to 
shift its subcellular localization from the nucleoli to the nucleoplasm86. In a 
final example, citrullination of the bipartite nuclear localization signal of 
Inhibitor Of Growth Family Member 4 (ING4) did not affect its nuclear 
localization directly85,117. ING4 had been shown to induce acetylation of K382 
of p53, increasing p53 transcriptional activity and thereby driving p21 
expression, mediated through binding to p53 at the NLS region85,117. 
Citrullination of ING4’s NLS by PADI4 disrupted the interaction with p53, 
decreased the acetylation of p53 and interfered with downstream p21 
expression85,117. This also caused more rapid degradation of ING485,117. 
Although NLS type motifs make good candidates for direct effects of 
regulation by citrullination due to their arginine content, they do not follow a 
single well-established mechanism of action. In the instance of ING4, the 
bipartite NLS motifs appear to primarily make use of lysine residues, which 





1.6.3 Extracellular effects and inflammatory signals 
Various inflammatory signalling proteins are modulated by citrullination. Host 
defence peptides are an ancient part of mammalian innate immune systems: 
one such peptide, LL-37 in humans, binds to the negatively charged lipid 
domains of endotoxin, to LPS, to lipoteichoic acid (LTA) and polyI:C and also 
to cell free immunostimulatory DNA118,119. LL-37 acts to dampen the 
inflammatory response to these agents (such as the release of TNFα and 
nitric oxide by macrophages)118,119. The cationic nature caused by multiple 
arginine and also lysine residues within LL-37 aids the interaction with these 
negatively charged inflammatory agents118,119. LL-37 becomes citrullinated in 
conditions of sepsis and the citrullinated peptide binds very weakly to these 
agents, which abrogates the reduction in proinflammatory effect118,119. 
Inflammatory effects of citrullination have also been found to modulate the 
activity of chemokines including IL-8 (CXCL8), CXCL10, CXCL11, and 
CXCL12120,121. In these cases, by contrast to LL-37, citrullination acted to 
dampen signalling potency120,121. Citrullination of CXCL10 and 11 reduced 
chemoattraction and signaling capacity, without affecting receptor 
binding120,121. Similarly, citrullination of IL-8 reduced the induction of 
neutrophil extravasation and chemotaxis120,121. Given that 14% of natural 
leukocyte-derived IL-8 was found to be citrullinated and the efficiency of 
PADI catalysis in serum, rapid innate immune modulation effects may be 
found in other NETotic conditions (cells undergoing cell death via NET 
formation) and in various immune contexts120,121. Finally, a recent proteomics 
screen of the rheumatoid arthritis (RA) associated citrullinome identified 
several citrullinated serine protease inhibitors (P1-Arg-containing serpins) 
from RA serum, synovial fluid, and synovial tissue, confirming earlier work in 
vitro and in RA patients122,123. The serpin-protease complex involves an 
interaction between a protease that attempts to catalyse proteolysis of the 
inhibitory serpin122,123. This takes place on a reactive peptide bond between 
arginine and serine contained in the serpin amino acid sequence, which 
becomes bound with high affinity and irreversibly inhibits the protease 
stoichiometrically122,123. Citrullination of this arginine, found in antiplasmin, 
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antithrombin, t-PAI, and C1 inhibitor, was shown to disrupt interaction with 
the corresponding proteases and prevented inhibition122,124. Extracellular 
serpins (which comprise about two-thirds of all human serpins) have been 
shown to modulate proteolytic cascades found in blood clotting 
(antithrombin), in inflammatory and immune responses (antitrypsin, 
antichymotrypsin, and C1-inhibitor) and in tissue remodelling (PAI-1)124-126. 
Given the inhibitory activity of serpins on neutrophil elastase, granzyme B, 
cathepsins and others, further work to elucidate the crosstalk between 
neutrophils, NETosis and the activation of PADIs in these extracellular 
immune networks would be very interesting. These may also be relevant to 
the effect of PADI enzymes in cancer contexts127,128. 
 
1.6.4 Liquid-liquid phase separation 
Another interesting effect that can be modulated by post-translational 
modifications to arginine are liquid-liquid phase separation type 
interactions83. Cells have different compartments for isolating complex 
biochemical reactions in space, including well known membrane bound 
compartments such as the mitochondrion or lysosome. Other compartments, 
however, are not membrane bound such as nucleoli, centrosomes, Cajal 
bodies, stress granules and P granules. In these cases, it has begun to 
emerge that these unbound compartments can arise from the phase 
separation of complex biological mixtures into liquid droplets129,130. If the 
components of the compartment have a higher affinity with each other than 
the surrounding mixture they can demix and form phase separated liquid 
droplets131. For the fused in sarcoma (FUS) RNA binding protein, comprised 
of a low complexity disorded domain (LC domain) attached to a structured C-
terminal domain comprised of multiple RGG motif repeats, its solution can 
reversibly revert between a dispersed state into liquid droplet and hydrogel 
states83. These proteins have a role in producing ribonuclear protein 
granules. Recent experiments have revealed that FUS phase separation can 
be modulated by the arginine methylation state of RGG motifs in the 




methylated state after conversion by PRMTs, interact with tyrosines in the N-
terminal domain via cation pi interactions83. Unmethylated arginine residues 
have the strongest interaction, methylated arginines somewhat weaker, but 
citrullinated residues abolish this interaction83. Adding a small amount of 
unmethylated arginine FUS to a predominantly methylated arginine FUS pool 
drives rapid phase separation83. This is particularly interesting for 
citrullination, as RGG motifs have separately been identified as a common 
PADI substrate motif (comprising approximately 1/5 of PADI substrates)91. 
Citrullination of various RGG motif proteins, including FUS, were shown to 
abolish their protein aggregation91, likely both by competitively eliminating 
arginine methylation but also through eliminating cation-π interactions with 
tyrosine residues83. The methylated RGG motif is also well known for 
mediating an interaction with the Tudor domain containing protein SMN (an 
arginine methylation reader protein)132. This interaction was shown to be 
suppressed by PADI4 citrullination in the same context91. Precise mixtures of 
modified and unmodified FUS proteins provide a possible physiological 
mechanism to interconvert between phase separation states. This is 
especially interesting in light of the many ribonuclear proteins containing 
RGG motifs and low complexity domains and also in light of roles for phase 
separation emerging in other nuclear process such as in interphase 
chromosome structure133 or heterochromatin domain 
compartmentalization134,135. It is particularly interesting in light of the large 
number of ribonuclear proteins, RNA binding proteins and RGG motif 
containing proteins that are substrates for citrullination (personal 
communication, unpublished tandem mass spectrometry (MS/MS) data from 
Christophorou et al.). As such, other roles for mechanisms of PTM regulation 
in this area are likely to emerge. 
 
Along the same lines, a recently identified citrullination of Arg1810 in the C-
terminal domain of RNA polymerase II (RNAP2), also a target of arginine 
methylation may also be connected106. The C-terminal domain (CTD) of 
RNAP2 is dynamically modified, which recruits different protein complexes 
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that modulate transcription136,137. Loss of citrullination of RNAP2 appeared to 
result in the accrual of RNAP2 close to transcriptional start sites, whereas 
citrullinated RNAP2 recruits the positive transcription elongation factor P-
TEFb that releases paused RNAP2 and promotes gene expression106. Given 
that RNA binding proteins such as FUS can sequester the CTD of RNAP2 in 
phase separated droplets138,139, this may offer a possible extension to the 
relevance of modified arginine in liquid-liquid phase separation and 
transcription– balanced between methylated arginine on the one hand and 
citrullinated arginine on the other140-142. 
 
1.7 Peptidyl arginine deiminases (PADIs) 
There are five PADI paralogues in mammals (PADI1-4 and PADI6), which 
are carefully regulated, both transcriptionally and enzymatically (Figure 1.7 
and 1.9)69,143. The genomic context of the five mammalian paralogous genes 
is conserved across species. PADI1, PADI3, PADI4, and PADI6 are located 
in close proximity and transcribed in one direction, whereas PADI2 is located 
on the reverse strand and at a greater distance to the cluster of paralogues 
(Figure 1.10)143. PADI paralogues show restricted expression to specific 
tissues and cell types and also show stringent restriction on enzymatic 




Figure 1.9: Genomic region containing the five PADI genes. A: The genomic region in 
humans containing the five paralogous PADI genes is shown as a track using Ensembl with 
PADI4 highlighted in green. PADI2 is located further from the other 4 paralogues in the 





Figure 1.10: PADI4 and known post-translational modifications: A: Crystal structure of 
calcium soaked human PADI4 (1WD9) shows the three domains PAD_N (cornflower blue), 
PAD_M (orange), PAD_C (forest green), with calcium ions shown as magenta spheres and 
residues in the catalytic triad shown in yellow. B: Domain cartoon of PADI4 shows the 
currently annotated phosphorylation sites in PhosphoSite detected in either high-throughput 
or low-throughput proteomic experiments in the literature. 
 
1.7.1 Physiological roles for PADI paralogues 
In terms of normal biological functions, PADIs are relatively poorly 
characterized, especially compared to their roles in disease contexts69. 
PADI1 and PADI3 are known for a handful of roles in hair and epidermal 
contexts69. Terminally differentiated epithelial cells undergo controlled cell 
death with broad cellular proteolysis: citrullination of filaggrin results in the 
dissociation from keratin filaments which aids hydrolysis147. By contrast, 
citrullination of trichohyalin increases its protein solubility, aiding 
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transglutaminase mediated cross-linking and strengthens the hair 
follicle148,149. Citrullination of vimentin, alongside phosphorylation, is 
proposed to play a role in the regulated polymerization and depolymerisation 
of vimentin proteins150-153. The role for PADI3 in keratinocytes is supported 
by genome wide association studies (GWAS) that find SNPs in PADI3 that 
are significantly associated with uncombable hair syndrome, hair shape, and 
hair colour154-156.  
 
PADI6 has the clearest biological phenotype, but is enigmatic as its catalytic 
activity has yet to be demonstrated. PADI6 is essential for early cleavage 
divisions: PADI6 knockout mice are infertile, with fertilized oocytes unable to 
progress past two cell division and form oocyte cytoplasmic lattices157-159. 
This phenotype has recently been confirmed in mutations in humans as 
well160-162. However, PADI6 shows some divergence in the conservation of 
the active site and calcium binding residues from the other paralogues 
(Figure 1.11). As the catalytic cysteine is replaced by alanine and two of the 
six binding residues in Ca1 and Ca2 are conserved differently, this has been 
widely taken as evidence that PADI6 cannot support enzymatic activity. 
However, the cysteine to alanine residue is sandwiched between two other 
highly conserved cysteines, which could provide alternative catalytic 
nucleophiles and it may be that PADI6 is merely regulated differently from 
the other paralogues enabling activity in vivo (Figure 1.11). Interestingly, 
PADI6 was found to undergo cell-cycle dependent phosphorylation, which 
allowed subsequent interaction with the 14-3-3 protein YWHAB163. This 
YWHAB interaction was confirmed structurally164. If catalytic activity by 
PADI6 can be clearly demonstrated, it is an intriguing possibility that a 
phosphorylation dependent interaction might provide a mechanism for PADI6 
regulation. 
 
PADI2 and PADI4 are the best-studied paralogues, but individual knockout 
mice are superficially healthy. Recent literature points to a role for PADI2 in 




known to extensively modify MBP in normal myelin, but have been shown to 
destabilize myelin biochemically and show up regulation in Multiple Sclerosis 
lesions89,166-168. It is not fully clear what roles PADI2 or PADI4 play in the 
normal functioning of myelin development. The other biological role for 
PADI2 and PADI4 is in innate immune defence. As early as the 1880-90s, 
Elie Metchnikoff discovered the role of neutrophils in undergoing 
phagocytosis of infectious agents169; it is particularly remarkable therefore 
that in 2004 a completely new mechanism of neutrophil response to infection 
was discovered: neutrophil extracellular trap (NET) formation170. Although 
PADI4 was assigned a role in neutrophils as having an essential role in NET 
formation171,172, further characterization and more precise means to detect 
NET formation have meant the precise roles of PADI4 and PADI2 are less 
clear and conflicting data exist from mouse models173. Different stimuli (some 
involving citrullination, some not) can induce NET-like structures and different 
types of NET-like structure formation are induced by different stimuli174,175; it 
is not fully clear which forms are physiological or relevant as a response to 
infection. Further work will also be required to tease out the precise role of 
citrullination. This is both because highly pleiotropic stimuli are commonly 
used as NET agonists174-177 and no tools or stimuli to precisely activate PADI 
enzymes exist. PADI4 does appear to be responsible for the citrullination 
observed in neutrophils173,177, but conclusions beyond that should be more 
tentative based on the present data. 
 
The final role for PADIs has emerged in development. Pan-PADI inhibition 
halts embryonic development at the 4-cell stage, and PADI4 was found to 
play a role in preimplantation development by use of RNA interference9,157. 
PADI4 was also shown to be induced and inference of its enzymatic activity 
switched on from citrullination of histone 3 during reprogramming of mouse 
neural stem cells to induced pluripotent stem cells (iPS cells)5,9,178. There is 
an additional described role for PADI1 in the uterus/early embryo 
development179. Mechanistically, PADI4 affects chromatin decondensation as 
was shown in neutrophils by histone citrullination8,180. This effect was then 
23 
 
also found to be relevant in the context of reprogramming, where direct 
citrullination of linker histone H1 displaced it from chromatin in vitro9. 
Whether this is a precise enough mechanism to describe the fine-tuning of 
reprogramming efficiency is much less clear. This is especially true since the 
scale of decondensation in neutrophils is so dramatic that chromatin 
architecture is completely dismantled181,182. In reprogramming cells, however, 
the resultant iPS cells can redifferentiate down any lineage. Mechanisms for 
the regulation and activation of PADIs, especially if their activation has such 
a dramatic cellular effect, remain obscure. 
 
Figure 1.11: Multiple sequence alignment of all human PADIs. Human PADI1, PADI2, 
PADI3, PADI4 and PADI6 sequences were obtained from UniProtKB, aligned using Mafft G-
ins-I and figure prepared using BoxShade with 70% consensus for greyscale shading. The 
catalytic triad residues are coloured in red, other active site residues coloured in yellowy 
orange, and residues used in PADI2 for calcium binding coloured in magenta, noting that 
calcium site 6 of PADI2 is not conserved for example in PADI4. PADI protein domains are 
shaded with PAD_N in cornflower blue, PAD_M in orange, and PAD_C in forest green. 
 
1.8 PADIs and disease 
As this chapter has established, although many specific examples have 
accumulated in the literature of the effects of citrullination in regulating cell 
biological events, clear physiological roles for PADIs are less well 




connections of aberrant citrullination to disease, predominantly resulting from 
too much citrullination55,183. Intriguingly, these connections have been to 
diverse autoimmune diseases, about which little is known in terms of cause 
or mechanistic biological understanding. In addition, roles for PADIs have 
been found in a variety of cancer contexts. Particularly strong connections 
have been found to multiple sclerosis (MS) and rheumatoid arthritis (RA). 
Other connections to a diverse range of other autoimmune and some non-
autoimmune disease etiologies have also been discovered, including 
psoriasis184,185, systemic lupus erythematosus186-188, type I (autoimmune) 
diabetes189-191 and Epstein barr virus; as well as in non-autoimmune contexts 
such as glaucoma192, deep vein thrombosis193, sepsis194,195, allergy196, prion 
diseases197, Alzheimer’s198 and hypoxic injury55,199,200.  
 
The double knockout of PADI2 and PADI4 has not been produced, but single 
knockouts of PADI2 and PADI4 are generally viable and fertile55. Limited 
penetrance of preweaning lethality has been reported in some colonies. 
Knockout studies in mice have produced confusing and conflicting results in 
disease models. Where this has been rigorously tested for, compensation 
effects with other paralogues have been observed. In the overexpression 
model of PADI2, endogenous expression of PADI4 was found to be elevated 
at both the RNA and protein level201. Results in general point to the likelihood 
of overlapping functionality and auto-regulatory effects between different 
paralogues171-173,201-206, but the absence of a double knockout means no firm 
conclusions can be drawn on compensation effects. Consistent with this, 
many studies using PADI inhibitors have shown potentially therapeutic 
effects of pan-PADI inhibition in disease models. As enzymes, PADIs 
generally are thought to pose a promising therapeutic target183 and a 
possible avenue to a better understanding of disease mechanisms. The 






1.8.1 PADIs and Multiple Sclerosis 
Citrullination has emerged as a hallmark of multiple sclerosis (MS). MS is an 
autoimmune demyelinating disease causing lesions that affect white matter 
in the brain. Myelin basic protein (MBP) is a multi arginine containing cationic 
protein that forms the main protein component of myelin and is the second 
highest abundance protein in the central nervous system. Myelin is 
considered to be one of the key distinguishing features of jawed verterbrates; 
protein components of myelin surround lipids, which together form insulation 
around axons. MBP was found to be citrullinated at multiple residues in 
children, but the extent of citrullinated MBP decreases in postnatal 
development (from ~45% down to ~20% in healthy adults as a proportion of 
arginines that are found to be converted to citrulline)89,166. Interestingly MBP 
citrullination was also found to be elevated in multiple sclerosis (to the same 
levels as in early development ~45%) as compared to healthy control adult 
tissue (~18%), and are dramatically elevated in an acute fulminating form of 
MS, the Marburg variant (~80-90%)89,166. Various studies showed that 
citrullinated MBP exhibits an increased rate of proteolysis and disrupted 
protein-lipid bilayer interactions which result in destabilization of the myelin 
sheath207. This has been hypothesized to expose the immune system to the 
MBP fragments that are found to be auto-antigens in the disease, promoting 
the autoimmune aetiology. It is interesting that an increase of citrullination in 
the normal appearing white matter (NAWH) around lesions can be detected 
in MS patients over white matter taken from controls. In white matter, myelin 
protein components GFAP, MBP and MOG are all substrates for 
citrullination55.  
 
Provision of an immunodominant epitope of MBP (“immunization of animals 
with spinal cord homogenates, individual myelin proteins, or by adoptive 
transfer of myelin-specific T cells”) drives a mouse model of MS called 
experimental autoimmune encephalomyelitis (EAE)203. The research on 
citrullination and MS was somewhat confounded when a paper reporting a 




and could also develop EAE203. Subsequent studies established from the 
same knockout PADI2 mice taken from the same colony205, showed that 
MBP citrullination could in fact still be detected in these mice in contrast to 
the original report and cast doubts on those original conclusions204,205. This 
revised understanding is consistent with transgenic mice overexpressing 
PADI2 that show a myelination phenotype and a recent PADI2 knockout 
model that showed PADI2 is required for proper oligodendrocyte 
myelination208. Paralogue compensation has been suggested as a possible 
reason for these discrepancies208, for which PADI4 is the likely candidate, but 
no conclusions can be made on the evidence to date204. As PADI4 is also 
found to be elevated in the NAWH of MS patients and endogenous PADI4 
expression was found to go up when PADI2 was overexpressed, the 
expression of different paralogues may be co-dependent and intricately 
regulated. In a different model, PADI2 overexpression was sufficient to cause 
an EAE-like disease, indicating a causatory role201.  
 
Additional support is provided by four different mouse models of MS, two 
EAE-like and two other models, that were shown to be alleviated by PADI 
inhibition (using 2CA, a pan-PADI inhibitor)206,209,210. A further structurally 
unrelated non-covalent inhibitor (with increased potency for PADI2, but with 
inhibitory activity on PADI1 and PADI4) also showed efficacy in the EAE 
model211. Most recently a fifth and new MS model, cuprizone autoimmune 
encephalitis (CAE), was developed where biochemical perturbation of MBP 
precedes an autoimmune inflammatory aspect of the disease, that drives a 
potent EAE-like disease in the absence of an exogenous antigen or 
antibodies167. Cuprizone, a copper chelator known to cause reversible 
demyelination (and used in remyelinating models of multiple sclerosis), was 
used briefly to perturb myelin structure, but without causing demyelination167. 
An immune stimulus was then used, but without the inclusion of exogenous 
myelin peptides (that are required in EAE models), to observe whether 
endogenous biochemically disrupted myelin might substitute for the 
exogenous peptides and drive a similar secondary inflammatory 
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demyelination167. The immune stimulus had no effect on untreated myelin, 
but drove a secondary inflammatory demyelination disease phenotype after 
cuprizone pre-treatment (CAE disease phenotype)167. Importantly, PADI 
inhibition (pan-PADI inhibition with BB-Cl-amidine and also with KP-302211, a 
structurally unrelated inhibitor with 2-fold increased potency to PADI2) 
blocked the CAE phenotype, even when only administered during the initial 
cuprizone treatment167. These data point to a possible model of MS which 
posits that disrupted myelin and oligodendrocyte death drives a second 
inflammatory demyelinating part of disease167,212. It also shows the myelin 
perturbation that drove the subsequent inflammatory demyelination was 
dependent on PADI activity, confirming the earlier data showing the potential 
importance of PADI activity in disease aetiology167. 
 
Three lines of evidence are of particular importance: 1) increases in PADI 
expression and activity in normal appearing white matter from multiple 
sclerosis patients213, 2) that multiple structurally unrelated PADI inhibitors are 
efficacious in models of EAE206,209-211, especially in the most recent CAE 
model167, and 3) the causative role for driving an EAE-type disease in PADI2 
overexpressing mice201, which show a concomitant increase in PADI4 
expression. This suggests a direct causative role for PADI enzymes, and in 
particular for both PADI2 and PADI4, in multiple sclerosis. The hypothesis 
that citrullinated myelin precedes a secondary inflammatory demyelination is 
compelling, especially in light of the failure of direct immunomodulatory 
therapeutics, sometimes called the “inside out” view of MS. Even if 
remyelination is made easier, a secondary autoimmune attack will reverse 
this repair and regenerate symptoms. 
 
Further work is required to determine precisely how citrullinated myelin 
components may be immunogenic and how PADIs impact on the human 
disease. PADI inhibitors, with a possible requirement for dual PADI2 and 




intervention. Recent roles for PADI2 in oligodendrocytes will also need to be 
considered carefully with respect to therapeutic inhibition165,208. 
 
1.8.2 PADIs and Rheumatoid Arthritis 
Citrullination also relates strongly to RA, in which immune cells attack cells 
that line the joints, with a long disease progression. PADI inhibition has been 
promising in disease models of RA and points potentially towards 
mechanism. Cl-amidine and PADI4 knockout reduced disease severity in the 
type II collagen induced and GPI induced arthritis models202,214-216, but not in 
the K/BxN or collagen antibody-induced arthritis models214,217. The efficacy of 
PADI inhibition or knockout in the first two models is consistent with a role in 
autoimmune priming in which tolerance is broken as opposed to a role in the 
aspect of immune recruitment and joint destruction. Treatment with 
antibodies, rather than the antigen, bypasses the aspect of breaking of 
tolerance in terms of disease aetiology. Much of what is missing to resolve 
these observations lies in our incomplete understanding of how PADI4 
protein becomes activated and how PADI4 plays a precise role in neutrophil 
biology. 
 
Several connections between RA and citrullination have also been 
discovered. The first derives from genetic association studies between SNPs 
in PADI4 and RA disease; an initial study found SNPs in PADI4 to be 
significantly enriched in a Japanese RA cohort218. Although this could not be 
reproduced in studies using UK, French and Spanish RA cohorts219-221, it was 
subsequently confirmed by multiple other cohorts222-224 and in various meta-
analyses including to the locus 1p36 which contains the PADIs225-227. The 
inconsistencies between studies were subsequently suggested to be due to 
insufficient power to detect the genetic association225-227. 
 
The second connection to citrullination has had widespread implications for 
diagnosis, if not yet fully for mechanism. Although little is understood about 
the cause of RA, one of the main diagnostic features is the presence of 
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specific autoantibodies in patient serum. Classically, rheumatoid factor was 
used to identify RA, but it is also present in many other diseases associated 
with chronic inflammation, and in up to 5-10% of healthy people in addition. 
Detecting the presence of anti-citrullinated protein antibodies (ACPAs) has 
emerged as a powerful and more specific diagnostic test for RA; RA is now 
typically classified between ACPA positive and negative forms in the clinic. 
Approximately 75% of patient cases present as ACPA positive228,229. Notably, 
citrullination appears not to be a bystander or secondary effect to the 
inflammation as ACPAs are highly specific for RA, appear very early (up to 9 
years before the presentation of symptoms), and are associated with the 
most erosive cases of RA228,229. Gene environment interactions in RA also 
associate with citrullination such as smoking and the HLA genotype. The first 
ACPA epitope was found to be citrullinated fibrinogen, but not unmodified 
fibrinogen. Various anti-citrullinated protein epitopes have since been 
discovered. 
  
The third connection derives from the role of PADI4 in neutrophils and NET 
formation. What is known conclusively is that neutrophils and activated 
neutrophils play an essential role in both the initiation and progression of 
RA230. The elucidation, firstly of the precise role for PADI4 in NET formation 
will be important to establish the connection strongly between citrullination 
and RA. Secondly it remains to be convincingly demonstrated that the role of 
PADI4 in NET formation is the same as that responsible for the connection of 
PADIs to RA173,177. The suggestion that cross-reactive antibodies appearing 
in the synovial fluid and found in RA increase the calcium sensitivity of 
PADI4231 provides a mechanism in principle for how the two aspects could 
progressively exacerbate disease aetiology, but unambiguously establishing 
how these two aspects relate will be crucial moving forward. 
 
The association of the related homocitrulline (carbamylated lysine) with RA 
provides a final interesting additional suggestion that the biochemistry of 




the breaking of tolerance232-235. Lysine carbamylation, which can be mediated 
non-enzymatically or by the byproduct of myeloperoxidase (MPO) is a post-
translational modification that produces homocitrulline (chemically identical to 
citrulline, but with one additional carbon atom in the side chain)232-235. MPO 
converts thiocyanate to cyanate, which can enzymatically carbamylate lysine 
such as when MPO is released by activated neutrophils232-235. Alternatively, 
urea in the body is in equilibrium with cyanate, so if urea concentrations are 
high then non-enzymatic carbamylation of lysine residues can occur232-235. 
What is remarkable is that 8.75% of RA patients (comprising approximately a 
third of ACPA negative patients) present with autoantibodies to anti-
carbamylated proteins188,232-235. That an enzymatically unrelated process 
gives rise to the same biochemical moiety with similar autoimmune 
consequences is suggestive that something about the biochemistry of 
citrullinated residues might be mechanistic for the process of breaking 
tolerance in RA. That citrullination has emerged as a hallmark for such a 
variety of autoimmune conditions would be indicative of this. 
 
1.8.3 PADIs and cancer 
PADIs have been found to play roles in cancer127,128. This has been primarily 
observed due to overexpression of PADIs in tumour contexts including breast 
cancer236, prostate cancer}237, colorectal cancer238,239, leukaemia240,241, and 
in late stage adenoma/carcinoma (such as esophageal squamous cell 
adenoma)242,243. Roles have been found firstly for their role as an epigenetic 
modifier in regulating gene expression and in creating a permissive 
decondensed chromatin environment mediated by histone citrullination. 
Secondly, roles have been found in promoting cancerous transformation both 
through effects of citrullination on oncogenes and tumour suppressors244, but 
also in hormone dependent cancer activation (e.g. breast and prostate)236,237. 
Thirdly roles have been found for their regulation of inflammation and cell 
signalling in a cancer specific context. PADI inhibitors have shown initial 
promise in breast cancer and are toxic to various cancer cell lines. A 
particularly interesting example with therapeutic potential has connected the 
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roles of PADIs in autoimmunity to those in cancer contexts123. It was 
recognized that certain mutated antigens can be recognized by tumor 
reactive T cells245,246 and that citrullinated antigens pertain to cancer 
contexts247-249. Presentation of citrullinated peptides on major 
histocompatibility complex class II (MHC class II) molecules in tumour cells 
could therefore provide a target for a CD4+ T cell mediated 
immunotherapeutic approach directed specifically against tumour cells247-250. 
This has been recently demonstrated for citrullinated enolase250. 
 
One of the most interesting connections to cancer possibly relates to the role 
of PADI4 in stem cells9,241,251. Analyzing normal haematopoietic stem cells 
(HSCs) and leukaemia progenitor cells revealed a signature of genes that 
were upregulated in both cell types and included PADI4252. Genes that 
regulate both self-renewal and oncogenesis are particularly interesting from 
the perspective of targeting cancer stem cells. This also would appear to be 
a particularly interesting area for future research in looking at any 
connections or mechanisms in common between the role of PADI4 in self-
renewal or in induced pluripotent stem cells and the high expression of 
PADI4 that is seen in normal HSCs. 
 
1.9 Targeting PADIs 
Given the connections to disease and the tractability of PADIs as enzymes 
for small molecule perturbation, efforts have been made to target the 
PADIs76,183,253,254. The first PADI inhibitor to be described was paclitaxel, 
which independently from its role in microtubule stabilization, was found to 
weakly inhibit PADI2255. Other weak reversible PADI inhibitors have been 
discovered including streptomycin, chlortetracycline and minocycline256. The 
first major breakthrough in targeting PADIs was Cl-amidine, which was based 
on the success of irreversible inhibitors in targeting cysteine proteases257-259. 
Short synthetic peptides (benzoyl l-arginine ethylester and benzoyl l-arginine 
amide), which have been used in mechanistic studies of PADIs as efficient 




haloacetamidine warhead260,261. The resultant molecule reacts covalently 
with the PADI active site cysteine257-259. This led to the generation of F-
amidine, and then Cl-amidine, which was more effective260,261, and have 
been widely used. More recently a modified more hydrophobic and cell 
permeable analogue of Cl-amidine, called BB-Cl-amidine, improved the half 
maximal inhibitory concentration (IC50) in cells262,263. Not all PADIs are 
targeted as efficiently by Cl-amidine, but since such high concentrations (200 
µM) are used to compensate for its poor cell permeability, it is generally 
considered to be a pan-PADI inhibitor. Some progress has also been made 
in generating reversible inhibitors. The first showed selectivity for PADI4, 
targeting a loop in the calcium-unbound apo-structure264. A second reversible 
inhibitor with some selectivity for PADI2 (but which still inhibits PADI1 and 
PADI4) has also been described211. This will be addressed further in the 
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Chapter 2: Materials and Methods 
 
2.1 Biochemical methods 
2.1.1 Bacterial transformations 
Chemically competent DH5α Escherichia coli (E. coli) (sub-cloning efficiency, 
Invitrogen) were used for production of DNA and BL21 DE3 cells (New 
England BioLabs) for the production of recombinant proteins. Competent E. 
coli were thawed on ice for 10 min from -80˚C and pipetted into 50 µL 
aliquots in pre cooled sterile Eppendorf tubes. An appropriate amount of 
plasmid (1 pg–100 ng) was added to each tube, which was flicked 4–5 times 
to mix and incubated on ice for 30 min. Bacteria were heat shocked at 42°C 
for 45 sec, placed on ice for 2 min, and 450 µl room temperature SOC media 
(MRC Human Genetics Unit (HGU) Technical Services) was added for 
outgrowth at 37˚C with shaking for 1 h. Cells were mixed by inverting and two 
different amounts (50 µL, 450 µL) were spread onto L-agar plates 
supplemented with the appropriate antibiotic (final concentrations of 
ampicillin at 100 µg/mL; kanamycin at 50 µg/mL; chloramphenicol at 13 
µg/mL; L-agar plates coated with the appropriate antibiotic were prepared by 
MRC HGU technical services). Plates were inverted and incubated at 37°C 
overnight to allow for colony growth. 
 
2.1.2 Starter cultures and plasmid preparation 
Single colonies were picked in the morning using a sterile toothpick and 
inoculated into 3 mL Luria-Bertani (LB) broth (MRC HGU Technical Services) 
in Falcon Round-Bottom SnapCap tubes supplemented with the appropriate 
concentration of antibiotic. These were grown at 37˚C with shaking at 300 
rpm until the afternoon and 500 µL used to inoculate 50 mL of LB media 
cultures, which were grown overnight at 37˚C with shaking at 300 rpm in a 
New Brunswick Scientific G25 environmental shaker. The next day pellets 
were harvested at 4500 rpm for 20 min. Qiagen Maxiprep kit was used to 




DNA was eluted into TE buffer, pH 8.0 or sterile MilliQ water (buffers 
prepared by MRC HGU Technical Services). 
 
2.1.3 Obtaining DNA sequences 
Sequences for the putative peptidyl arginine deiminase from Cyanothece sp. 
8801 and Porphyrmonas gingivalis were obtained from National Center for 
Biotechnology Information (NCBI) databases. Sequences were designed to 
be flanked by EcoRI (at the 5’ end) and XhoI (at the 3’ end) restriction sites 
and were synthesized by ThermoFisher Scientific GeneArt. Vectors for 
PADI2beta, PADI2 and PADI3 were a generous gift from Dr Ana Mendanha 
Falcao and Prof Castelo Branco, Karolinska Institutet. Other PADI 
sequences were obtained from Dr Christophorou. All sequences were 
subcloned using InFusion cloning methods into a modified pGEX 6P-1 
bacterial expression vector which contains an additional 6xHis tag included 
C-terminally to the glutathione S-transferase (GST) tag sequence, at the N-
terminus of the target protein (generous gift from Dr Martin Reijns, MRC 
Human Genetics Unit). InFusion subcloning was performed by Gavriil 
Gavrilidis and Abigail Wilson. 
 
2.1.4 Glycerol stocks 
To make glycerol stocks, 500 µL of an overnight bacterial culture was added 
to 500 µL of 50% glycerol in dd H2O in a 2 mL Cryogenic Vial and gently 
mixed before freezing at -80˚C. Bacteria were recovered from the glycerol 
stock by scraping frozen bacteria with a sterile loop from the cryovial without 
allowing the glycerol stock to thaw. Cells were streaked on to agar plates 
with the appropriate antibiotic. Plates were inverted and incubated at 37˚C 
overnight to grow colonies, which were picked to prepare starter cultures for 
further propagation.  
 
2.1.5 Recombinant protein production 
A single colony was picked from an agar plate to inoculate a starter culture 
flask of 30 mL 2TY media (MRC HGU Technical Services) containing the 
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appropriate antibiotic in the evening. This was grown overnight at 37˚C with 
shaking at 220 rpm. The next morning, an empty incubator was prepared 
with 2L flask adaptors and set to 18˚C. For each protein, 3x 2L culture flasks 
were prepared with 400 mL of 2TY media per flask and appropriate antibiotic. 
4mL (1:100 dilution) of mixed starter culture bacteria was used to inoculate 
each large 2L flask. These were grown at 37˚C for approximately 2 hours 
with shaking at 220 rpm. Optical density at a wavelength of 600 nm (OD600) 
was measured at 1 hour and then regularly after that. At OD600=0.6, cultures 
were induced with isopropyl β-D-1-thiogalactopyranoside (IPTG) (Sigma) at a 
final concentration of 0.5 mM and flasks were transferred to the pre-cooled 
18˚C shaker. These were incubated overnight with shaking at 220 rpm. 
Bacteria were pelleted at 8000 x g at 4˚C for 15 min, weighed and frozen at -
80˚C.   
 
2.1.6 Protease and Phosphatase inhibitors 
For protease inhibitors, a Roche cOmplete™, Mini, 
ethylenediaminetetraacetic acid (EDTA)-free Protease Inhibitor Cocktail 
tablet was dissolved in the buffer freshly. For phosphatase inhibitors Roche 
Phos-STOP inhibitor tablet was dissolved in the buffer freshly. For large 
buffer volumes, protease inhibition was achieved using 1mM PMSF. 
 
2.1.7 Fast protein liquid chromatography (FPLC) 
Bacterial pellets were thawed on ice, transferred into 50mL falcon tubes and 
lysis buffer was added at 4mL per g of bacterial pellet.  Lysis buffer 
comprises binding buffer supplemented with 1 mM (final) dithiothreitol (DTT) 
(Sigma), 2 mM (final) MgCl2 (Sigma) and benzonase (1 µL) (Sigma). Falcons 
were rotated at 4˚C to dissolve the pellet for 20 min, sonicated with a 
Soniprep 150 for 7 cycles, 45 sec on, 45 sec off at amplitude 8. Lysates were 
cleared by centrifugation at 20 000 x g for 20 min and the supernatant 
passed through a polyethersulfone (PES) 0.22 µm syringe filter (Millipore) 
before loading onto an fast protein liquid chromatography (FPLC) machine 




Media was removed and cells washed once in ice-cold phosphate buffered 
saline (PBS). 100 µL of modified 2x Laemmli (120 mM Tris-HCl, 20% 
glycerol, 4% SDS, pH 6.8) was added to each well and scraped using a 
silicon cell scraper (Corning). The extract was transferred to a 1.5 mL 
Eppendorf tube, boiled at 95˚C for 5 min and spun quickly. Samples were 
passed through a 25G needle ten times, sonicated for 5 min using a 
Bioruptor® water bath sonicator at high power in 30-second cycles or 
sonicated for 3 x 30 secs using an Ultrasonic disintegrator Soniprep 150. 
Samples were sometimes stored at –80°C prior to normalization. Total 
protein concentration was determined using the nanodrop and 
concentrations were equalised in 2 x Laemmli buffer. Equalised protein 
mixtures were added 9:1 to a pre-prepared mixture of 10% bromophenol blue 
in 98% β-mercaptoethanol. Samples were then boiled for 5 min and spun 
quickly and loaded for SDS PAGE gel running or stored at –80˚C. 
 
2.1.11 SDS-PAGE running 
Samples were heated at 95˚C for 5 min and spun quickly before loading. 
Polyacrylamide gels were run for 40 min at 200 V in running buffer using 
either a Bio-Rad Mini-PROTEAN II or CRITERION system with 4-20% TGX 
Stain-Free pre-cast gels. 30 µg of total protein was loaded per well as 
standard using SDS-PAGE. Proteins were stained with Coomassie Blue stain 
or subjected to Western Blotting.  
 
2.1.12 Coomassie staining 
Coomassie staining was performed by incubating in Coomassie stain  (Acetic 
acid 10% (w/v), 30% Methanol in 0.25% (w/v) Coomassie® brilliant blue) for 
30 min before washing in Destain solution (Acetic acid 10% (w/v), 30% 








2.1.15 Antibody use for Western blotting 
The following commercial antibodies were used at these stated dilutions: 
GAPDH ab127428 GR259405-4 (1:10000), NPM1 ab37659 lot# GR187575-
1 (1:500), H3CitR2 ab212082 monoclonal (1:2000), PADI4 ab50332 
GR291996-8/291996-1 (1:2000), total histone H3 ab10799 (1:1000), anti-
calmodulin EP799Y ab45689 (1:1000), anti-GST Glutathione S-Transferase 
ab19256 (1:1000), anti-mouse Padi2 ab50257 (1:1000), abcam anti-6xHis 
ab18184 (1:1000) from Abcam; non-phosphorylated (Active) β-Catenin 
(Ser45) (D2U8Y) XP®Rabbit mAb #19807 (1:1000), non-phosphorylated 
(Active) β-Catenin (Ser33/37/Thr41) (D13A1) Rabbit mAb #8814 (1:1000), 
total β-Catenin (D10A8) XP® Rabbit mAb #8480 (1:1000), GSK-3β (D5C5Z) 
XP® Rabbit mAb #12456 (1:1000) from Cell Signaling Technologies; and 
total β-Catenin (1:1000) from BD Millipore. The polyclonal H3CitR(2,8,17) 
ab5103 antibody is known to show lot to lot variability. A number of different 
lots were tested and validated using activation conditions in HL60 cells and 
only the following two lots were used: GR99830-1 (1:2000) and GR247556-1 
(1:5000). 
 
2.1.16 Mod-Cit Western blotting 
100 µg total cell lysate was loaded per lane and SDS-PAGE run for 40 min at 
200 V. Proteins were then transferred onto nitrocellulose wetted in transfer 
buffer for 1 hour at 400 mA. 10 mL reagent A was made fresh before use per 
two membranes during transfer. Reagent A was prepared by diluting 0.5 mL 
0.5% FeCl3 in 5 mL MiliQ water on ice, before dropwise addition with 
constant mixing of 2.5 mL 98% H2SO4 and 2 mL 85% H3PO4 in a fume hood 
and leaving to cool at 4˚C (Sigma). After transfer, membranes were washed 
twice in MilliQ, blocked with 0.1% ovalbumin in MilliQ for 15 min at RT with 
agitation and washed twice again in MilliQ. Reagent B (0.5% diacetyl 
monoxime, 0.25% antipyrine, and 0.50 mol/L acetic acid) was prepared in 
advance and stored frozen at -20˚C (Sigma).  Reagent A and B were thawed 
and mixed 1:1 and incubated with the membrane overnight, protected from 




modification mixture was 0.0125% FeCl3, 2.3 mol/L H2SO4, 1.5 mol/L H3PO4, 
0.25% diacetyl monoxime, 0.125% antipyrine, and 0.25 mol/L acetic acid. 
Membranes were then washed 4-5 times in MilliQ water, blocked in 3% milk 
in TBS with 0.1% Tween-20 detergent added (TBS-lo-T) for 1h at RT, and 
incubated with anti-ModCit primary antibody at a 1:500 dilution for 3 h at RT 
followed by incubation at 4˚C overnight. Membranes were then washed three 
times with TBS-T. Secondary antibody incubation was with goat anti-Rabbit 
secondary at a 1:2,000 dilution in TBS-T for 3 h at RT. Standard detection 
procedures as above were used. 
 
2.1.17 Nuclear and cytoplasmic extraction 
The Thermo Scientific Pierce NE-PER Nuclear and Cytoplasmic Extraction 
kit was used for stepwise separation and preparation of cytoplasmic and 
nuclear extracts from cultured cells according to manufacturer’s 
recommendations. 
 
2.1.18 Cyclic peptides 
Lyophilised cyclic peptides, synthesized by Dr. Louise Walport (University of 
Tokyo), were initially reconstituted in 20 µL dimethyl sulfoxide (DMSO) with 
additional 15 µL added increasingly until the solid peptide could be dissolved. 
0.5 µL was diluted in 2.5 µL DMSO before measuring concentrations using 
the Nanodrop 8000 UV/Vis spectrophotometer with absorbance measured at 
280 nm. Extinction coefficients (ε) were obtained using the ProtParam tool on 
the ExPASY Bioinformatics Resource Portal from the Swiss Institute for 
Bioinformatics (https://web.expasy.org/protparam/) and concentrations 
calculated with the Beer Lambert law (A = ε.c.l). For biotinylated peptides ε 
was given to be 4470 M-1cm-1. Fluorescent peptides were measured at 495 
nm instead of 280 nm, using the ε of the fluorescein amidite (FAM) 
fluorophore of 76900 M-1cm-1. 10 mM stocks of peptide were prepared, 





2.2 Cell biological methods 
All procedures were carried out in a Class II Biological Safety Cabinet. 
 
2.2.1 Mouse ES cell culture 
E14 embryonic stem (ES) cells were cultured in serum media following 
Christophorou et al. 20141, but without pencillin/streptomycin. To passage 
cells, medium was aspirated and cells washed gently in PBS. 3 mL of pre-
warmed Accutase® was incubated over the surface of the flask for 2 – 2.5 
min until cells detached and 9 mL of full serum medium added to inactivate 
the Accutase®. Cells were centrifuged at 1200 rpm for 4 min and medium 
was aspirated. The cells were resuspended and triturated ten times in 1 mL 
of full serum medium using a P1000 pipette to break up clumps of cells 
remaining in colonies. Cells were counted using a haemocytometer and 
reseeded in pre-warmed full serum medium (see below for seeding 
densities). Medium was replaced daily and cells not allowed to attain greater 
than 80% confluency. Health, colony formation and confluency were 
assessed at each media change. To freeze cells, 2-3 million cells per 500 µL 
full serum medium was added to 500 µL of Cryomix (full serum media 
containing 20% DMSO and 20% fetal calf serum (FCS), MRC HGU 
Technical Services). Cells were mixed by gentle pipetting and frozen in a Mr 
Frosty box at -80˚C overnight before transfer to liquid nitrogen storage. For 
reviving cells, vials were removed from liquid nitrogen and kept under dry ice 
until thawing. A single 1 mL vial (2-3 million cells as above) was thawed 
rapidly at 37˚C in a water bath and added to 9 mL pre-warmed medium to 
dilute the DMSO content. Cells were centrifuged at 1200 rpm for 4 min, 
media aspirated and cells resuspended in 5 mL full serum medium. These 
were seeded in a T25 flask containing 6 mL medium. Medium was changed 
daily and cells split having attained 70-80% confluency and passaged 







then cultured in neural stem cell media for 4 days and subsequently in 
mouse ES cell media supplemented with recombinant LIF (103 units, ESGRO 
recombinant murine LIF) for 2 days before freezing following Theunissen et 
al. or subsequently Christophorou et al.1,2. These cells (i.e. before addition of 
2i media at day 6 of a reprogramming experiment) are referred to as “pre-iPS 
cells”. As cells reprogram, they begin to express the endogenous murine 
Oct4, in place of the exogenous transduced Oct4, and therefore express 
GFP. A normal successful reprogramming experiment cultures pre-iPS cells 
in KSR2i media (KSR media supplemented with 1µM PD0325901 
AxonMedChem and 3 µM CHIR99021 AxonMedChem) for an additional 8 
days and achieves ~5% reprogramming efficiency by day 14 as read out by 
the proportion of GFP positive cells. Culturing in full serum media, or in Cl-
amidine reduces the efficiency of reprogramming after Christophorou et al.1. 
 
2.2.3 HL-60 cell culturing 
HL-60 promyelocytic leukaemia cells (ATCC® CCL-240™) were maintained in 
Roswell Park Memorial Institute 1640 medium (RPMI) (ThermoFisher) was 
supplemented with 2 mM L-Glutamine and 10% FCS (MRC HGU Technical 
Services). Cultures were passaged by centrifugation at 1000 rpm for 5 min 
with subsequent resuspension at a density of 1x105 viable cells per mL in 
Corning® T-75 flasks (catalog #431464). Cell concentrations were not 
allowed to exceed 1x106 cells per mL. Medium was renewed every 2 to 3 
days. Terminal differentiation was induced by culturing in media 
supplemented with 1.25% DMSO (Hybri-Max, Sigma) over 5 days after which 
robust PADI4 expression can be detected by Western blotting3. The 
morphology of the cells changes to become smaller and more densely 
coloured (less transparent- presumably due to granule formation) under a 
microscope and the cells no longer divide. 
 
2.2.4 Neutrophil isolation from peripheral blood and short-term culture 
The protocol for isolation of primary human neutrophils was adapted with 




MRC Centre for Inflammation Research, Queen’s Medical Research Institute 
(QMRI) and then subsequently performed at the Institute for Genetics and 
Molecular Medicine (IGMM). All procedures were carried out at room 
temperature unless otherwise stated. All centrifugation steps were performed 
with capped rotor buckets. Falcon brand 15 and 50 mL tubes were used for 
the preparation. 3.8% sodium citrate solution was prepared in advance from 
3.8 g tribasic dihydrate (Sigma #25116) dissolved in 100 mL Baxter 
UKF7114 sterile water. 6% Dextran solution in saline was prepared in 
advance from 6 g Dextran 500 (Sigma #31392) dissolved in 100 mL warmed 
0.9% NaCl solution (Baxter). All solutions were then sterile filtered using a 
0.22 µm PES filter unit. Percoll was obtained from GE Healthcare #17-0891-
02. 1x and 10x PBS used throughout were without Ca2+/Mg2+ (Sigma). 
 
Freshly drawn blood from healthy adult volunteers (presenting without hay 
fever due to high eosinophil populations that co-purify in this protocol with 
neutrophils) was collected either at the QMRI or Western General Hospital 
directly into 3.8% sodium citrate solution (4 mL of 3.8% citrate per 40 mL of 
blood in a 50 mL falcon tube) which was mixed by gentle inversion of tube 
with parafilm covering the cap. Blood was centrifuged at 350 g for 20 min 
(minimum or zero brake was used: Acc1/ Brake 0 Hettich centrifuge, 
Acc0/Brake 0 Mistral centrifuge). After centrifugation platelet-rich plasma 
(PRP) layer was aspirated without disturbing the pelleted cells. Autologous 
recalcified plasma (autologous serum) was prepared by adding 220 µl of 1 M 
CaCl2 per 10 mL plasma in glass tubes and incubated at 37°C for 1 hour. 
Autologous serum was separated from the platelet plug and transferred to a 
Falcon tube for use on the same day, but can be frozen and stored at -20˚C. 
Leukocytes were separated from erythrocytes by Dextran sedimentation: 6 
mL of 6% Dextran in saline solution was added to each tube (2.5 mL Dextran 
per 10 mL cell pellet) and then made up to 50 mL using pre-warmed saline at 
37°C. Cells were fully resuspended by careful, gentle mixing before allowing 
to sediment through the dextran for between 20 and 30 min (not more than 
30 min) at room temperature by gravity. During this period, discontinuous 
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Percoll gradients were prepared. Room temperature stock Percoll solution 
was made isotonic using 10x PBS to yield a 90% “stock” solution by mixing 
27 mL Percoll with 3 mL 10x PBS. The 81% Percoll layer solution was made 
with 8.1 mL Percoll “stock” and 1.9 mL 1xPBS; the 70% Percoll solution 
using 7 mL Percoll “stock” and 3 mL 1xPBS; and the 55% Percoll solution 
with 5.5 mL Percoll “stock” and 4.5 mL 1xPBS. A discontinuous gradient was 
prepared by placing 3 mL of 81% Percoll (bottom layer) at the bottom of a 15 
mL Falcon tube with 3 mL of 70% Percoll (middle layer) overlayered onto the 
bottom layer slowly to avoid any mixing of the two different percentage 
Percoll layers. After dextran sedimentation, the leukocyte-rich upper layer 
was retained and transferred to a fresh 50 mL tube and topped up to 50 mL 
with saline and then centrifuged at 350g for 6 min (Acc5/ Brake 5 for both 
Hettich and Mistral centrifuges). Pellets from 2 x 50 mL Falcons were then 
resuspended in a combined 3 mL of 55% Percoll solution and overlayed as 
the final top layer onto the previously prepared Percoll gradient with care as 
before not to disturb the layers. Completed gradients were centrifuged at 
720g for 20 min, (Acc1/ Brake 0 Hettich centrifuge, Acc0/Brake 0 Mistral 
centrifuge). Leukocytes were harvested at the 70%/81% interface (residual 
erythrocytes should pellet at the bottom of the Falcon and mononuclear cells 
can be harvested at the 55%/70% interface). Harvested leukocytes were 
then washed twice in PBS with centrifugation at 230 x g for 6 min, (Acc5/ 
Brake5 Hettich and Mistral centrifuges). Cells were analysed by cytospin and 
also by flow purity using Fluorescence-Activated Cell Sorting (FACS) with 
CD16 and CD14 mouse antibodies (mAbs) to ensure neutrophils (CD16 
positive cells) represented at least 95% of the cell population. Cells were 
finally resuspended in appropriate buffer for short-term cell stimulation for 
PADI4 activation. Diff-Quick (Gamidor, Oxford, UK) was used to stain 
neutrophils prepared by cytospin (neutrophils have distinctive lobular nuclear 
morphology; eosinophils have distinctive orange granules). 







2.2.5 Cell culture treatments 
Cell culture treatments were performed as stated in experimental figure 
legends in Iscove's Modified Dulbecco's Medium (IMDM), GMEM, ES Serum 
media, ES KSR media, in Locke’s solution (10 mM 4-(2-hydroxyethyl)-1-
piperazineethanesulfonic acid (HEPES), pH7.3, 150 mM NaCl, 5 mM KCl, 2 
mM CaCl2, 0.1% glucose). Materials for cellular treatments were recombinant 
TNF alpha (human, suitable for cell culture, Sigma), LPS (Sigma), 
Interleukin-8 (IL-8) recombinant from E. coli (human, Sigma), N-Formyl-Met-
Leu-Phe chemotactic peptide (fMLF) (Sigma), calcium ionophore A23187 
(Sigma), all-trans-retinoic acid (ATRA) (cell culture, Sigma), DMSO (Hybrid-
Max, Sigma), PD0325091 (AxonMedChem), CHIR99021 (AxonMedChem), 
Cl-amidine (Cayman Chemical), BB-Cl-amidine (Cayman Chemical), alpha 
amanitin (generous gift from Dr Ryu-Suke Nozawa, MRC HGU, Sigma), 
actinomycin D (Sigma), mouse Wnt3a recombinant (Peprotech), BML284 
(Cayman Chemical). 
 
2.2.6 Cellular Methods 
2.2.6.1 Citrullination Lysate Assay 
Mouse ES cells were cultured for 1-2 days in serum media on six well plates 
pre-coated with gelatin. Cells were washed in 1 mL PBS supplemented with 
2 mM EDTA (MRC HGU Technical Services) and once in PBS. 100 µL of 
active lysis buffer (20 mM Tris, 1% NP-40, 5 mM DTT, 137 mM NaCl with 
protease inhibitors) was added to each well. Cells were scraped with a silicon 
scraper and combined into a single Eppendorf. 0.2 µL of 1 M MgCl2 (2 mM 
MgCl2 final) and 0.2 µL benzonase (Sigma) per 100 µL of lysate was added 
and incubated at 4˚C with rotation for 30 min. Sample was sheared with 25G 
needle 10 times and centrifuged at 10000 rpm at 4˚C for 5 min to clear cell 
debris and supernatant transferred to a new clean tube on ice. The overall 
lysate for the total number of conditions was pooled and split into each assay 
condition. Any supplements (CaCl2, EDTA, recombinant bovine Calmodulin, 
peptide, Cl-amidine, GSK484, vehicle) were added at stock concentration in 
a single droplet to the tube lid before the assay was initiated. To begin the 
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assay tubes were spun quickly and incubated at the desired temperature and 
time with shaking in an Eppendorf heating block. To quench the assay 
samples were boiled at 95˚C for 5 min before freezing directly on dry ice.  
 
2.2.6.2 Transfections 
Transfections were performed using Lipofectamine 2000 (Invitrogen). The 
procedure is written here for mouse ES cells seeded in six well plates, but 
was scaled up according to manufacturer’s instructions. In the morning, 
mouse ES cells were seeded in six well plates such that, by the next day, 
cells have attained approximately 50% confluency in colonies. Per well of 
transfection, 4 µg of plasmid DNA was mixed with 250 µL of pre-warmed 
OptiMEM medium (Gibco) in an Eppendorf. In a second Eppendorf, 10 µL 
Lipofectamine 2000 was mixed with 250µL OptiMEM (ThermoFisher) and 
incubated for 5 min at RT. The Lipofectamine 2000 mixture was then added 
to the first Eppendorf containing plasmid DNA without pipetting, and mixed 
by flicking and inverting the tube. This was then incubated for 20 min at RT. 
Cells to be transfected were washed once with PBS and incubated with 2 mL 
of plain GMEM (ThermoFisher) supplemented only with recombinant LIF 
(1:500 homemade, or 103 units of ESGRO recombinant murine LIF). After 
incubation has finished, the Lipofectamine DNA mixture was added dropwise 
to the cell while rocking the plate to mix and returned to the incubator. At four 
to six hours after transfection, fresh medium was replaced on the cells. 
 
The Pierce™ Protein Transfection Reagent (ThermoFisher) was used 
according to manufacturer’s instructions and tested using FAM tagged 
peptides 1, 2 and 3. These pilot experiments were not continued once activity 
was clear from direct usage on cells. 
 
2.2.6.3 Nucleofection and generation of stable cell lines 
Nucleofections were performed using the Lonza 4D-NucleofectorTM System  
according to manufacturer’s instructions. pB-CAG-Ctrl or pB-CAG-hPADI4 




expression vector, pCAG-PBase (2 mg), by nucleofection according to the 
manufacturer’s instructions (Lonza) and as described in Christophorou et al.1. 
ES E14 cells constitutively expressing the hygromycin resistance gene and 
human PADI4 were selected and expanded in media containing 200 mg/mL 
hygromycin (Sigma). Other vectors introduced using the same method were 
piggyBac-AVI-PADI2b-IRES-GFP, piggyBac-AVI-PADI3-IRES-GFP, 
piggyBac-PADI2-Hygromycin, and piggyBac-BirA-Hygromycin. In detail, a 
T25 flask of cells was incubated with Accutase to detach cells, centrifuged at 
1200 rpm for 4 min and resuspended in 5 mL volume media after triturating 
in a 1 mL volume. Cells were then put in an uncoated T25 flash to allow cells 
to recover for 20 min in the incubator. Cells were counted and 5x104cells per 
sample were collected in a 15 mL Falcon tube and centrifuged as above to 
pellet. An extra mock condition for nucleofection without plasmid and a final 
untreated condition for assessing death kinetics under hygromycin treatment 
were always included. Each sample is resuspended in 20 µL of Nucleofector 
solution. Plasmids of 0.3 µg pB-CAG-Vector and 0.6 µg pCAG-PBase were 
added to a 1.5 mL Eppendorf per sample, prepared using EtOH sprayed 
pipettes and filter tips. The 20 µL cell suspension in Nucleofector solution 
was added to the DNA, mixed and transferred to the 16 well Amaxa cuvette 
ensuring there were no air bubbles. The CG-104 (ES cell) program was used 
to nucleofect a 16-well cuvette. Cell suspension was then made up to 2 mL 
volume of pre-warmed media and seeded onto a six well plate. After 24 
hours of recovery, the cells were put into 200 µg/mL hygromycin selection 
alongside the wild type non-nucleofected cells to assess death kinetics. 
Selection was continued until the wild type cells were dead (1-2 weeks). 
Cells were expanded and frozen with plasmid expression assessed by 
Western blotting. 
 
2.2.6.4 TOPFlash assay 
The Cignal TCF/LEF Reporter assay (TOP-GFP) (Qiagen) was used to 
assess the effect of PADI4 inhibition on Wnt3a driven transcriptional output. 
Mouse ES cells stably expressing hPADI4 were seeded in six well plates on 
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day 1. On the following day, 10 µL reporter DNA plasmid was transfected per 
well using Lipofectamine 2000 as above, except that four hours after 
transfection with Lipofectamine 2000, cell media was replaced into serum 
withdrawal media. Cells were treated the morning after transfection, by 
washing once in PBS and then replacing into Serum withdrawal media 
prepared with vehicle, 100 ng/mL recombinant Wnt3a (Peprotech), 100 
ng/mL recombinant Wnt3a + 200µM Cl-amidine (Cayman Chemical), or 100 
ng/mL recombinant Wnt3a + 10µM BB-Cl-amidine (Cayman Chemical) using 
a P1000 pipette. The negative control FOP plasmid (with mutated and 
inactive TCF/LEF binding sites, referred to as FOP-GFP) was treated with 
100 ng/mL Wnt3a treatment and was additionally included. A GFP-
expressing plasmid was used as a positive control to assess approximate 
transfection efficiency. Three replicate plates were tested which were 
staggered and treated independently at all stages. After 24 hours treatment, 
cells were washed in PBS, incubated in 300 µL Accutase, and then 
inactivated in full serum media. Cells were washed once more in PBS, 
resuspended in 250µL PBS, and kept on ice for analysis by fluorescence 
activated cell sorting (FACS) using a BD Accuri C6 flow cytometer. Gating 
was performed to include live cells. Data analysis gave similar results 
whether normalised or not against GFP positive cells from the positive 
control of transfecting GFP included on each plate (~30% of the total 
population GFP positive and live in single cells after treatment). 
Representative FACS plots are presented along with average data. 
Significance was assessed using an unpaired two-tailed t test. 
 
2.2.6.5 Toxicity assay 
To test cell toxicity of the cyclic peptides, differentiated HL-60 cells were 
seeded in a 24 well plate and either DMSO, control peptide_9 or inhibitory 
peptides 2 and 3 were added.  Control peptide_9 was used as a control for 
the effect of lyophilized cyclic peptides on cell toxicity. After pipetting to mix, 
50 µL of cell suspension was mixed in 150 µL Muse assay buffer. The 




with an untreated well of differentiated cells used to gate the machine. 
Toxicity of peptides was additionally assessed using the Promega CellTox™ 
Green Cytotoxicity Assay, which was used according to manufacturer’s 
instructions. 
 
2.3 Mass spectrometry methods 
2.3.1 General BS3 conjugation protocol 
For optimizing the antibody pulldown, bis(sulfosuccinimidyl)suberate (BS3) 
reagent (Thermo Scientific #21580) was used to crosslink the primary 
antibody to protein A or protein G Dynabeads at the start of the pulldown to 
minimize the extent of signal from the heavy chain after detection by 
immunoblot. As BS3 is moisture-sensitive the vial was let to equilibrate to RT 
before opening to minimize condensation, with storage at -20˚C. Fresh 5 mM 
BS3 solution was prepared in conjugation buffer (250 µL per sample). The Ig-
coupled Protein A or Protein G Dynabeads® were washed twice in 400µL 
BS3 Conjugation Buffer (20 mM Sodium Phosphate, 0.15M NaCl pH 7.5) by 
placing on a magnet and discarding the supernatant. The Dynabeads were 
then incubated in 250 µL 5 mM BS3 at RT for 30 min with rotation. The cross-
linking reaction was quenched in 12.5 µL BS3 Quenching Buffer (1M Tris-HCl 
pH 7.5) for 15 min at RT with rotation. The cross-linked Dynabeads were 
washed three times in 400 µL of IP bind buffer before proceeding with the 
immunoprecipitation. 
 
2.3.2 Immunoprecipitation and tandem mass spectrometry (IP-MS/MS) 
protocol for HL60s 
25 µL beads per MS/MS condition were washed in buffer (20mM Tris, 
150mM NaCl, 0.5% NP-40, with protease inhibitors and PhosSTOP). In 225 
µL ND buffer, 3.57 µL PADI4 ab50332 were conjugated per 25 µL washed 
Dynabeads (ThermoFisher) for 1 hour at RT with rotation. Dynabead washes 
were performed by placing tubes on a magnet and discarding the 
supernatant, before resuspending. 5 mM BS3 solution was prepared freshly 
in Conjugation Buffer. The immunoglobulin Ig-coupled Dynabeads were then 
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washed twice in 200 µL Conjugation Buffer and incubated in 250 µL BS3 (5 
mM) for 30 min at RT with rotation. The crosslinking reaction was quenched 
in 12.5 µL quenching buffer for 15 min at RT with rotation, before washing in 
200 µL  buffer. Cell lysis began 20 min before the hour-long antibody 
conjugation was complete. Each T75 flask of 10 x106 HL60 cells for cell 
treatment was pelleted, washed in PBS containing protease inhibitors, 
transferred into Eppendorfs and 100 µL Denaturing buffer was added (20 mM 
Tris, 1% SDS, 10 mM DTT). Cells were mixed by vortexing for 3 seconds, 
boiled for 10 min at 95˚C and then diluted into 900 µL  buffer. Lysates were 
passed through a 25 G needle, incubated on ice and 50 µL retained as input 
in a fresh tube. 950 µL of lysate was added per 50 µL pre-conjugated beads 
mix (now at 2X volume) and rotated overnight at 4˚C. The supernatant was 
retained and frozen as flow through along with the input for running by 
Western blot as required. For submission to Mass spectrometry, beads were 
then washed three times in ND buffer and twice in 100 mM ammonium 
bicarbonate (AMBIC) before freezing the beads dry (without supernatant) on 
dry ice. MS/MS was run at the IGMM Mass spectrometry facility. I then 
performed subsequent data analysis from the raw data using PEAKS7.5 
software. 
 
2.3.3 IP-MS/MS for mES cells stably expressing hPADI4 
2.3.3.1 Conjugating antibody or biotinylated peptide 7 to Dynabeads 
2.3.3.1.1 Antibody 
In low protein-binding tubes, 50 µL Protein A Dynabeads (ThermoFisher) 
were added per condition, washed in 500 µL PBS + 0.02% Tween-20 and 
resuspended in 300 µL PBS + 0.02% Tween-20. 1.4 µL hPADI4 ab50332 
antibody was added per condition, and incubated for 45 min at RT with 
rotation before transferring onto ice. Prior to adding cell lysates, beads were 







2.3.3.1.2 Biotinylated peptide_7 
In low protein-binding tubes, 20 µL Protein A Dynabeads (ThermoFisher) 
were added per condition, washed in 2 x 300µL PBS + 0.02% Tween-20 and 
resuspended in 300µL PBS + 0.02% Tween-20. 2.5 µL of biotinylated 
peptide 7 stock was added per condition, and incubated for 45 min at RT with 
rotation before transferring onto ice. Beads were then washed twice in PBS, 
3 times with 500 µL PBS with 0.1% BSA with a final wash in 500 µL Wash 
buffer (10 mM Tris-HCl pH 7.5, 150 mM NaCl, with protease inhibitors and 
PhosSTOP). 
 
2.3.3.2 Cell treatment, lysis, pulldown and washes for interactome 
analysis 
Cells were grown in 10cm3 dishes and vehicle or 100 µL Cl-amidine (20 mM) 
(Cayman Chemical) was added to each dish 90 min before cell treatment. 
Dishes were grown in triplicate and each set of replicates (3 sets of 4 
conditions) was staggered by 30 min. Growth media was aspirated and 
replaced with treatment media: 1) 30 mL full serum media with vehicle; 2) 30 
mL full serum media supplemented with 3µM CHIR99021 (AxonMedChem); 
3) 30 mL full serum media supplemented with vehicle and 100µL Cl-amidine 
(20mM) (Cayman Chemical); or 30 mL full serum media supplemented with 3 
µM CHIR99021 (AxonMedChem) and 100µL Cl-amidine (20mM) (Cayman 
Chemical). Cells were incubated for 45 min in treatment media. Treatment 
medium was then aspirated, and cells washed once in 12 mL ice-cold PBS. 
1mL ice cold PBS with protease inhibitors and PhosSTOP was added, cells 
scraped from dish and transferred to a pre-cooled Eppendorf. Cells were 
pelleted by centrifugation at 500 x g for 3 min at 4˚C and supernatant 
discarded. Each cell pellet (one per 10cm3 treated dish) was resuspended by 
pipetting in 200 µL of ice-cold Lysis buffer (10 mM Tris-HCl pH 7.5, 150 mM 
NaCl, 0.2% NP-40, with protease inhibitors and PhosSTOP, 25 units/µL 
Benzonase (Sigma), 2.5mM MgCl2 and 1mM phenylmethylsulfonyl fluoride 
(PMSF) (Sigma) and incubated on ice for 30 min without rotation, vortexing 
briefly every 10 min. The cell lysate was then centrifuged at 14,000 rpm for 
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10min at 4˚C and transfer supernatant to a fresh pre-cooled tube. 400 µL 
Wash Buffer (10 mM Tris-HCl pH 7.5, 150 mM NaCl (with protease inhibitors 
and PhosSTOP) was added to each of the tubes of pre-conjugated beads 
and 190 µL of the cleared lysate and incubated at 4˚C overnight with rotation. 
Beads were washed three times in Wash buffer and transferred to a new 
tube. Beads were washed a further two times in 100 mM Ammonium 
bicarbonate (Sigma), all remaining supernatant was aspirated and beads 
frozen on dry ice. 
 
2.3.3.3 Cell treatment, lysis, pulldown and washes for PTM analysis 
Cell treatments were performed on 12 x10 cm3 dishes each treated with 
10mL full ES serum media supplemented with either 9 µL DMSO vehicle or 9 
µL CHIR (from 10 mM stock). Plates were treated in pairs (untreated, 
treated). Cells were washed once in 10 mL PBS, once in 1mL of PBS 
supplemented with protease inhibitors and PhosSTOP, scraped and 
transferred to a fresh Eppendorf. Cells were pelleted by centrifugation at 500 
x g for 3 min at 4˚C, resuspended in 150 µL Denaturing lysis buffer (20 mM 
Tris pH 7.5, 1% SDS, 10 mM DTT), vortexed for 3 seconds, boiled for 5 min 
and then kept on ice. The next pair of plates were then harvested. Each 
condition was diluted in 1350 µL NDh buffer (20 mM Tris pH 7.5, 137 mM 
NaCl, 1% NP-40, with protease inhibitors and PhosSTOP). Benzonase 4 µL 
and 2 mM MgCl2 was added and samples incubated for 15 min at 4˚C with 
rotation. Samples were sonicated using the Soniprep150 at amplitude 10 for 
two cycles of 30 seconds on/off and then incubated for a further 15 min at 
4˚C with rotation. Lysates were centrifuged for 5 min at 4400 rpm on bench 
top centrifuge at 4˚C. 1400 µL lysate was added to a low binding tube 
containing beads pre-conjugated with antibody or peptide and incubated 
overnight at 4˚C with rotation. Beads were wash three times in NDh buffer, 
once in PBS + 0.02% Tween-20 and transferred to a new tube. Beads were 
then washed twice in 100 mM ammonium bicarbonate, all remaining 





2.3.4 Enzyme coverage 
Digestion analysis of human PADI4 was performed using the Expasy 
ProtParam tool from the Swiss Institute for Bioinformatics and using R or 
Excel, which showed that use of trypsin, chymotrypsin, AspN and Glu-C 
would improve theoretical coverage from 61.09% using trypsin alone to 
97.7% with the four enzymes in combination, assuming 100% digestion 
efficiency and MS/MS coverage of peptides of between 7-30 amino acids 
inclusive. An initial multiple enzyme digestion experiment pilot was performed 
by Dr Clive D’Santos at the CRUK Facility, Cambridge, but digestion 
efficiencies were found to be low. A modified digestion protocol adapted from 
Giansanti et al. was discussed for future optimization work in-house4 if and 
when phosphoproteomic experiments could be established at the same time.  
 
2.3.5 Rapid immunoprecipitation mass spectrometry of endogenous 
proteins (RIME) methods 
Rapid immunoprecipitation mass spectrometry of endogenous proteins 
(RIME) methods were performed by adaptation from Mohammed et al. 5. 
Briefly, after cell treatment, each T175 flask of cells was resuspended in 37.5 
mL plain Locke’s solution and 2.5 mL 16% Methanol free formaldehyde 
added and incubated for 8 min at RT. 2 x 840 µL of 2.5 M stock glycine was 
added per condition and mixed to a final 0.1 M concentration in order to 
quench excess formaldehyde. Cells were pelleted, resuspended in 10 mL 
PBS supplemented with protease inhibitors into a 15 mL Falcon before 
washing into 1 mL PBS supplemented with protease inhibitors and continuing 
with cell lysis and mass spectrometry as used elsewhere in this thesis. 
 
2.3.6 MS/MS procedure 
The mass spectrometry experiments were performed by the IGMM Mass 
spectrometry facility by Dr Niall Quinn or Dr Jimi Wills using the following 
protocol. Dry frozen beads, prepared as described in Section 2.3.3 above, 
were incubated for 30 min at 27˚C with trypsin in 2M urea (Sigma), 50 mM 
Tris pH8 (MRC HGU Technical Services), and the resulting supernatant 
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transferred to a fresh tube.   This was then incubated overnight at 37˚C with 
50 µL 50 mM Ammonium bicarbonate, 10% acetonitrile (ACN) (Sigma) and 
100 ng modified trypsin.  The solution was acidified using 5 µL 10% 
trifluoroacetic acid (TFA) and diluted to 2% ACN by adding 195 µL 0.1% TFA 
(Sigma). 100 µL of the resulting peptide solution was loaded onto an 
activated (using 20 µL methanol), equilibrated (using 100 µL 0.1% TFA) C18 
stop-and-go-extraction (STAGE) tip, and washed with 100 µL 0.1% TFA.  
The bound peptides were eluted into a Protein LoBind 1.5 mL tube 
(Eppendorf) with 2 x 20 µL 80% ACN 0.1% TFA and concentrated to below 8 
µL volume in a vacuum concentrator.  The final volume was adjusted to 12 
µL in 0.1% TFA. Online liquid chromatography was performed using a 
Dionex Rapid Separation Liquid Chromatography Nano.  Following the C18 
clean-up, 5 µL peptides (approximately a fifth of the beads input) were 
injected twice onto a home-pulled, home-packed C18 analytical column over 
a gradient of 2%-40% ACN in 40 min, with 0.1% TFA throughout.  Eluting 
peptides were ionised at +2kV before data-dependent analysis on a Thermo 
Q-Exactive Plus. MS1 spectra were acquired with a mass-to-charge ratio 
(m/z) range 300-2000 and resolution 70,000, and top 10 ions were selected 
for fragmentation with normalised collision energy of 30, and an exclusion 
window of 30 seconds.  MS2 spectra were collected with resolution 17,500.  
The Automatic Gain Control targets for MS1 and MS2 were 3e6 and 1e5 
respectively, and all spectra were acquired with lockmass and 1 microscan. 
An initial analysis was performed by the IGMM facility using MaxQuant and I 
performed subsequent analysis on the raw data files using both MaxQuant 
and PEAKS7.5. 
 
2.3.7 MaxQuant analysis 
MaxQuant analysis was performed using default settings on raw data 
generated from the Thermo Q-Exactive Plus with various changes outlined 
here. Briefly, raw files were loaded and andromeda quantification was used. 
Search database settings were used from databases previously used at the 




parameter groups and group-specific parameters, but in general samples 
were digested with trypsin and this was therefore not required. Label-free 
quantification (LFQ) was performed with minimum number of neighbours set 
to 1. The MaxQuant LFQ software performs two searches, firstly to model the 
error and the second search for quantification using that error. Separate 
variable modifications were included in both searches. Re-quantification was 
not used, and matching was performed using ‘from and to’ settings. MS/MS 
was not required for LFQ comparison. Contaminants were included so that 
trypsin levels could be assessed across samples. Default cut-offs were used 
for identification and match between runs was switched on under the 
advanced identification settings panel. Fixed modification of 
carbamidomethylation was typically included as standard in MaxQuant 
analyses. Variable PTM searches for Citrullinations/ Phosphorylations/ 
Ubiquitination/ Deamidation(N/Q) result in much longer computational 
processing time. Peaks7.5 was therefore generally used for PTM analysis 
and MaxQuant used as an initial way to process samples for analysis across 
samples by LFQ intensity. 
 
2.3.8 PEAKS analysis 
Reference Proteomes for searching fasta files were used from the IGMM 
MS/MS facility.  Identification was performed using precursor mass 8 ppm, 
fragment mass 0.08 Da, enzyme (trypsin), no non-specific cleavages and 
allowing 3 missed cleavages. The relevant database was selected using 
Uniprot format with the following edited rules: Id= “>..\|\(\w+\)” and Desc= 
“>..\|\w+\|\(.+\)”. Quantification was performed with error tolerance 8ppm, RT 
shift 6 min and default colouring used (red for enrichment, green for depletion 
using log2 ratios). Replicates were defined as being in the same group for 
statistical analysis of differential interacting proteins. Other settings were 
performed using default settings. Analysis took approximately 24-48 hours. 
Statistics are reported as -10log10(p) for which a value >20 is equal to a p-




2.4 Chemical genetic screen 
Various different seeding densities (from 10 up to 10000 cells per well), 
H3CitR2 antibody concentrations (1:50-1:2000) and fixing methods (ice cold 
methanol, 4% PFA for 10 min, 4% PFA for one hour) were tested to optimize 
a high content microscopy acquisition protocol that could detect signal for 
nuclear H3CitR2 levels in mouse ES cells which grow in 3D colonies in order 
to set-up a chemical genetic screen using a 96 well plate of inhibitors 
prepared in DMSO as used in Williams et al.6. That work had used a high 
throughput Western method for detection, but an immunofluorescence 
approach with detection by high content microscopy was taken here. This 
was adapted from a protocol that was used in Hari et al. that had been used 
to detect the Senescence-Associated Secretory Phenotype from IMR-90 
fibroblast cells7,8. The resulting optimized protocol for mouse ES colonies is 
provided. Mock inhibitor plates were prepared by adding DMSO (Hybrid-Max, 
Sigma) or CHIR99021 (AxonMedChem) with enough to result in a 10µM final 
concentration in 96 well plates in 1 µL total DMSO and then allowing to dry 
before freezing the plate. Chemical inhibitor library plates had been provided 
in the identical format, which was a generous gift from Dr Greg Findlay (MRC 
PPU) and Prof Nathanael Gray (Harvard University). Mouse ES cells stably 
expressing human PADI4 were seeded very sparsely at one tenth the usual 
seeding confluency to a density of 1000 cells per well for treatment the 
following day. All incubation steps were performed with gentle agitation. 
 
1 µL of DMSO, followed by 100 µL Serum media, was added to each well of 
the inhibitor plate using a multichannel pipette and shaken for 2 min at RT to 
dissolve the inhibitor. The 96-well cell plate was aspirated and washed once 
in PBS. A multichannel Liquidator pipette was then used to transfer the 
media/inhibitor solution from the inhibitor plate to the cell plate. The 96-well 
plate was then incubated with inhibitors for 15 min at 5% CO2 and 37˚C in a 
cell incubator. Media was then discarded, cells washed twice using the 
Liquidator pipette with PBS before adding 4% PFA solution in a fumehood 




the cell plate was washed twice as before in cold PBS. Cells were then 
permeabilised by incubating in PBS containing 0.2% Tween-20 containing 
3% BSA for 1 hour at RT. Cells were then blocked in a PBS solution 
containing a 0.2% solution of cold water fish skin gelatin (Sigma) and 3% 
BSA for 1 hour. Cells were then incubated overnight at 4˚C in 1:500 H3CitR2 
dissolved in 3% BSA in PBS. In the morning prior to image acquisition, the 
plate was washed three times in PBS containing 3% BSA and 0.2% Tween-
20. Anti-rabbit Alexa 488 was used at 1:1000 dilution in PBS containing 3% 
BSA and 0.2% Tween-20 prepared immediately before the final plate wash of 
the cells. 30 µl secondary antibody was added per well before incubation for 
30 min in the dark. Cells were then washed three times again in PBS. 30 µl 
Hoechst 33258 (1 µg/mL in PBS) was then added per well and incubated for 
30 min in the dark. Cells were then washed three times again in PBS before 
acquisition using an Image Xpress Micro XLS. A count of the total number of 
cells per well is made by counting the nuclei in the 4′,6-diamidino-2-
phenylindole (DAPI) channel. The stained area was set to include the 
nucleus only. Cell parameters were set to determine the minimum and 
maximum width of identified cells so that positively stained cells could be 
identified in MetaXpress with appropriate signal intensity above background. 
The minimum stained area was set to 100 µm2. Integrated nuclear intensity 
was normalized to the integrated nuclear intensity for the secondary only 
antibody control. Alternatively, the average nuclear intensity over two runs 
was calculated and shown alongside secondary only intensity. An analogous 
condition at the same seeding density under the same conditions was 
prepared on a six-well plate and analysed by Western blot as a control for 
activation. Significance was assessed using an unpaired two-tailed t test. 
 
2.5 Computational methods 
2.5.1 Collecting orthologous PADIs 
Two methods were used to obtain orthologous PADI sequences from 
sequence databases. Firstly, a list of proteins was collected with significant 
similarity (E value < 1x10-3) to the metazoan PAD_C domain by HMMER 
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searches against Reference Proteomes and UniProtKB databases9. For 
completeness, additional more sensitive sequence searches and iterative 
searches were performed: using tblastn and psiblast against nr/nt; using 
jackhammer against reference proteomes and UniProtKB; and using hhpred 
against Pfam-A, COG_KOG and PDB_mmCIF7010-14. The number of species 
with a putative PADI orthologues from UniProtKB was tabulated along with 
the total number of species contained in UniProtKB. Secondly, the EggNOG 
database was employed, which, briefly, makes use of a graph-based 
unsupervised clustering algorithm to infer orthologous groups from 2031 
genomes across the tree of life (ENOG410ZKF3: 217 proteins from 74 
species) 15. Phylogenetic reconstruction for the identified PADI orthologues 
was performed within EggNOG as implemented within the ETE3 suite 
(eggnog41) and described at http://eggnogdb.embl.de/#/app/methods15,16.  
 
2.5.2 General phylogenetic tools 
For all phylogenetic trees, branch support information was visualized and 
figures produced using FigTree v1.4.3 and iTOL17. Amino acid sequences for 
PADI homologues were obtained from UniProtKB, NCBI and Pathosystems 
Resource Integration Center (PATRIC) databases using HMMER and BLAST 
searches10,18,19. PADI2 was used for species with multiple PADI paralogues, 
as it closest resembles the PADI gene in metazoa with one PADI (such as 
fish)20, and with the PADI2 from metazoan species with three PADIs such as 
birds or reptiles (Figure 3.3). 
 
2.5.2.1 Phylogenetic analysis of other citrullinating enzymes 
Sequences of the arginine deiminase from Giardia lamblia (gADI)21 and the 
porphyromonas-type peptidylarginine deiminase from Porphyromonas 
gingivalis (pPAD)22 were used as a seed for Hidden Markov Model (HMM) 
searches of reference proteomes to identify sequences from other species of 
similar length and most significant similarity9,18. These were aligned with 25 
representative PADI sequences using MAFFT L-ins-I23 and singly aligning 




phylogenetic tree24,25. The LG empirical rate matrix with 8 categories of rate 
variation under the FreeRate model (LG +R8) was used, as determined by 
ModelFinder26,27 according to the corrected Akaike Information Criterion. The 
Ultrafast Bootstrap 2 with 1000 replicates28, Shimodaira-Hasegawa (SH)-like 
approximate likelihood-ratio test (aLRT) with 1000 replicates29-31, and aBayes 
parametric tests32 were used to assess node support. The displayed tree is 
shown unrooted with solid circles indicating consensus node support of 
>95%. 
 
2.5.2.2 Phylogenetic analysis of PADI orthologues 
All putative bacterial PADI sequences in the PATRIC database were 
obtained from BLAST searches10,18,19. In addition, sequences from metazoa 
were subsampled to maximize the inclusion of different lineages. The human 
PADI2 sequence was searched against UniProtKB to subsample sequences 
from 35 fungal species that represent the broadest distribution of affinity with 
PADI2 as determined by HMMER bitscore9. This was done to provide 
representation from the maximum sequence diversity of fungal PADIs. 
Fragment sequences were excluded.  The collected sequences were aligned 
using MAFFT L-ins-I and singly aligning columns were removed23. IQTree 
was used to produce a maximum likelihood phylogenetic tree24,25. The WAG 
empirical rate matrix with 10 categories of rate variation under the FreeRate 
model with base frequencies counted from the alignment (WAG +R10 +F) 
was used as determined by ModelFinder according to the corrected Akaike 
Information Criterion27,33. Ultrafast Bootstrap 2 with 1000 replicates, SH-like 
aLRT with 1000 replicates, and aBayes parametric tests were used to assess 
node support28-32. The tree is shown rooted at the midpoint with solid circles 
indicating consensus node support of >95% and a number of critical nodes 
for testing different evolutionary hypotheses were labelled in full as they are 






2.5.2.3 Phylogenetic analysis of subsampled PADI orthologues 
Bacterial PADI sequences were subsampled to maximize sequence diversity. 
Both the closest and the most distant bacterial homologues were retained 
with respect to the metazoan sequence to allow for the broadest distribution 
of protein sequences (to a total of 50 sequences). Firstly, a maximum 
likelihood phylogenetic tree was produced using IQTree as above using the 
best empirical rate matrix according to ModelFinder (WAG + R5 +F0). This 
reproduced the topology obtained with the full tree. Three further analyses 
were performed: 
1: Maximum likelihood phylogenetic analysis was performed using 
IQTree under the C20 empirical profile mixture model of evolutionary 
rate matrices using CIPRES Gateway on XSEDE34. 
 
2: Bayesian phylogenetic inference was performed using MrBayes 
v3.2.6 x64 using CIPRES Gateway on XSEDE with mixed model 
MCMC jumping across different fixed empirical rate matrices and 5 
different gamma distributed rate categories35. Analysis was performed 
with 4 runs each of 1000000 chains. The average standard deviation 
of split frequencies was observed to be <0.005, parameters all had an 
effective sample size (ESS) > 500 and potential scale reduction factor 
(PSRF) of 1.000 (to 3 significant figures). The summary tree was 
generated with a burn-in of 25% over the runs. Posterior probability 
was used for node support– i.e. where posterior probability was 100, 
the topology was congruent in every tree sampled by the Markov 
chain Monte Carlo (MCMC) after burn-in. The aminoacid model prior 
was set as ‘mixed’ such that the MCMC jumps across different models 
i.e. mixture of models with fixed rate matrices. Poisson, Jones, 
Dayhoff, Mtrev, Mtmam, Wag, Rtrev, Cprev, Vt and Blosum models 
were used and all have equal prior probability. The WAG model had 
posterior probability of 1.000, and standard deviation <0.0001 – and 
was exclusively sampled from the posterior33. This is consistent with 




according to ModelFinder and the corrected Akaike information 
criterion from the maximum likelihood analysis in IQTree.  
 
3: Bayesian phylogenetic inference was performed using PhyloBayes 
under the CAT-GTR model36,37. This is an infinite mixture model of 
rate matrices making use of a Dirichlet process prior. The alignment 
contains 1100 aligned positions and 50 taxa. 8 chains were performed 
in parallel for 24 hours such that more than 20000 cycles were 
achieved as recommended in the PhyloBayes manual using the MRC 
IGMM and University of Edinburgh computing cluster Eddie3. Readpb, 
bpcomp, tracecomp tools in PhyloBayes and Tracer software were 
then used to analyse runs. Posterior consensus trees were generated 
for each run and were reproducible across the eight different runs. 
The trace plots for independent runs were also analyzed to assess for 
apparent stationarity aiming for an ESS of at least 100. Maxdiff was 
observed to be < 0.1 (maxdiff= 0.06209, meandiff= 0.00330). 
 
Tree topologies were congruent across the four different methods. Ultrafast 
bootstrap 2 values over 1000 replicates (for the Maximum likelihood 
methods) or posterior probabilities (for the Bayesian methods) are presented 
in the table for the nodes labelled in the tree critical to different evolutionary 
scenarios. Additional topology testing was performed in PAUP*4.0a163 and 
in IQTree. 100 random trees were generated along with the maximum 
likelihood constrained tree where fungal and metazoan sequences were 
constrained to be monophyletic. The SH-test, approximately unbiased (AU) 
test and expected likelihood weight (ELW) tests were performed and all other 







2.5.2.4 Phylogenetic analysis to exclude synapomorphic regions from 
the alignment 
Phylogenetic analyses from Figure 3.4 were repeated using an alignment 
with the PAD_N domain removed and with an alignment in which both the 
PAD_N domain and regions of synapomorphy (Figure 3.6) were removed. 
Maximum likelihood analysis using IQTree with ModelFinder used to select 
the best performing fixed empirical rate matrix (WAG + R5 +F0) as 
above24,25,27,28. Topologies were congruent with analysis of the whole 
alignment and node support values (Ultrafast Bootstrap 2) for the clades 
labelled in Figure 4 were provided. 
 
2.5.3 Synapomorphy analysis 
2.5.3.1 Domain annotation 
Pfam annotates three PAD domains in metazoa (PAD_N, PAD_M and 
PAD_C). Putative locations for the PAD domains within target PADI 
sequences (from bacteria and fungi) were identified by aligning each target 
sequence to five metazoan sequences with TCoffee41. Putative domain 
sequence regions were then used as a target query for HMMER or HHPred 
searches18,42. HMMER searches were made against the UniProtKB database 
and HHPred searches were made firstly against a database of HMM profiles 
of protein domains in the Protein Data Bank (PDB_mmCIF_4_Aug) and 
secondly against a database of profiles from Pfam (Pfam-A_v31.0)13. A 
PAD_N domain can be found using HHPred in cyanobacterial sequences 
diverging after SPM and NX clades but could not be found in fungal, other 
bacterial species or earlier diverging cyanobacterial PADI sequences. Once 
individual sequences were identified as possessing a specific domain 
architecture, multiple sequence alignments were made of groups of 
sequences with common putative domain architecture and this was used as 
a query for each type of search.  
 
For the reported E values in Figure 3.5, the following method was used. All 




using TCoffee, PAD_C, PAD_M and PAD_N domains extracted from the 
cyanobacterial sequences, and secondly PAD_C and PAD_M domains from 
the clade containing a mixture of bacterial and fungal sequences. This 
alignment was used as a seed for searches with HHPred against a database 
of profiles made of the entire human proteome, and against a database of 
profiles of Pfam domains (Pfam-A_v31.0). HHPred searches were performed 
using the MPI Bioinformatics Toolkit of the Max Planck Institute for 
Developmental Biology, Tübingen, Germany13,43. 
 
2.5.3.2 Multiple sequence alignment of PAD_N domain 
Amino acid sequences were aligned using MUSCLE or TCoffee 
algorithms41,44 and visualized using Jalview45. Putative PAD_N domains from 
SPM/NX clade cyanobacterial PADI sequences were identified using HHPred 
showing significant statistical evidence for affinity (E-value: 2.5E-05)13,43. 
These were aligned with the PAD_N domain from human PADI paralogues 
and Rhincodon typus (whale shark). The alignment was presented with the 
program Belvu using a colouring scheme indicating the average BLOSUM62 
scores (which are correlated with amino acid conservation) of each alignment 
column: red (>3.5), violet (between 3.5 and 2) and light yellow (between 2 
and 0.5)46. PsiPred47 was used to predict secondary structure for the 
cyanobacterial PAD_N domains (beta sheets). The secondary structure of 
the PAD_N domain of human PADI2 was identified from the crystal structure 
(PDB: 4n2a)48. 
 
2.5.3.3 Synapomorphy of calcium binding sites 
Representative fungal, actinobacterial, cyanobacterial, and metazoan PADI 
sequences were then analysed for the conservation of all of the calcium-
binding sites (a minimum of three residues coordinate each calcium binding 
site) and for other critical residues contained at the active site (Figure 6). 
PADIs from the following species were used: 1) metazoan PADIs from Homo 
sapiens, Xenopus laevis, Oncorhynchus mykiss, Callorhinchus milii, 
Branchiostoma floridae, Priapulus caudatus; 2) cyanobacterial PADIs from 
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Cyanothece sp. 8801, Stanieria cyanosphaera, Chlorogloeopsis fritschii PCC 
6912, Crocosphaera subtropica, Aphanothece sacrum, Cyanothece sp. 
7424; 3) fungal PADIs from Fusarium sp. FOSC 3-a, Periconia 
macrospinosa, Paracoccidioides lutzii, Blastomyces parvus, Ajellomyces 
capsulatus, Emmonsia crescens and; 4) actinobacterial PADIs from 
Streptomyces silvensis, Alteromonas lipolytica, Streptomyces sp. 3214.6, 
Erythrobacter xanthus, Kibdelosporangium aridum, Nocardia brasiliensis 
ATCC 700358. Sequences were aligned using MAFFT L-ins-I and compared 
to functionally annotated regions in Slade et al. 2015 and from crystal 
structures23,48,49. 
 
2.5.3.4 Structural analyses 
Structural homology searches were performed using the Dali server v3.1 with 
the extracted PAD_C domain used as query50. Superposition of known 
structures was performed in Chimera51 using the MatchMaker tool52. Briefly, 
the two structures (PDB: 4n2c and 1xkn) were aligned for the best-aligning 
pair of chains using the Needleman-Wunsch algorithm and BLOSUM62 
matrix. A secondary structure score of 30% was included. The superposition 
was iterated by pruning long atom pairs such that no pair exceeds 2.0 Å.  
 
2.5.4 Divergence time analyses 
2.5.4.1 Estimating PADI divergence time by calibrated phylogenetic 
analysis with metazoan divergence times from the fossil record 
BEAST v2.4.8 was used to produce a time tree of the clade of subsampled 
PADIs from metazoa and the full clade of closest SPM/NX clade 
cyanobacteria contained within the PATRIC database using the GTR model 
with 4 gamma distributed rate categories53-55. The following metazoan 
species were used: Homo sapiens (HS), Mus musculus (MM), Alligator 
mississippiensis (AM), Chelonia mydas (CM), Gallus gallus (GG), Xenopus 
laevis (XL), Oncorhynchus mykiss (OM), Callorhinchus milii (CM), 
Branchiostoma floridae (BF), Priapulus caudatus (PC). Node times were set 




mean 797.0, sigma 72.5 (clade of HS, MM, AM, CM, GG, XL, OM, CM, BF, 
PC); mean 692.5, sigma 57.5 (clade of HS, MM, AM, CM, GG, XL, OM, CM, 
BF); mean 473.5, sigma 14.0 (clade of HS, MM, AM, CM, GG, XL, OM, CM); 
mean 435.0, sigma 6.5 (clade of HS, MM, AM, CM, GG, XL, OM); mean 
311.0, sigma 7.5 (clade of HS, MM, AM, CM, GG); mean 89.5, sigma 3.0 
(clade of HS, MM). Metazoan divergence times from the fossil record were 
obtained from timetree.org with bounds on the distributions chosen to span 
the range of times from the literature centered on the median value56. The 
calibrated Yule model was used as the tree prior. XML files were generated 
in BEAUti and the MCMC analysis was run using BEAST2 on the CIPRES 
Gateway on XSEDE. An initial MCMC run of 5,000,000 chains was run for 
each clock model57,58. Then full analysis was run with two independent runs 
of 10,000,000 chains for the strict clock, uncorrelated lognormal (UCLN) and 
uncorrelated exponentially distributed (UCED) clock models and three 
independent runs of 10,000,000 chains for the random local clocks model. All 
models were additionally run under the tree prior (i.e. in the absence of 
sequence data) and assessed. Analysis of parameters was performed in 
Tracer to assess apparent stationarity for the different tree parameters and 
for acceptable ESS values and congruence was assessed across the 
independent runs. The predicted divergence time of the metazoan and 
cyanobacterial clades was given by the marginal posterior distribution of the 
age of the root of the whole tree. This is given by the TreeHeight parameter. 
The 95% confidence interval of the TreeHeight parameter for all runs under 
each of the clock models did not exceed 1300. These data were plotted as a 
violin plot showing 95% confidence intervals. 
 
2.5.4.2 Accumulated genetic divergence analysis relative to other 
proteins 
Bitscore density is calculated by taking the bitscore of a query sequence to 
the target sequence produced by hmmer and dividing by the bitscore of the 
query sequence to itself (longer sequences have higher bitscores), which 
gives a value between 0 and 118. The bitscore densities of the similarity of 1) 
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the cyanobacterial homologue to the human sequence: ∆bitscoreDCy-Hu 
(AC+AH) and 2) of the branchiostomal homologue to the human sequence: 
∆bitscoreDBr-Hu (XB+XH) were both calculated (Figure 3.9A). A measure of 
the total accumulated genetic divergence between late-diverging 
cyanobacteria (Cyanothece spp.) and the last common ancestor of 
Branchiostoma spp. and Homo sapiens was then calculated by subtracting 
∆bitscoreDBr-Hu from the ∆bitscoreDCy-Hu. This accumulated genetic 
divergence (AGD) value was calculated for (1) 26 ribosomal proteins (uS2, 
uS3, uS4, uS5, uS7, uS8, uS9, uS10, uS11, uS12, uS13, uS17, uS19, uL1, 
uL2, uL3, uL4, uL5, uL6, uL11, uL13, uL14, uL15, uL22, uL23, uL24), (2) 19 
sequences whose proteins are mitochondrially located so are reasonable 
endosymbiont-derived gene transfer candidates (EGT candidates) from the 
mitochondrion (OTC, ASS1, ARLY, CPS1, PGK, ENO, GAPDH, PK, NAXE, 
G6PD, RPIA, FUMH, SDHB, SDHA, CS, MDHM, DLAT, DLDH, ACLY), and 
(3) all 10 proteins still encoded in the mitochondrial genome (MT-ATP6, MT-
CO1, MT-CO2, MT-CO3, MT-CYB, MT-1, MT-2, MT-3, MT-4, MT-5)59. It is 
notable that by definition, only very highly conserved proteins have an AGD 
that can be calculated in this extreme example between the last common 
ancestor of late diverging cyanobacteria and humans: if a protein has 
diverged substantially then the similarity of the human homologue to the 
cyanobacterial will not be discernible and no bitscore can be calculated. AGD 
values of proteins in each category were then tested for deviation from a 
normal distribution using the Shapiro Wilk test (W = b2 ⁄ SS)60. As the 
calculated p value > 0.05, the null hypothesis was retained and the data 
treated as being normally distributed. Kurtosis and skew were also within the 
range of the normal distribution. The AGD for PADI proteins (AGDPADI proteins = 
0.066) was then compared to the mean AGD of each category of control 








2.5.4.3 Extent of evolution analysis with DNA sequences 
Nucleotide sequences for rRNA were obtained from the SILVA database61. 
Nucleotide sequences for PADIs were obtained from NCBI and exons 
extracted. Comparisons were made with EMBOSS Needle using the 
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Chapter 3: The evolutionary origin of the peptidyl arginine deiminases 
 
3.1.1 Introduction 
The evolutionary provenance of the peptidyl arginine deiminase family of 
enzymes remains unresolved. Paralogues of the peptidyl arginine 
deiminases appear in bony fish, birds, reptiles, amphibians and mammals, 
but are missing from many eukaryotes including plants, yeast, and insects. 
The PADI gene is therefore widely thought to have appeared first in the last 
common ancestor of teleosteans and mammals1-4. Crystal structures hint at a 
possibly more ancient origin as they reveal that the catalytic domain adopts 
the same pentein fold as a variety of other widely distributed proteins that 
otherwise show little similarity in terms of amino acid conservation5,6. These 
proteins include a broad family of guanidino-group (the functional group of 
the side chain of arginine and agmatine) modifying enzymes with hydrolase, 
dihydrolase and amidinotransferase catalytic activity. The pentein fold 
containing enzymes share a broad catalytic core of a Cys, His and two polar 
guanidine binding residues – Asp or Glu6. These residues are arranged 
within an α/β propeller fold possessing characteristic fivefold rotational 
pseudosymmetry5,6. 
 
PADIs comprise three protein domains in total (PAD_N, PAD_M and PAD_C) 
and bind up to six calcium ions (4 in the PAD_M, and 2 in the PAD_C), which 
allosterically regulate the catalytic domain (PAD_C) of the enzyme7,8. The 
PAD_M domain consists of a DNA binding p53-like immunoglobulin (Ig) type 
fold, while the PAD_N domain is a cupredoxin-like fold that has lost metal 
binding residues. Mammalian genomes encode two of the possible ancient 
homologues of PADIs’ catalytic PAD_C domain (N(G),N(G)-dimethylarginine 
dimethylaminohydrolase [DDAH] and Glycine amidinotransferase [AGAT]), 
but their possibly homologous domains are very divergent in sequence 
identity and catalyse different reactions. DDAH and AGAT also lack the N-
terminal and middle domains (PAD_N and PAD_M, respectively). Two other 




(pPAD, gADI).  These also possess catalytic domains with a pentein fold, 
which are distinct from the PAD_C domain. These two enzymes also lack the 
N-terminal and middle domains (PAD_N, PAD_M), are very sequence 
divergent, and have different substrate specificity9,10. The citrullinating 
enzyme, pPAD, found in Porphyrmonas gingivalis, shows close affinity to the 
catalytic domain of bacterial and eukaryotic Agmatine deiminases (AgD), 
while the second, gADI, found in Giardia lamblia shows close affinity to free 
L-arginine deiminases (ADI). Interestingly, both of these citrullinating 
enzymes are extended variants of AgD and ADI proteins where an additional 
Ig-like domain is connected to the AgD or ADI core, analogously to PADIs 
which possess an Ig-like PAD_M domain. However, neither the Ig domains in 
porphyrmonas-type PAD or Giardia lamblia ADI show any affinity to the 
PAD_M Ig-like domain using profile-to-profile searches11 or using the Dali 
server12, and crystal structures of pPAD do not reveal any structural 
homology with the Ig-like PAD_M domain found in the PADIs either13. The 
activity of free arginine deiminases or agmatine deiminases (or truncated 
forms of pPAD or gADI) on protein substrates has not been systematically 
tested to date so it is not known whether the Ig-like extension is responsible 
for conferring citrullinating activity. Given that Ig domains are widely 
distributed, it would not be surprising, however, for an Ig-like extension to 
confer activity to protein substrates by convergent evolution in tandem with a 
pentein fold containing catalytic domain as for the vertebrate PADIs13. In 
either case, it is unlikely that these other citrullinating enzymes clarify the 
evolutionary provenance of the vertebrate peptidyl arginine deiminases. 
 
Lateral or horizontal gene transfer (HGT) is the non-ancestral inheritance of 
genetic information14,15. Outside of the established endosymbiont transfer of 
mitochondrial genes to the nuclear genome and virus-mediated transfer, 
evidence as to whether individual xenologous genes with recent or ancient 
horizontal origin persist in the human genome is contentious16-21. In the 
original draft of the human genome, many xenologous gene candidates were 
proposed, but this analysis was later rebutted in a string of subsequent 
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papers17,22-28. In 2015, over a decade later, a second list of 145 possible HGT 
candidates persisting in the human genome was proposed by Crisp et al. by 
a similar method on the basis that a possible homologue could be identified 
in bacteria but not in multiple Drosophila and Caenorhabditis species 
(Additional file 3, Genome Biol. 2015)18. This list included the five human 
PADI genes. Although the authors acknowledge that conventional vertical 
descent could also explain this pattern, they argue that HGT is more 
parsimonious than the many independent gene losses required. Recently, 
however, this genome-wide approach to search for possible HGT events in 
vertebrates was once again disputed (Salzberg, Genome Biol. 2017)20, and 
45 of the highest confidence candidates were reanalyzed and rebutted on a 
case-by-case basis. In the instance of the PADI gene, this reanalysis showed 
that a PADI can also be identified in Priapulus caudatus (a marine worm) and 
therefore that the lack of PADI in at least Drosophila spp. must be explained 
by gene loss20. Salzberg additionally recalculates the HGT index used by 
Crisp et al. for many of the possible HGT candidates, including the PADIs, in 
light of additional sequences that can be identified. This shows that they no 
longer pass the original parametric criterion for HGT (which was put forward 
previously by a subset of the authors in Crisp et al.)18,20,21,29. While writing, a 
recent report was also published on the biochemical activity of a possible 
PAD-like enzyme in some species of fungi30. 
 
The evolutionary origin of vertebrate PADIs and, therefore, of the introduction 
of citrullination into the human lineage remain enigmatic. As a result, PADIs 
merit detailed individual consideration; in particular to identify all bone fide 
PADI homologues across life, and to consider the proposal that PADIs were 
horizontally transferred into the vertebrate lineage18,20. It was also hoped this 
might provide insight as to the regulation of the mammalian PADI enzymes in 








• Elucidate the evolutionary origin of the mammalian PADI family. 
• Consider in detail the contested possibility of HGT into the vertebrate 
lineage against vertical descent. 
• Test activity and calcium dependence of cyanobacterial PADI. 
 
3.2.1 Identifying orthologous PADIs 
I began by collecting all PADI orthologues across life. To do this, all 
sequences across cellular life in current sequence databases were obtained 
that contain a PAD_C domain, as defined by having significant sequence 
similarity using searches with HMMER. This was supplemented by iterative 
jackhmmer searches and Position-Specific Iterated BLAST (PSI-BLAST) 
searches as well as tblastn searches of genomic databases. This extended 
the analysis from Salzberg showing that the earliest diverging animals with a 
PADI (that have been sequenced to date) are Branchiostoma belcheri (a 
cephalochordate), Saccoglossus kowalevskii (a hemichordate) and Priapulus 
caudatus (a marine worm)20. Unexpectedly, a large number of related PADI 
sequences were also identified, not only in bacteria, but also in fungi. This 
confirms the recent report of biochemical PAD activity in Aspergillus spp.30. 
These proteins possess fully conserved catalytic residues, well-conserved 
calcium-binding residues and well-conserved substrate binding residues 
annotated from the mammalian PADIs; they are therefore likely to be bona 
fide PADI enzymes (details in Figure 3.6). To quantify this distribution and 
assess the number of species with a missing PADI, the table in Figure 3.1A 
was prepared showing the proportion of species that retain a PADI 
orthologue out of all sequences contained in Reference Proteomes or 
UniProtKB. A second approach using the EggNOG database was also used 
to collect putative PADIs that it identified as being orthologous, by making 
use of an unsupervised clustering algorithm of all proteins contained in 2031 
genomes across cellular life31. Figure 3.1B shows an initial phylogenetic tree 
of all identified PADI orthologs from the EggNOG database. As described 
previously18,20, PADIs are not ubiquitous across the metazoa, instead being 
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most prevalent across vertebrates and present also in Priapulus caudatus 
(Figure 3.1A). PADIs are also not ubiquitous across bacteria, with 
cyanobacteria most frequently containing a PADI homologue. None of the 




Figure 3.1: Taxon sampling of putative PADI orthologues. A: Table showing the number 
of species possessing a sequence with significant sequence similarity (E value < 1x10-3) 
using HMMER searches to the PAD_C domain of vertebrate PADIs from the UniProtKB 
database B: Phylogenetic tree of PADI orthologs identified using EggNOG4.5 showing 
metazoan sequences (183) and fungal sequences (21) each collapsed into a single clade 
respectively (Section 2.5.1). 
 
An unrooted maximum likelihood phylogenetic tree was then made with an 
alignment of PADI, ADI, and AgD sequences that included the sequences of 
the citrullinating enzymes in Porphyrmonas gingivalis (pPAD) and Giardia 
Lamblia (gADI) as well as sequences most similar to these citrullinating 
enzyme variants from HMMER searches. PADIs form a single monophyletic 
clade: each of the types (PADI, ADI, AgD types) appears to be evolutionarily 
distinct because they form clear outgroups (Figure 3.2). This is consistent 
with the annotation in Pfam that pPAD contains an Agmatine deiminase type 
catalytic domain whereas gADI contains a free arginine deiminase catalytic 
domain, clearly distinct from the bacterial and fungal PADIs which possess 
the metazoan PAD_C catalytic domain. This means that a consideration of 
PADI evolution can be restricted to the previously described animal 






Figure 3.2: PADIs are distinct from ADIs, AgDs, gADI (arginine deiminase from Giardia 
lamblia) and pPAD (porphyromonas-type peptidylarginine deiminase from 
Porphyromonas gingivalis) sequences. The pPAD sequence from Porphyromonas 
gingivalis was searched against UniProtKB using HMMER to obtain 8 sequences with 
highest affinity. The gADI sequence from Giardia lamblia was similarly searched against 
UniProtKB using HMMER.15 sequences with high levels of similarity were obtained. These 
were aligned with 25 PADI sequences subsampled from different domains of life using 
MAFFT L-ins-I and singly aligning columns were removed. IQTree was used to produce a 
maximum likelihood phylogenetic tree using the LG empirical rate matrix with 8 categories of 
rate variation under the FreeRate model (LG +R8) as determined by ModelFinder. Ultrafast 
Bootstrap 2 with 1000 replicates, SH-like aLRT with 1000 replicates and aBayes parametric 
tests were used to assess node support (). The tree is shown unrooted with solid circles 




This phyletic distribution is consistent with an evolutionary model in which 
PADI genes are products of vertical evolution but were lost independently in 
many separate lineages20. In this scenario, gene loss would need to have 
occurred in all early-branching lineages leading to at least 306 non-
opisthokont eukaryotes and in other lineages, for example those leading to 
Drosophila and Caenorhabditis. 
 
3.2.2 Phylogenetic analysis of PADI orthologues 
To resolve patterns of gene loss and gain across the tree of life, detailed 
phylogenetic analysis of PADI sequences was undertaken. Firstly, a large 
number of PADI orthologue sequences were aligned and a maximum 
likelihood approach was used to produce an initial phylogenetic tree. Very 
strong bootstrap support (>95%) was obtained for a clade restricted to 
cyanobacterial and animal PADIs, which excludes a fully supported outgroup 
clade containing fungal, actinobacterial and proteobacterial sequences 
(Figure 3.3). Full node support placed fungal PADIs in a clade with 
actinobacterial sequences. This tree topology was surprising as it is 
inconsistent with the known species tree: animal sequences have closer 





Figure 3.3: Phylogenetic analysis of putative PADIs. All putative bacterial PADI 
sequences in the PATRIC database were obtained. In addition, sequences from metazoa 
were subsampled to maximize the inclusion of different lineages. The human PADI2 
sequence was searched against UniProtKB to subsample 35 fungal sequences representing 
the broadest distribution of HMMER affinity. Sequences were then aligned using MAFFT L-
ins-I and singly aligning columns were removed. IQTree was used to produce a maximum 
likelihood phylogenetic tree using the WAG empirical rate matrix with 10 categories of rate 
variation under the FreeRate model with base frequencies counted from the alignment 
(WAG +R10 +F) as determined by ModelFinder. Ultrafast Bootstrap 2 with 1000 replicates, 
SH-like aLRT with 1000 replicates and aBayes parametric tests were used to assess node 
support. The tree is shown rooted at the midpoint with solid circles indicating consensus 
node support of >95% and a number of critical nodes labelled in full. Full methods are in 
Section 2.5.2.2. 
 
Phylogenetic methods, in particular single gene phylogenetic trees, are not 
infallible. As such the topology may simply represent the failure of 
phylogenetic inference in the case of this individual gene, such that an 
artifact, such as model misspecification, might explain the affinity of the 
separate eukaryotic PADIs to different bacterial PADI types. This might be 
indicated for example by low bootstrap values or a changing tree topology 
under different models of rate variation. A common approach for an initial 
maximum likelihood analysis uses a best-fitting fixed rate matrix of amino 
acid substitution rates (derived empirically from large datasets of proteins) to 
produce the tree32-34. This could be potentially confounded if there is 
evolutionary rate variation over different parts of the tree or deviation from 
typical protein substitution rates. In particular, attention has been drawn in 
the literature to heterotachous evolution where the evolutionary substitution 
rate of a given site may change over time, and also to covarion evolution 
where rate changes over time in one site may be dependent on the rate 
changes at other sites in a protein35. Long-branch attraction, the most 
famous confounding effect on phylogenetic tree topologies, is a special 
example of heterotachy in which fast evolving branches that may be 
unrelated erroneously branch together in a tree topology36. The corollary 




evolution37. Heterotachy might be particularly plausible in the PADI example 
given the very divergent species with orthologues under analysis (animal, 
fungal, cyanobacterial).  
 
To validate the tree topology, and informed by the large tree, PADI 
sequences with decreasing HMMER bitscore similarity to a profile from 
metazoan PADIs were therefore subsampled to cover a broad representation 
of homologue sequences for more computationally expensive phylogenetic 
analyses. Three approaches were used to address possible heterotachous 
effects: a Bayesian approach with MCMC model jumping that enables the 
MCMC process to sample over various different fixed empirical rate 
matrices38, a maximum likelihood approach using a mixture model of 20 
different fixed amino acid rate matrices (C20)39, and a Bayesian approach 
that allows for infinite mixture model categories by making use of a Dirichlet 
process prior (CAT-Poisson and CAT-GTR)40. These methods have been 
shown to be more robust to long-branch artifacts and more broadly to 
saturated sequence artifacts due to the more sophisticated treatment of 
across-site rate heterogeneity36,41-43.  
 
Figure 3.4: Subsampled phylogenetic analysis with different evolutionary rate models. 
A: Bayesian phylogenetic inference using MrBayes with mixed model jumping across 
different fixed empirical rate matrices (predominantly sampling across the WAG model); B: 
Maximum likelihood inference using IQTree with ModelFinder with the best performing fixed 
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empirical rate matrix (WAG + R5 +F0); C: Maximum likelihood inference using IQTree with 
the C20 mixture model of rate matrices; and D: a Bayesian phylogenetic inference using the 
CAT-GTR model with an infinite mixture model of rate matrices by using a Dirichlet process 
prior. Tree topologies were congruent across the different rate matrix models. Ultrafast 
boostrap 2 values over 1000 replicates (for the Maximum likelihood methods) or posterior 
probabilities (for the Bayesian methods) are presented in the table for the nodes labelled in 
the tree. Full methods are in Section 2.5.2.3. 
 
In all of the analyses, only a single topology was recovered that supports a 
clade of cyanobacterial and animal sequences to the exclusion of a clade of 
fungal and actinobacterial sequences (Figure 3.4). Posterior probabilities or 
bootstrap values for this topology were high, approaching 100% for each of 
the four diverse methods (Ai, Aii: Figure 3.4). The analysis was also repeated 
using other bootstrap algorithms including the full non-parametric bootstrap, 
again obtaining full support44,45. Topology constraint tests rejected a number 
of randomly generated trees to rule out possible specific biases in bootstrap 
resampling. Lastly, a constrained tree for the expected model of vertical 
evolution was generated where eukaryote PADIs were restricted to a 
monophyletic group. As expected from the degree of node support in the 
original trees, these alternative trees and constraint tree were all significantly 
rejected (p<0.0001) by multiple statistical tests (Section 2.5.2.3)46-48.  
 
3.2.3 Protein domain analysis of PADI orthologues 
An analysis was then undertaken to assess how the PADI protein domain 
architecture is distributed across orthologues. This was firstly done using 
Pfam annotations, which are powered by HMMER searches49 and can be 
found online. All metazoan PADIs possess three Pfam domains, annotated in 
Pfam as PAD_N, PAD_M and PAD_C domains. The closest cyanobacterial 
PADIs appear to possess two Pfam domains, a mammalian PAD_M domain 
and a PAD_C domain, but do not possess the PAD_N domain. More distant 
cyanobacterial PADI sequences and other bacterial and fungal PADIs, by 






Figure 3.5: Domain architecture analysis of PADI orthologues. A and B: Phylogenetic 
analyses from Figure 3.4 were repeated using an alignment with the PAD_N domain 
removed (middle row), and with an alignment in which both the PAD_N domain and regions 
of synapomorphy were removed (A, bottom row). Maximum likelihood inference using 
IQTree was used in all three cases and ModelFinder was used to select the best performing 
fixed empirical rate matrix (WAG + R5 +F0). Topologies were congruent with analysis of the 
whole alignment (top row) so the node support values (Ultrafast Bootstrap 2) for the clades 
labelled in Figure 3.4 have been provided in the table for the trees produced using the 
truncated alignments. A (right hand panel): The region aligning to the metazoan domains 
was extracted from sequences belonging to the clades (firstly of cyanobacterial sequences, 
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and secondly of a mixture of bacterial and fungal sequences) that had been used for 
phylogenetic analysis. An HMM profile was made and searched with HHPred against a 
database of profiles made of the entire human proteome, and against a database of profiles 
of Pfam domains. The E values are given for these searches where significant sequence 
similarity could be identified from HHPred searches. C: Putative PAD_N domains from 
SPM/NX clade cyanobacterial PADI sequences were identified using HHPred showing 
significant statistical evidence for affinity (A). These were aligned with the PAD_N domain 
from human PADI paralogues and Rhincodon typus (whale shark). The alignment was 
presented with the program Belvu using a colouring scheme indicating the average 
BLOSUM62 scores (which are correlated with amino acid conservation) of each alignment 
column: red (>3.5), violet (between 3.5 and 2) and light yellow (between 2 and 0.5). Peach 
arrows shown below the cyanobacterial sequences indicate PsiPred predicted secondary 
structure (beta sheets). Green arrows (beta sheets) correspond to the known secondary 
structure of the PAD_N domain of human PADI2 as identified from the crystal structure 
(PDB: 4n2a). Figure in 3.5C was prepared with Dr Luis Sanchez-Pulido, who also assisted 
with HHPred analysis. 
 
Manual inspection revealed possibly significant alignment in the N-terminus 
of the bacterial and fungal sequences with animal PADIs. Consequently, 
more sensitive profile-to-profile HMM searches11 were used to explore this 
and to identify domains that might have been overlooked by Pfam. A multiple 
sequence alignment was made firstly of cyanobacterial species contained in 
the monophyletic clade of metazoan sequences (Figure 3.5A, sequences 
coloured in dark blue), and secondly of the remaining bacterial and fungal 
sequences (Figure 3.5A, sequences coloured in black, orange and pink). By 
comparing the alignment with crystal structures of human PADI2 and PADI4, 
regions corresponding to each of the three Pfam domains were extracted 
and used as a seed for HHPred searches against a database of profiles of 
the human proteome and a database of profiles of all domains contained in 
Pfam. These results revealed that the outgroup bacterial and fungal 
sequences additionally possess a more divergent version of the PAD_M 
domain, but no PAD_N domain – the PAD_N region is completely absent in 
those bacterial and fungal orthologues. The closest cyanobacterial 
homologues, by contrast, possess both a PAD_M domain (with much closer 




PAD_N cupredoxin type domain. Although not identifiable by HMMER, this 
was identified as significantly sequence similar using HHPred (E value<1x10-
7) (Figure 3.5A, right panel). With Dr Luis Sanchez-Pulido, PsiPred was then 
used to predict the secondary structure of the PAD_N domain from three-
domain cyanobacterial sequences50. With Dr Luis Sanchez-Pulido, a multiple 
sequence alignment of the cyanobacterial PAD_N region with the metazoan 
PAD_N was prepared using Belvu51 (Figure 3.5C). This shows that the 
secondary structure of the cyanobacterial PAD_N domain predicted using 
PsiPred aligns well with the experimentally determined secondary structure 
of the human PAD_N domain from PADI2 derived from X ray crystal 
structure data (Figure 3.5C). 
 
A synapomorphy is a character or sequence feature, different from that of an 
ancestor, which distinguishes members of a monophyletic clade from other 
organisms in different clades. In this instance, late-diverging cyanobacterial 
and animal PADIs share a synapomorphic protein domain (PAD_N) that is 
absent from earlier diverging cyanobacterial, other bacterial and fungal 
sequences. Taken on its own, this is a very surprising result as it indicates 
cyanobacterial and metazoan PADIs comprise a monophyletic group to the 
exclusion of fungal and bacterial sequences. This evidence corroborates the 
topology derived from phylogenetic analysis. Phylogenetic analyses were 
then repeated on a multiple sequence alignment where the PAD_N domain 
was removed. The same topology was recovered with high bootstrap values 
showing that the two lines of evidence (phylogenetic and PAD_N domain 
analysis) are independent from each other (Figure 3.5B). 
 
3.2.4 PADI orthologue protein features and synapomorphy 
In light of the above findings using the PAD_N domain, a similar analysis was 
undertaken to analyse calcium-binding residues and other annotated 
functional features of the mammalian PADI sequence for their conservation 
and distribution in bacterial and fungal orthologues. PADIs require very high 
calcium concentrations for catalytic activity in vitro, and even single point 
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mutants of calcium binding residues can abolish activity7,8. At high calcium 
concentrations the catalytic nucleophilic cysteine residue moves as much as 
5-12 Å into its catalytically competent conformation. The allosteric binding of 
up to six calcium ions (five in PADI4) thereby allows formation of the active 
site cleft and is required for catalytic activity. In detailed analysis of PADI2, 
crystal structures were solved at eight different calcium concentrations8. This, 
together with important earlier work on PADI47, revealed an exquisite mode 
of allosteric regulation by sequential calcium ion binding. At low calcium 
concentrations, high affinity calcium site 6 in the PAD_M domain (specific to 
PADI2, not conserved in PADI4) and 1 in the PAD_C domain retain calcium 
binding, but all other calcium sites remain uncoordinated. Operating as a 
“calcium switch”, binding sites 3-5, located within residues 153-179 in the 
PAD_M domain, show sequential binding of calcium (3 and 5, then 4) at 
increasing calcium concentrations. Of these, calcium site 4 derives one 
conserved binding residue from the PAD_C domain (D389), distant from its 
other coordinating residues in linear sequence. This is used to explain how 
the binding sites in the PAD_M domain can communicate allosterically with 
the distant PAD_C domain. Finally, calcium-binding site 2, also located in the 
PAD_C domain and adjacent in linear sequence to a loop that contains D389 
from Ca site 4, becomes occupied only at the highest calcium concentrations 
(10 mM) in the fully active holo-conformation (fully calcium occupied 
structure) of human PADI2. A similar full occupancy was observed in the 
earlier crystal structure of calcium saturated human PADI4. The final calcium 
binding (Ca2), in particular, stabilises the catalytically competent 
conformation, which results in a fully structured active site cleft.  In the 
catalytic conformation, the nucleophilic cysteine moves ~5 Å as compared to 
the low calcium enzyme conformation. Representative fungal, 
actinobacterial, cyanobacterial, and metazoan PADI sequences were then 
analysed for the conservation of all of the calcium-binding sites (a minimum 
of three residues coordinate each calcium binding site) and for other critical 





All catalytic residues and substrate binding residues are fully conserved 
among all PADI homologues (Figure 3.6). In addition, calcium-binding sites 3 
and 1 appear to be fully conserved, while calcium site 5 is likely to be mostly 
conserved as well. Functionally, Ca6 is likely to be conserved as the 
substitution of D125 to N and E131 to D, which is present in both 
actinobacterial and fungal sequences, is likely to preserve ion binding. 
Intriguingly, however, calcium sites 2 and 4 appear to be conserved only in 
cyanobacterial and metazoan sequences. The fungal and actinobacterial 
sequences diverge from binding sites 2 and 4 to a different amino acid motif 
in common between these other bacterial and fungal homologues, which 
may or may not retain the calcium coordinating function. Critically, only 
cyanobacterial and animal sequences conserve the calcium switch residue 
D389 (residues: 369-389) (substituted to Gly in both actinobacterial and 
fungal sequences, and therefore chemically inequivalent and incompetent for 
metal coordination). This indicates that the ordered, sequential calcium 
binding in the PAD_M domain that is responsible for the allosteric 
communication with the catalytic PAD_C domain in human PADI28 is likely 
only to be conserved in cyanobacterial and metazoan PADIs. As a result, a 
potentially different mode of calcium regulation operates in the fungal and 





Figure 3.6: Analysis of synapomorphic regions. Six PADI sequences from each of 
metazoa, cyanobacteria, actinobacteria and fungi were aligned using MAFFT L-ins-I. 
Consensus sites across the six species or sites shared across two amino acids are shown 
with standard single letter amino acid abbreviations. In the absence of consensus 
conservation to one or two amino acids across the species, the site is shown as “nc”. 
Numbering is given above the alignment and corresponds to the ungapped site of human 
PADI2 so that residues can be compared to Slade et al.8. Sites showing conservation across 
all four domains are coloured in green, sites showing synapomorphy between metazoa and 
cyanobacteria are coloured in purple, and sites showing synapomorphy between fungi and 
actinobacteria are coloured in yellow. A figure of the crystal structure of PADI2 from Homo 
sapiens is also presented with PAD_N domain coloured in black, PAD_M domain in grey 
and PAD_C domain in white. Synapomorphic regions are coloured in cyan and calcium ions 
are shown as yellow spheres. Methods are in Section 2.5.3.3. 
 
Looking in close detail at regions specific to the outgroup sequences 
revealed that fungal and actinobacterial sequences additionally share 
features that are not present in the metazoan and cyanobacterial PADIs. This 
includes a conserved region within calcium binding site 3-5 that is absent 
from the metazoan and cyanobacterial sequences (Figure 3.6: amino acids 




sequences are highlighted in yellow). Also of interest is a highly conserved 
10 amino acid beta sheet that connects the PAD_M and PAD_C domains 
and which is conserved in full in the cyanobacterial and metazoan sequences 
(Figure 3.6: amino acids 292-302). In fungal and actinobacterial sequences 
the region is also conserved closely, but to a different 10 amino acid 
sequence containing a distinctive triple histidine motif (Figure 3.6, amino 
acids 300-302). 
 
This analysis therefore reveals features shared between cyanobacterial and 
animal sequences that differ or are absent from fungal and bacterial 
outgroups. It additionally reveals features shared only between fungal and 
actinobacterial sequences and missing from metazoan and cyanobacterial 
PADIs. The topology of phylogenies built either with or without these 
synapomorphic sequence features was congruent (Figure 3.5B), indicating 
that the synapomorphies represent independent additional support for the 
closer affinity of vertebrate and cyanobacterial PADIs than to their other 
homologues, just as for the analysis using the PAD_N domain. As these 
occur at the level of the amino acid sequence and at the level of a protein 
domain, they are robust to convergent evolution52 and to differences in rate 
variation across the tree, and therefore provide strong support of the 
phylogenetic topology (Figure 3.3). It is implausible that these blocks of 
sequence of up to ten amino acids were derived by chance, independently, in 
actinobacterial and fungal PADIs and thereby act as synopomorphic motifs 
as they imply common ancestry to actinobacterial and fungal PADIs that is 
distinct from the ancestry of cyanobacterial and metazoan PADIs. 
 
3.2.5 Molecular clock analysis and divergence time analysis 
Evidence presented thus far can be reconciled with evolutionary vertical 
descent if the last universal common ancestor (LUCA), which lived at least 
3.35 billion years ago53, harboured two paralogous PADI genes which then, 
as they were transmitted to bacterial, archaeal and eukaryotic lineages, were 
largely deleted except for vertebrate, fungal, actinobacterial and 
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cyanobacterial lineages in which one, but never both, were retained. In this 
hypothetical scenario, there are two large gaps where PADI paralogues are 
missing from modern genomes and must have been independently lost 
twice. Firstly, a missing PADI of the three-domain cyanobacterial/metazoan 
type was lost from lineages leading to every other species in life. Secondly a 
missing two-domain PADI of the fungal/actinobacterial type must be 
separately accounted for in independent gene losses in lineages leading to 
all other species except for those fungi and bacteria that maintain it (Figure 
3.1A).  
 
Evidence for this highly unparsimonious model of vertical descent would be 
rates of PADI sequence evolution, bridging the gaps in the species 
phylogeny where PADI orthologues are missing, that do not appear to be 
anachronistic either with respect to (1) geologically defined timings, or (2) 
other genes that are known to have been acquired vertically from the LUCA. 
By contrast, strong additional evidence for horizontal gene transfer would be 
anomalously slow rates of PADI sequence evolution across species bridging 
the hypothesized gap. It is worth noting that PADI sequence evolution could 
be much faster than other genes and still be consistent with vertical 
evolution, since rates of evolution can vary extensively in different lineages. 
The inconsistency, manifesting as evidence for likely horizontal transfer, 
would be rates that are much slower than an established minimum amount 
(determined either by geological or relative timings). 
 
Tree topology places the first gap as occurring between closest 
cyanobacterial PADI homologues and PADIs in the earliest diverging 
metazoa (Figure 3.3). Analysing these orthologues in isolation, a 
phylogenetic tree was made using all cyanobacterial PADI sequences with a 
representative set of metazoan PADIs (Figure 3.7). Known cyanobacterial 
clades derived from the latest multi-gene predictions of cyanobacterial 
species trees were used to annotate the PADI paralogue tree. Notably, the 




cyanobacterial clades. The closest ancestral PADI homologues to the 
metazoan sequences are found in two clades of late-diverging cyanobacterial 
species: the NX clade (containing Nostocales sensu lato + others) and the 
SPM clade (containing Synechocystis + Pleurocapsa + Microcystis)54. 
Subsequently, rates of PADI evolution were analysed using PADI genomic 
sequences from these NX and SPM cyanobacterial clades and from 
metazoa. These were obtained from the PATRIC database.  
 
 
Figure 3.7: Phylogenetic analysis of metazoan and cyanobacterial PADIs. All putative 
PADIs from cyanobacteria were aligned with a subsampled set of metazoan sequences 
using MAFFT L-ins-I and singly aligning columns were removed. IQTree was used to 
produce a maximum likelihood phylogenetic tree using the WAG empirical rate matrix with 5 
categories of rate variation under the FreeRate model (LG +R8) with base frequencies 
counted from the alignment as determined by ModelFinder. Ultrafast Bootstrap 2 with 1000 
replicates, SH-like aLRT with 1000 replicates and aBayes parametric tests were used to 
assess node support. The tree is shown unrooted with Ultrafast Bootstrap 2 node support 
labelled on the tree. Colours and names of clades are used as in Uyeda et al. 201654. 
Species that were not analysed in Uyeda et al. 2016 are coloured in cyan and metazoan 




Firstly, analysing the clade of cyanobacterial and animal PADI sequences 
using a Bayesian phylogenetic approach allowed their divergence time to be 
predicted using known fossil ages of metazoans55-57 as calibrations under a 
strict molecular clock model (Section 2.5.4.1). This yielded an estimate of 
approximately 1 billion years (Figure 3.8) for the age of their last common 
ancestor, far younger than the 3.35-4.52 billion years known to separate 
bacteria and eukarya (Figure 3.8)53. Divergence times of vertebrate and 
cyanobacterial PADIs were then estimated using several relaxed clock 
models (UCLN, UCED, random local clocks)57 (Figure 3.8B). These relaxed 
clocks increased the uncertainty in the estimate but, in all three cases, 
estimated an even more recent mean divergence time. Under all 
approaches, the divergence times were not congruent with the geologically-
defined divergence (p < 10-8) (Figure 3.8B). These divergence time estimates 
are instead consistent with a horizontal acquisition more recently than that of 
the mitochondria and are approximately dated to the divergence time of the 





Figure 3.8: Estimated divergence time of cyanobacteria and metazoa based on PADI 
sequences with respect to geologically defined constraints from the fossil record. A: 
Metazoan sequences and SPM/NX clade of cyanobacterial sequences taken from the 
PATRIC database are used for Bayesian phylogenetic analysis. Bayesian phylogenetic 
analysis was performed using BEAST under the uncorrelated lognormal (UCLN) clock model 
using a calibrated Yule model as the tree prior (Chapter 2.5.4). Divergence times from the 
fossil record are used as normally distributed priors for six different nodes from metazoa. 
The marginal posterior distribution of the age of the root of the whole tree is used to estimate 
the divergence time; all nodes are labelled with the 95% credible interval for the marginal 
posterior distributions of the node ages. B: Estimated divergence times for running the 
analysis under different clock models (strict clock, random local clocks, UCLN and UCED), 
with the marginal posterior distribution of the age of the root of the whole tree given as a 




Secondly, analysing a large number of the most conserved proteins in life 
(ribosomal proteins, essential metabolic enzymes, chaperones), taken from 
species that bridge the closest PADI homologues (in cyanobacteria and in 
metazoa), approximates a mean minimum extent (the difference in units of 
bitscore density) of accumulated genetic divergence occurring in both 
lineages over this time scale. To do this analysis, the bitscore density of the 
similarity of the cyanobacterial homologue to the human sequence 
∆bitscoreCy-Hu (AC+AH) and the bitscore density of the similarity of the 
branchiostomal homologue to the human sequence ∆bitscoreBr-Hu (XB+XH) 
were calculated (Figure 3.9A). A measure of the total accumulated genetic 
divergence between late-diverging cyanobacteria (Cyanothece spp.) and the 
last common ancestor of Branchiostoma spp. and Homo sapiens was 
calculated by subtracting ∆bitscoreBr-Hu from the ∆bitscoreCy-Hu, as illustrated 
in Figure 3.9A. This was performed on 26 highly conserved proteins and the 
mean was calculated (Figure 3.9B). The distribution of calculated 
accumulated genetic divergence for these different highly conserved proteins 
did not deviate significantly from a normal distribution (Shapiro-Wilk test). As 
a positive control for the hypothesized horizontal trajectory in Figure 3.9A, I 
then analysed proteins of likely endosymbiont gene transfer (EGT) origin (19 
sequences) as well as proteins encoded in the mitochondrial genomes (10 
sequences). A full list of analysed proteins is provided in Section 2.5.4.2. 
Since mitochondrial and EGT-derived proteins were acquired more recently 
than the LUCA, the mean of the total accumulated sequence change for 
each protein is expected to be much lower than that for vertically transferred 
genes (Figure 3.9A). It was therefore hypothesized that they may mimic more 
closely the extent of accumulated genetic divergence that would be expected 
for an anciently horizontally transferred gene (such as is hypothesized for the 
PADI gene). As expected, EGT and mitochondrially encoded proteins have 
an average accumulated genetic divergence which is significantly lower than 
that of vertically acquired proteins (Figure 3.9B). Results plotted in Figure 
3.9B and 3.9C revealed that the total accumulated genetic divergence for 




standard deviations below that calculated for vertically transferred protein 
sequences. PADIs show less sequence change than all proteins individually 
analysed over this timescale and less even than ribosomal RNA (Section 
2.5.4.3).  Indeed, they fall 2 standard deviations even below the mean of 
EGT candidate genes or the mean of genes derived from the mitochondrial 
genome (Figure 3.9B and C). In a model of vertical descent, PADIs would 
therefore be under greater constraint than any sequence known in life58. 
 
 
Figure 3.9: Analysis of the Accumulated Genetic Divergence of PADIs compared to 
very well conserved proteins. A: Schematic of how the Accumulated Genetic Divergence 
(AGD) of a given protein between its homologues in Homo sapiens, Branchiostoma spp. and 
Cyanothece spp. is calculated. The bitscore density of the similarity of the cyanobacterial 
homologue to the human sequence ∆bitscoreCy-Hu (AC+AH) and the bitscore density of the 
similarity of the branchiostomal homologue to the human sequence ∆bitscoreBr-Hu (XB+XH) 
are calculated. In a vertical scenario the AGD, given by (AC+AX) – XB, will be much greater 
than zero. In a horizontal scenario, (ZC+YX) may be approximately equal to XB and so the 
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AGD, given by (ZC + YX) – XB may be close to zero. B: The AGD was calculated for 26 
vertically transferred proteins, 19 candidate EGT proteins, and 10 proteins encoded in the 
mitochondrial genome and the mean was calculated and plotted against the AGD for PADI 
proteins. C: The difference in bitscore density between mitochondrial protein sequences 
from various species and their human counterpart was calculated and plotted against the 
age of the last common ancestor for each pair (human and mouse, human and fish, human 
and branchiostoma, human and cyanobacteria). This was similarly calculated for PADIs from 
the same species pairs and plotted on the same graph. 
 
To contextualize these data, in absolute terms, the similarity of 
cyanobacterial and branchiostomal PADIs to human PADIs is almost 
identical: 70.20% vs 70.90% respectively by pairwise amino acid similarity to 
the human sequence. In a model of vertical evolution, however, a much 
greater amount of time has elapsed since the cyanobacterial and human 
genes have shared a last common ancestor than the genes from the other 
species pair (branchiostoma and humans). Under the assumption of 
horizontal transfer, the explanation for the observation of such little change in 
sequence is more mundane. An HGT event from late-diverging 
cyanobacteria to a last common ancestor within the animal lineage, although 
ancient, would have occurred much more recently than the LUCA and 
somewhat more recently than the mitochondrion too (Figure 3.9A, Figure 
3.12). HGT can therefore fully account for the slow rates of evolution 
observed even compared to the rate of evolution of EGT candidates and 
mitochondrially encoded proteins. This evidence (Figure 3.9) therefore is 
complementary to and independent from the estimates derived from 
divergence time predictions based on the fossil record (Figure 3.8).  
 
Although rates of evolution may differ (even extensively) between different 
lineages (heterotachy), a minimal amount of nearly neutral genetic 
divergence nonetheless accumulates over evolutionary timescales in all 
lineages, even in the best-conserved genomic sequences in life58. Under the 
assumption of vertical descent, the observed PADI sequence changes are 
anachronistically low relative to other vertically acquired genes (6 standard 




across the phylogeny, calibrated using timings from the metazoan fossil 
record under various relaxed molecular clock models57, requires a common 
ancestry of cyanobacterial PADIs and animal PADIs that is considerably 
more recent (at approximately 1 billion years ago; Figure 3.8) than the well-
defined last common ancestry of cyanobacteria and eukarya (approximately 
4 billion years ago)53. 
 
3.2.6 Catalytic activity and calcium dependence of cyanobacterial PADI 
Given the high conservation of cyanobacterial PADI to metazoan PADIs, 
including all necessary catalytic residues and calcium binding residues, I 
hypothesized that it was likely that it might be catalytically active.  To assess 
whether the cyanobacterial protein is capable of citrullination, a recombinant 
version of the three-domain PADI from Cyanothece sp. 8801 (referred to as 
“cyanoPADI”) was prepared. DNA encoding the three-domain cyanoPADI 
sequence was synthesized commercially by Thermo Fisher GeneArt. This 
sequence, and the sequence for human PADI4, were sub-cloned into a 
bacterial expression vector with an N-terminal Glutathione S-Transferase- 
6xHistidine (GST-His) tag (sub-cloning was performed by Gavriil Gavriilidis 
and Abigail Wilson). The GST tag helps to solubilize the mammalian protein 
and purification with the His tag provides a good yield from affinity 
purification. N-terminal tags (Flag, 6xHis, and the larger GST) have been 
shown previously not to affect the activity of PADI4 in vitro59. The two 
proteins were purified under identical conditions from bacterial cell lysates. 
GST-His-CyanoPADI and GST-His-humanPADI4 were then used directly in 
in vitro citrullination assays (Chapter 2.2.6.1). Detection of proteins was 
carried out by Western blot, and loading assessed using an antibody to the 
GST tag and to two housekeeping proteins (NPM1, GAPDH). Mouse cell 






Figure 3.10: Cyanobacterial PADI enzyme from Cyanothece sp. 8801 (cyanoPADI) is 
catalytically active in vitro. Immunoblot analysis of citrullination assays using recombinant 
GST-His tagged enzymes on A: mouse embryonic stem cell lysates and B: recombinant 
human histone H3 with detection by Mod-Cit and H3CitR2 respectively. NPM1 and total 
histone H3 are presented as loading controls. Recombinant cyanobacterial protein 
production was performed with Gavriil Gavriilidis. Data shown in A are representative of n = 
3; the Mod Cit detection was performed once. Data shown in B are representative of n = 2. 
 
Analogously to the human enzyme, cyanoPADI citrullinated multiple proteins 
in mouse cell lysates (Figure 3.10A), as detected by Mod-Cit, which is an 
antibody to chemically modified citrulline residues (Chapter 2.1.16). 
CyanoPADI, like human PADI4, showed an absolute dependence on calcium 
for activity (Figure 3.10). This demonstrates that the calcium-dependent 
regulation found in mammalian PADIs is also a feature of the ancestral 
cyanobacterial protein and provides evidence that the conserved calcium-
binding sites, used in the evolutionary analysis as signifiers of 
synapomorphy, are functional. Despite the absence of histones in bacteria, 
cyanoPADI catalysed citrullination of arginine 2 on the N-terminal tail of 
recombinant human histone H3 (Figure 3.10B), which is a known target of 
mammalian PADI4. Thus cyanoPADI is a bona fide calcium-dependent 
peptidylarginine deiminase with sufficient similarity or promiscuity to catalyse 
citrullination of mammalian target substrates. It was noticeable that a slight 




His proteins in the activated (calcium-treated) conditions. This may be due to 
a modification to the protein, which is most likely due to autocitrullination as 
has been shown for PADI460, but could also be citrullination of the affinity tag, 
or less likely an activated conformation of the protein behaving differently 
under denatured protein electrophoresis conditions. The assay was repeated 
at 15˚C and 37˚C and activity was reproduced, showing the cyanobacterial 
enzyme is active at a physiologically relevant temperature in the ocean 
(Figure 3.10B). A variety of other metal ions did not substitute for activation 




Figure 3.11: Cyanobacterial PADI enzyme from Cyanothece sp. 8801 shows a different 
Ca2+ dependency in vitro. Immunoblot analysis of citrullination assays using recombinant 
GST-His tagged enzymes on A: mouse embryonic stem cell lysates for which data shown 
are representative of n = 3, and B: recombinant human histone H3 with detection by 
H3CitR2 for which data are shown from a single preliminary experiment. NPM1 and anti-His 
are presented as loading controls.  
 
Finally, given the high calcium requirement of the mammalian enzyme, the 
citrullination assay was repeated at a wide range of calcium concentrations 
113 
 
to test whether there was any variation in calcium dependence between the 
human and cyanobacterial PADI enzymes (Figure 3.11). Human PADI4 
showed some activity in CaCl2 concentrations as low as ~250 µM in vitro on 
Arg2 of histone 3 (Figure 3.11A) with an incubation time of 30 minutes. 
However, cyanoPADI showed no activity on the same substrate even at 1 
mM CaCl2, with activity demonstrated only at CaCl2 concentrations greater 
than 5 mM (Figure 3.11A). It was then tested in a pilot experiment whether 
the stricter Ca2+ dependence could also be observed on a direct recombinant 
substrate in the absence of mouse cell lysate proteins (Figure 3.11B). This is 
important because it is possible that there is a cofactor present in mouse cell 
lysates that can activate the human enzyme, but not the cyanobacterial 
PADI. This pilot experiment showed the same pattern (Figure 3.11B). Robust 
activation of the cyanobacterial PADI occurred only at 1000 µM CaCl2, 
compared to PADI4 activation occurring as low as 250 µM CaCl2. This will 
need to be repeated at exactly the same time point of incubation as used for 
the lysate assay as there is discrepancy in the minimum concentration of 
Ca2+ ions required in longer incubations. Testing this comparison at different 
incubation times will assist in making firm comparisons.  
 
Nonetheless this work shows that cyanoPADI has a stricter requirement for 
calcium than the mammalian PADI proteins and in preliminary terms these 
experiments indicate this effect is observed independently from the presence 
of cofactors in the cellular lysate. This suggests the intrinsic affinity for 
calcium may have evolved to be higher in the vertebrate lineage. The 
intrinsic affinity of human PADI4 for calcium ions may therefore be higher 
than for cyanoPADI. Testing for the full calcium dependence on 
cyanobacterial PADI activity on a recombinant substrate in further more 
quantitative biochemical experiments will therefore be very interesting (such 





3.3 Discussion of horizontal gene transfer 
HGT is established for its importance in prokaryotes14, and although 
suggested examples in eukaryotes are increasingly abundant in the 
literature, the strength of evidence varies enormously between individual 
cases62,63. HGT examples are therefore regularly contested. Two extremes of 
evidence for HGT into eukaryotes exist. On the one hand, recent examples 
of HGT into a very limited number of species can be relatively convincing if 
contamination can be definitively ruled out64. HGT is argued by parsimony 
because the alternative of vertical descent requires near complete gene 
losses of the missing ancestral homologues across the tree of life. On the 
other hand, examples of ancient HGT of a gene showing wider taxonomic 
distribution after transfer are unlikely to be caused by contamination, but may 
more easily be products of vertical transfer that are confounded by gene loss 
and rate variation in different lineages. In such examples, if phylogenetic 
analysis of a single gene alignment shows multiple instances of gene-
species discordance, commonly used arguments for a vertical alternative to 
HGT become very convoluted23,65,66. The caveat remains, however, that this 
type of analysis is reliant on the assumed accuracy of phylogenetic inference 
of a single gene over long spans of evolutionary time. Neither case is 
conclusive, and unsurprisingly, many much less ‘conclusive’ cases lie 
somewhere between these extremes.  In addition, many individual HGT 
candidates into eukaryotes may be explained by the related phenomenon of 
endosymbiont gene transfer (EGT), such as genes of plastid or mitochondrial 
origin, which were subsequently acquired in the nucleus66-68. At some point, 
evidence for HGT almost inevitably descends into a discussion of parsimony. 
This unfortunately has had the effect of reducing the relative strength of 
cases of eukaryotic HGT down to one’s prior perceptions of the relative 
likelihood of HGT weighed against alternatives such as independent gene 
losses20,69. This has brought into question once again whether HGT has ever 
occurred into eukaryote genomes70-73. As Salzberg writes20: 
 
“My re-examination here suggests that HGT is very rare rather than 
widespread in vertebrate genomes, and that every hypothesized HGT event 
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needs to be subjected to careful scrutiny. […] Because HGT is such an 
unlikely event, the results of automated searches should be subjected to 
individual, close scrutiny with an eye toward explaining them through more 
mundane processes before concluding that these anomalies represent novel 
biological discoveries.” 
 
This chapter therefore attempts to address these concerns through 
consilience of evidence, presenting multiple independent methods that 
converge on horizontal transfer in the instance of the PADI gene.  
 
Here, three types of analyses of PADI sequence evolution were undertaken. 
The first two analyses – of phylogenetic tree topology and synapomorphies – 
are consistent with vertical descent (but with very large numbers of 
independent gene losses) or with horizontal transfer from an ancestral 
cyanobacterium into an early metazoan. Synapomorphic evidence that 
confirms the phylogenetic topology at the level of the protein sequence or a 
protein domain74-76 is particularly important: it is robust both to convergent 
evolution52 and phylogenetic artifacts derived from the analysis of a single 
gene over long periods of evolutionary time. Results from the third, molecular 
clock, analysis are not easily explained by vertical descent. This is because 
this scenario requires the rate of PADI sequence evolution to have slowed 
sharply in evolution twice, in lineages leading to metazoa and in 
cyanobacterial lineages, while being absent from all other lineages. This is 
measured to be anachronistic both in absolute terms with respect to fossil 
calibrations using molecular clocks, as well as in relative terms as compared 
to other vertically transferred proteins and even to mitochondrially encoded 
proteins.  
 
Ruling out EGT can often be very complex; it is conceivable that after a gene 
from the mitochondrion was transferred to the nucleus it could have 
duplicated and then undergone differential loss and rate variation in different 
lineages that lead to modern genomes. In the case of PADI genes, EGT can 
be ruled out as two distinct eukaryotic PADIs can be identified and shown to 




phylogenetic topology, and confirmed by synapomorphies in the sequence 
that rule out convergent evolution or phylogenetic artifacts. This is consistent 
with analyses of the rate of PADI evolution, which point to a more recent 
acquisition than the mitochondrion.  
 
The direction of HGT can be seen to be from cyanobacteria to metazoa and 
not in reverse. This is shown by phylogenetic analysis and confirmed by the 
synapomorphic evidence. In addition, two additional pieces of evidence are 
found: firstly, strong support is found for bacterial outgroup PADIs to both 
types of eukaryotic sequence (Figure 3.2) and secondly, the cyanobacterial 
PADI gene tree mirrors the expected species tree (Figures 3.8 and 3.10)54. A 





Figure 3.12: Schematic showing the proposed HGT event from cyanobacteria to 
metazoa as occurring in a last common ancestor of the NX/SPM clades of cyanobacteria, 
which possess a three-domain PADI and transferring to an ancient last common ancestor in 
the metazoan lineage. 
 
3.4 Discussion  
PADIs, therefore, provide an unusually compelling case of ancient horizontal 
transfer of a bacterial gene into eukaryotes and the acquisition of a new 
catalytic function. Although found in fungi and in animals, each PADI type 
was acquired independently from different bacterial sources, firstly by 
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animals from cyanobacteria and secondly by fungi from actinobacteria. In the 
case of the animal PADI gene, it was lost in many lineages shortly after 
transfer and only maintained widely in the vertebrate lineage, persisting into 
the human genome. Fish have a single gene, but duplications down the 
vertebrate lineage have resulted in five tandem repeated paralogues in 
mammals, each with controlled tissue-specific expression. The timing of 
transfer (neoproterozoic: 1000-542MYA) is coincident firstly with the 
presence of marine nitrogen fixing cyanobacteria with specialized arginine 
catabolic pathways77 that may have lead to the evolution of the 
cyanobacterial PADI, and secondly with the emergence of metazoa in the 
oceans78-80. 
 
The newly acquired catalytic function (i.e. citrullination) was co-opted in 
animals for very diverse functions in specific cellular contexts, ranging from 
neutrophils to pluripotent stem cells, and from oligodendrocytes to 
keratinocytes4,59,81. This functional diversity and locational specificity raises 
an interesting question as to the selective pressure for maintenance of PADIs 
after transfer. It is notable therefore that PADI6-knockout mice and 
inactivating mutations in human PADI6 cause female infertility82-85. To 
address why this product of horizontal transfer was maintained in the 
chordate lineage but not in multiple others, it would be interesting to know 
whether PADI2-knockout zebrafish are viable since fish possess only a 
single PADI paralogue. The roles for PADIs in classically animal-specific 
processes such as the maturation of myelin and hair follicles are particularly 
interesting from this evolutionary standpoint. 
 
As to the function in bacteria, literature searches of ribosomally synthesized 
and post-translationally modified peptide (RiPP) natural products revealed a 
recent paper that identified citrullinated peptides in bacteria, including in 
citrullassin A from Streptomyces albulus86. In this paper, a candidate 
citrullinating enzyme could not be identified. It is very interesting therefore 




arginine deiminase (which I identified from HMMER searches to the PAD_C 
domain, Figure 3.1A and was analysed in Figure 3.2). This therefore 
provides a concrete example of PADI activity in bacteria and a proper 
function for the putative bacterial PADI. A similar search of cyanobactins 
(small heavy post-translationally modified cyclic peptides produced by 
cyanobacteria) did not identify citrullinated residues in already published 
papers but this appears to be a likely possibility. In addition, a putative 
cyanophycinase was identified as being contained within the same operon as 
the putative PADI in Cyanothece sp. 51142. Cyanophycin is a polyarginine-
polyasparagine polymer used for cyanobacterial energy storage. It would be 
very interesting if this were modified to citrulline in cyanobacteria. PADIs are 
known to be highly efficient enzymes in mammalian cells and multiply modify 
myelin basic protein (up to 80% in a Marburg variant of MS87) as well as 
keratins. It is plausible that the multiple arginine residues in cyanophycin may 
provide multiple sites for citrullination in cyanobacteria and a similar mode of 
activity.  
 
Possibly related are considerations about the stringent PADI regulation 
observed in mammals. Calcium-binding residues are common to all PADI 
homologues and a similar mechanism of ordered calcium regulation is also 
most likely fully conserved in the closest ancestral cyanobacterial 
homologues. Fungal and actinobacterial sequences are likely to be regulated 
somewhat differently, but also in a calcium dependent manner as they still 
conserve at least three different sites. It would clearly be interesting to test 
this specifically by synthesizing a fungal and actinobacterial PADI homologue 
and generating point mutants. It is notable that human PADI4 is active at 
tenfold lower calcium concentrations than the ancestral cyanobacterial 
protein using mouse cell lysates. It is possible that a cofactor present in 
mouse cell lysates could support the lower calcium requirement of human 
PADI4 than cyanobacterial PADI in these assays. Alternatively, as CaCl2 
levels in the ocean are at 10 mM, this would support extracellular activity of 
the cyanobacterial protein if it were secreted. There is evidence for the 
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secretion or extracellular activity of PADI2 and PADI4 by neutrophils as well 
as for pPAD by Porphyrmonas gingivalis88-90. Whether an animal-specific 
evolutionary context may have resulted in the physiological regulation in 
human cells is an important additional possibility. The intracellular roles in 
mammals are likely to have derived from evolving a higher affinity to calcium. 
In mammals, there is likely still to be a requirement for an additional 
activating cofactor or a mechanism to support very high local calcium 
elevation in viable cells such as pluripotent stem cells, as even intracellular 
calcium concentrations spikes result in peaks of no more than ~1 µM 
concentration, with resting levels measured to be below 100 nM. If the 
cyanobacterial protein is active intracellularly, then the even higher calcium 
stringency of the cyanobacterial protein offers an analogous mystery. 
  
A final reflection, in light of the discovery of bona fide bacterial PADIs, relates 
to the lack of discovery of a ‘decitrullinase’ enzyme to date. ‘Decitrullination’ 
activity on free citrulline has precedent in nature from two enzymes in the 
urea cycle; citrulline is converted to argininosuccinate first by 
argininosuccinate synthase (ASS), and the succinyl group subsequently 
cleaved to free arginine by argininosuccinate lyase (ASL). The horizontal 
origin of animal PADIs complicates the possibility of finding a reverse 
enzyme (or enzymes) that may only have arisen or been maintained in 
species which possess citrullinating catalytic competency. At the very least, a 
search for a decitrullinase, if it does exist, should be expanded to include 
bacterial and fungal proteins. Alternatively models of protein degradation to 
explain the dynamic nature of arginine methylation could be invoked for a 
similar consideration of the removal and therefore dynamic nature of 
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Chapter 4: Activating PADI4 in Cells 
 
4.1 Introduction 
As reviewed in detail in the introduction, aberrant protein citrullination has 
been implicated in a diverse array of disease states1. This occurs through the 
deregulation of the PADI family of enzymes, which in most disease cases 
results in too much citrullination. This is particularly interesting due to the 
early promise shown by PADI inhibitors as therapeutic agents in disease 
models2. It has, nonetheless, proven very difficult to elucidate the 
mechanisms by which the PADIs are regulated physiologically and current 
understanding is limited beyond what is known in vitro. We therefore also 
lack mechanistic understanding of how the enzymes become deregulated in 
disease and how this contributes to disease phenotypes. The focus of this 
work is on understanding the physiological activation of one of the PADI 
paralogues: PADI4. 
 
4.1.1 PADIs are regulated by calcium ions 
PADIs are calcium-dependent enzymes. Although calcium is not directly 
involved in catalytic deimination, structural studies using PADI4 reveal that 
allosteric calcium ion binding drives an extensive conformational 
rearrangement from an inactive to active state of the enzyme (Figure 1.7 and 
4.1)3. Five calcium ions bind such that the active site cleft becomes ordered 
and the nucleophilic active site cysteine moves ~5-10 Å into its catalytically 
competent conformation3 (Figure 1.7).  
 
Following the analysis of the binding site restructuring of PADI4 in Arita et al., 
the crystal structures of the related paralogue PADI2 were solved in 
differentially calcium-bound states3-5. This revealed that sequential and 
cooperative calcium binding drives the conformational change: calcium 
binding in the PAD_M domain (calcium binding site Ca4) away from the 
active site also involves a residue in a loop from the catalytic PAD_C domain 




coordination of the first three calcium ions (sites Ca3-5) thereby aids binding 
of a final calcium ion near the catalytic site (Ca2), which is responsible for the 
restructuring of the active site (Figure 4.1). This also drives the movement of 
the nucleophilic active site cysteine. In the inactive conformation of PADI2 a 
‘gatekeeper’ arginine residue acts as an intramolecular pseudosubstrate and 
shields the active site, but moves out of the active site in the active enzyme 
conformation and is replaced by the nucleophilic cysteine5 (Figure 1.7). Both 
the calcium-switch region of the enzyme (Ca3-5) and gatekeeper arginine 
observed in PADI2 are also conserved in all active PADI paralogues and, 
although this has not been demonstrated in crystal structures of the other 
members, is likely to act as a switch for analogous regulation in the other 
paralogues of the PADI enzyme family– including PADI4. 
 
 
Figure 4.1: X-ray crystal structures of PADI4 with and without calcium ion binding. A: 
Left panel: X-ray crystal structure of PADI4 in the absence of Ca2+ binding shown coloured 
in white with protein surface displayed. The location of Ca binding sites 1 and 2 and Calcium 
binding site 3-5 are outlined in dashed transparent boxes. Right panel: X-ray crystal 
structure of PADI4 in the presence of 10mM CaCl2 bound to 5 Ca ions (1wd9) shown 
coloured in red with protein surface displayed. The front face (right hand of the protein as 
shown) where the active site is located is now ordered. B: Three panels of a front view of 
PADI4. Left panel: Front view of PADI4 structure in the absence of Ca2+ shown in white 
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(1wd8). Middle panel: Calcium bound PADI4 structure 1wd9 shown in red was 
superimposed on the previous 1wd8 structure coloured in white using MatchMaker in 
Chimera where best aligning chains using the Needleman-Wunsch algorithm are iteratively 
matched by pruning long atom pairs until no pair exceeds 2.0 Å. Right panel: Calcium 
bound PADI4 structure is shown in gray. Regions, which were disordered (and therefore 
absent from 1wd8) in the calcium-unbound structure, that have become ordered upon 
calcium binding in 1wd9 have been coloured in red. Figures were prepared in Chimera using 
PDB structures 1wd8 and 1wd9 which were deposited by Arita et al.3. 
 
4.1.2 Comparing the calcium activation in vitro and in cells 
The conformational switch described above, observed in PADI2, only occurs 
in the presence of a high concentration of calcium ions5. Concentrations of 
10 mM CaCl2 preserve the active form in crystallographic analysis3. Calcium 
switch regions are disordered and do not coordinate calcium ions at 50µM or 
100µM, only becoming ordered at 250µM5. Detailed biochemical studies on 
the in vitro calcium dependence of the PADI enzymes have also been 
undertaken6-9 and the calcium sensitivity for catalysis was found to be similar 
to the crystallographic studies (~250 µM Ca2+). Using the citrullination lysate 
assay, I obtain similar results (Figure 4.2A). The half maximal calcium 
concentration for the artificial small peptide substrate N-benzoyl-l-arginine 
ethyl ester (BAEE) was found to be 0.5 mM, but for a real substrate histone 
3, it was observed to be much higher at 3.3 mM6,10. 
 
In cells, however, PADI enzymes will not encounter such a high intracellular 
calcium concentration. Intracellular calcium is actively extruded from cells 
and maintained at a much lower level (~100nM)11. This is a requirement of all 
living cells not least because a high intracellular concentration of calcium 
ions would cause intracellular precipitation of DNA and RNA11,12. Studies 
measuring calcium in resting cells place the typical physiological intracellular 
calcium concentration at no greater than 100 nM11. Whilst intracellular 
calcium-signalling fluxes are widespread in cell biology, 1 µM would be a 
typical maximal physiological level, which is at least two orders of magnitude 





One method to activate PADI4 in cells is to use a calcium ionophore (Figure 
4.2B). In this instance, the elevated calcium concentration might be assumed 
(not unreasonably) to be responsible for the direct activation of the enzyme. 
Similarly, this reasoning ignores the scale of the calcium increase in cells. 
The calcium elevations caused by inflammatory stimuli and from ionophore in 
several studies have been measured, including in the same cell type where 
PADI4 is activated13 and the maximum concentration of calcium inside the 
activated cells was measured to also be at 1 µM even after ionophore 
stimulation13. Subsequent studies have shown PADI4 can be activated in 
these exact cells under the same concentration of calcium ionophore and 
extracellular calcium in the buffer medium14,15 and place the calcium 
requirement of PADI4 in vitro to be at least 100-fold higher. Other 
inflammatory stimuli (such as TNFα, or fMLF) can also cause intracellular 
calcium fluxes, but result in less extreme intracellular gradients than calcium 
ionophore and have been found to activate PADI4 robustly16. A particularly 
interesting inflammatory stimulus, lipopolysaccharides (LPS – isolated from 
the outer membrane of Gram-negative bacteria), is well characterized not to 
cause a spike in calcium levels during neutrophil stimulation, but still is 
observed to activate PADI4 strongly17-19 (and personal communication, Prof 
Philip Cohen). A discrepancy clearly exists between the in vitro and 
physiological calcium requirement of PADI4; the activation by calcium of 
PADI4 in vitro appears to be insufficient to reconcile PADI4 activation in cells. 
 
4.1.3 Previous efforts to understand PADI regulation 
Given that the activation of PADI4 by calcium is unlikely to function similarly 
in the body, many people have hypothesized about alternative mechanisms 
of PADI regulation that might be relevant in vivo and significant efforts have 
been undertaken to progress this gap in the field. 
 
One possibility is that the mobilization of free calcium ions inside cells, such 
as in chemokine receptor ligation or cellular differentiation, might achieve a 
local calcium concentration that is much higher than the average heightened 
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intracellular levels. This local concentration is likely to require an additional 
binding partner to mediate this. In particular, this would be required to explain 
how an intracellular elevation of calcium (or in the case of LPS, no elevation 
of cytosolic calcium, perhaps through a different mechanism) may be 
transduced to PADI4 in a specific and stringently regulated manner from 
such a diverse set of activating stimuli1. Efforts have been made to identify 
possible endogenous candidates, but these have so far remained elusive20-
22. This is, nonetheless, an attractive hypothesis and there are indications 
this may be relevant for another paralogue, PADI3, in terminally differentiated 
keratinocytes as it may be mediated through the calcium binding protein 
S100A323. A second important study showed that cross-reactive 
PADI3/PADI4 antibodies increase the calcium sensitivity of PADI4 in vitro, 
providing support for the possibility of an activating endogenous interacting 
partner10. Work described in Chapter 5, which was performed in parallel with 
the results of this chapter, in which Dr. Walport and I developed and 
characterized activating cyclic peptide molecules, provide further proof of 
principle that an interacting moiety can increase the calcium sensitivity of 
PADI4. 
 
A second possibility is that an activating post-translational modification to the 
PADI sequence may prime the enzyme for activation. In light of this, previous 
studies assessed autocitrullination of the enzyme as well as the dimerization 
state of the enzyme, and despite demonstrating evidence that both 
phenomena occur, it was found that neither of these mechanisms explained 
PADI4 activation20,24. More promisingly, a paper analyzing a Rheumatoid 
Arthritis susceptible single nucleotide polymorphism (SNP) W620R in the 
phosphatase PTPN22, showed that the presence of the SNP disrupted the 
interaction of PTPN22 with PADI4 and resulted in increased citrullination25. 
Importantly, the paper indicated that PADI4 may be physiologically 
phosphorylated25. This finding was corroborated by data on PhosphoSite, 
which shows phosphorylated residues were observed on PADI4 from 





Along the same lines, a different study of PADI4 showed evidence that active 
and inactive species of PADI4 may migrate at different speeds by SDS 
PAGE and may indicate post-translational modification21. Another study 
showed that different protein kinase C (PKC) inhibitors caused various 
effects on PADI4 activation and inhibition15. Neeli et al. attribute the effects to 
specific inhibition of different PKC isoforms15, but given these inhibitors have 
been shown elsewhere to be relatively unspecific26-28, they may target many 
other kinases in the cell (binding at the ATP binding pocket). Nonetheless, 
the paper is interesting as it indicates that PADI4 activity may be regulated 
by kinase modulation. In addition, some PKC enzyme isoforms are 
themselves modulated directly by calcium and this therefore may explain at 
least in part some of the confusing correlations between calcium flux and 
calcium-dependent PADI activation observed in that paper15. Finally, another 
study revealed that different bicarbonate concentrations can affect both in 
vitro and cellular PADI4 activity. This is unlikely to have an effect on cellular 
calcium fluxes29. 
 
Given the lack of progress in identifying a candidate PADI activator in cells, 
the most common rationalization has been that since many substrates of the 
PADIs can be found in the extracellular space, particularly in synovial fluid 
(cytokines, collagen, fibronectin and fibrinogen, or even histones in post 
NETotic conditions), enzyme activity might be restricted exclusively to roles 
outside the cell where high concentrations of calcium are made available 
(extracellular calcium is as high as 1-2 mM in synovial fluid or blood 
plasma)1,30,31. This may go some way to explain the activity of PADIs in 
several innate immune contexts, such as after apoptosis, necrosis, or 
NETosis17.  
 
4.1.4 Re-evaluating the physiological activation mechanism of PADI4 
It was the discovery of the role of PADI4 in the establishment of 
pluripotency32 that prompted a reevaluation of the physiological activation of 
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the enzyme (Figure 4.2 and Figure 4.3). This newly discovered role of PADI4 
appears to severely undermine the notion that PADI4 was only activated by 
obtaining access to extracellular calcium concentrations in dying or NETotic 
cells. In the context of the reprogramming of somatic cells to induced 
pluripotent stem (iPS) cells, mouse neural stem cells (which have no 
detectable PADI4 expression) begin to express PADI4 mRNA two days after 
the transduction of Yamanaka factors, and after eight days, are shown to 
possess activated PADI4, as interpreted by the detection of citrullinated 
histone 332. The increase in citrullinated H3 occurs two days after being 
treated with two kinase inhibitors against GSK3β and MEK1/2 in the 
presence of Knock-Out Serum replacement (KSR), a treatment known as 2i 
(and referred to in this thesis as KSR2i)32. These iPS cells, with stably 
elevated levels of citrullinated histone 3 at the end of a course of 
reprogramming (after 14 days), are perfectly viable and can then be re-
differentiated into any kind of cell. PADI4 can clearly be activated 
intracellularly and moreover in living cells (Figure 4.2C). 
 
 
Figure 4.2: Rethinking the physiological activation of PADI4: comparing PADI4 
activation in vitro, in HL60 cells and in mouse iPS cells. A: Immunoblot analysis of 




human PADI4. Serially diluted CaCl2 was supplemented in each assay condition and 
incubated for 30 min at 37˚C. B: Immunoblot analysis of H3Cit and PADI4 of whole cell 
extracts from the HL-60 promyelocytic leukaemia cell line either cultured in RPMI with 10% 
serum (Lanes 1,3) or terminally differentiated into neutrophil-like cells by culturing in the 
presence of 1% DMSO (Lanes 2,4). After differentiation, PADI4 expression is induced and 
PADI4 protein can be detected. Cells were then treated with either vehicle (Lanes 1-2) or 
with the calcium ionophore A23187 (Lanes 3-4) in Locke’s solution, before cell lysis and 
western blotting. C: Immunoblot analysis of whole cell lysates for a cellular reprogramming 
experiment, for H3Cit. Partially reprogrammed pre-iPS cells were cultured in KSR2i for 7 
days (Lanes 1-5). Lane 6 shows cells treated in KSR2i for 7 days in the presence of Cl-
amidine (200µM). Panel A is representative of n = 3. Dr Christophorou provided the blots for 
panels B and C, which reproduce established results from the literature32,33.  
    
This reevaluation seems important in addition for the well described role of 
PADIs in histone modification or transcriptional regulation34,35. PADI4 has 
been described in a variety of networks of transcription factors where 
chemical inhibition can reduce its interplay with other transcription factors 
and alter its function as detected by various chromatin immunoprecipitation 
(ChIP) analyses35-37. For this to be the case, resting activity of PADI4 must 
be able to take place in the nucleus of the cell. In these contexts calcium 
concentrations required in vitro are particularly implausible as the nucleus 
has been shown to be insulated from large or rapid cytosolic calcium 
increases38. 
 
4.1.5 Overarching aim 
The primary aim of this chapter is to explore the possibility that there is more 
to the physiological regulation of the PADI enzymes than direct calcium 
binding or extracellular enzyme activity, and that some mediator helps to 
achieve the active and catalytic conformation of the enzyme inside cells 
either by increasing calcium sensitivity, enabling a high local calcium 
concentration, or in priming the protein for reactivity (these hypotheses are 
outlined in Figure 4.3). As such, one of the most critical questions in the 
citrullination field remains open – to elucidate how PADIs are activated 





Figure 4.3: Schematic showing possible hypotheses concerning the physiological 
regulation of PADI protein in cells. Direct post-translational modification, local Ca2+ 
concentration or a protein-binding partner may enable PADI activation in vivo at a lower 
effective calcium concentration than that required in vitro. 
 
4.1.6 Objectives: 
• Establish cellular conditions for activating PADI4 tractable for detailed 
proteomic analysis.  
• Elucidate signalling pathways upstream of cellular PADI4 activation 
 
4.1.7 Overview of establishing tractable cellular systems for 
physiological PADI4 activation across innate immune and pluripotent 
cell contexts 
 
As the lab was new at the start of my PhD, I began by setting up different 
cellular systems for PADI4 activation that may be tractable for proteomic 
analysis. 
 
Firstly, it has been reported previously that PADI4 is activated in response to 
various pleiotropic inflammatory stimuli in primary human neutrophils and in 
terminally differentiated neutrophil-like cancer cells (HL-60 cancer cell line), 
responding as part of the innate immune system. In neutrophils, these stimuli 
are used to induce NETosis (or neutrophil extracellular trap formation)17,39, 




agents17,40,41.  Terminally differentiated HL60s are neutrophil-like cells but are 
poor at forming NETs, as only a low percentage are found to undergo 
NETosis, and show low antimicrobial activity42,43. NET forming stimuli, which 
have been reported in some cases to activate PADI4 in addition, include 
fMLF, LPS, IL-8, calcium ionophores (ionomycin and A23187), PMA, and 
TNFα. Reports in the literature are contradictory over whether PADI4 is 
essential for NETosis, and the role of PADI4 or citrullination in NET formation 
has not been clearly elucidated (see introduction for detailed discussion)44-46. 
Our interest, however, is not in NET formation per se, but on the 
mechanisms of PADI4 activation. I therefore began by setting up these two 
neutrophil or neutrophil-like systems in the lab and exploring different 
conditions to activate PADI4. The inflammatory stimuli that were shown to 
activate PADI4 in Neeli and Radic16 were used as the starting point for this 
work (LPS, TNFα, fMLF and IL-8). 
  
In tandem, I designed initial experiments to test the suitability of the cellular 
reprogramming system used in Christophorou et al. for assessing PADI4 
activation32. In this system, pre-iPS cells (cells which have been frozen at 
day 6 after transduction of the Yamanaka factors) are grown in serum or in 
KSR2i conditions. The endogenous Oct4 locus is additionally tagged with 
GFP in this cell line (neural stem cells tagged with Oct4-GFP, NSO4G) giving 
proxy readout of reprogramming efficiency. Culturing the cells in serum 
results in a very low efficiency of reprogramming concomitant with a low 
extent of PADI activation as detected by histone citrullination32. Culturing in 
KSR/2i increases the efficiency of reprogramming to approximately 5% in 
parallel with the observation of increased citrullination of histone 3. It is 
known that inhibition or knockdown of PADI4 decreases the efficiency of 
reprogramming32. However, neither the amounts of PADI4 nor the population 
of reprogramming cells can be controlled in this system. This would confound 
any differential MS/MS analysis of interacting proteins between inactive and 




Two effects would need to be carefully controlled to discover molecular 
events leading to the enzymatic activity switch of PADI4. Firstly, levels of 
PADI4 protein would need to be controlled across conditions and 
independent from the stimulus used to drive PADI4 enzymatic activation. 
Secondly, the cell type in the system would need to be controlled and 
similarly independent from the stimulus used to induce PADI4 enzymatic 
activity.  
 
As a result of the pitfalls of the reprogramming cell system, I decided to 
investigate activation conditions in a related mouse cell model system that is 
related to PADI4 in the pluripotent context, but which was controlled 
according to the essential criteria outlined above. I made use of an E14 line 
of mouse embryonic cell (mES) lines that stably express human PADI4 (mES 
PADI4 stable) and tested whether it might be possible to activate PADI4 in 
this cellular system. I used mES cells expressing an empty vector as a 
negative control (mES control stable) to isolate activation only of the 
exogenous protein. Despite the clear deviations of this cell line from a 
physiological situation (using exogenous protein expression), this presents a 
carefully controlled model system that could overcome the intrinsic 
deficiencies of the reprogramming system for the purpose of uncovering 
cellular mechanisms of PADI4 activation by MS/MS (detailed discussion 
Section 4.2.4). Subsequent validation of candidates in physiological systems 
will therefore be important. 
 
4.1.8 Detection of PADI activity 
Activation in cells was assessed by Western blot for the detection of an 
increase in histone 3 citrullination using two commercial antibodies: a 
polyclonal to H3CitR(2,8,17), referred to as H3Cit, and a monoclonal to 
H3CitR2 that became available during the work, referred to as H3CitR2. The 
first antibody is the best-characterized (and most sensitive) reagent to detect 
an increase in citrullination from cells, but is not without reported issues 




activation conditions prior to use and only used two lots that behaved in a 
controlled way under an established PADI4 activation stimulus (calcium 
ionophore activation in terminally differentiated HL60 cells) (Figure 4.2B, 
Figure 4.4). A specific problem was that some cross reactivity was observed 
with unmodified histone 3 so a clear increase in signal is required to 
conclude that enzymatic activation of PADI4 had occurred. Given the 
monoclonal antibody was shown to behave similarly to the polyclonal in our 
established condition, this was also employed during the work, but there may 
be contexts where the two antibodies do not behave identically. A whole cell 
lysis procedure was used for blotting, such that no material was discarded 
and histones could be reliably extracted to a comparable extent between 
conditions. Normalization was made to total cellular protein content as 
detected spectroscopically and verified using a loading control. A second 
detection method was with an antibody to chemically modified citrulline 
referred to throughout as Mod-Cit48,49. This approach chemically modifies the 
transferred blot with 2,3-butanedione monoxime, antipyrine, and FeCl3 in a 
strong acid solution. The antibody detects the chemically modified moiety 
independent of sequence context, but given the antibody is no longer 
commercially available, its use is limiting and was therefore restricted to 
confirm certain findings. A third method using immunofluorescence detection 
of citrullinated histone 3 by high-content microscopy was also established to 
enable more high-throughput analysis in the near future and confirm 
activation was occurring in fixed nuclei and not merely in whole cell lysates 
(discussed in Section 4.2.6). 
 
4.2 Results 
4.2.1 Granulocyte-like cells differentiated from the HL-60 cell line 
The HL-60 cell line is a human acute myeloid leukemia cell line, resembling 
promyelocytic cells, which can be terminally differentiated in vitro into 
granulocyte-like (neutrophil-like) cells using all-trans-retinoic acid or the polar 
solvent dimethyl sulfoxide (DMSO)50,51. Differentiation induces expression of 
PADI4, which in a resting state is not observed to be active (Figure 
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4.2B)16,33,52{Wang:2004hh}. To induce PADI4 activity, Neeli and Radic used 
a variety of inflammatory stimuli including fMLF, LPS, IL-8, TNFα, H2O2, 
ionomycin and calcium ionophore A2318716. I attempted to replicate these 
findings and found that calcium ionophore robustly induced activation of 
PADI4 in differentiated HL60 cells after 15 min (Figure 4.4A, Lane 9). In 
contrast to the Neeli and Radic paper16, however, I was unable to activate 
PADI4 in differentiated HL60s using TNFα, LPS and IL-8 (Figure 4.4A, Lanes 
2-4)16,53. 
 
Figure 4.4: Activation of PADI4 by calcium ionophore in differentiated HL-60 cells is 
increased by priming with LPS pre-treatment. A: Immunoblot analysis of H3Cit of whole 
cell extracts from terminally differentiated HL-60 cells cultured in 1% DMSO for 5 days. Cells 
were treated with TNFα, LPS, IL-8 for 30 minutes and then treated with vehicle (Lanes 1-4) 
or A23187 (Lanes 5-8) for 15 minutes before lysis and blotting. B: Immunoblot analysis of 
H3Cit of whole cell extracts from terminally differentiated HL-60 cells (cultured in 1% DMSO 
for 5 days). Cells were treated with vehicle (Lanes 1-2) or LPS (Lanes 3-6) for up to 60 
minutes before treatment with A23187 for 15 minutes (Lanes 2, 4-6). Data shown are 
representative of n = 3. Dotted line indicates the removal of irrelevant lanes from the same 
gel at the same exposure. 




After speaking to members of the Rossi lab (MRC Centre for Inflammation 
Research, QMRI), I attempted to prime the cells for activation by pre-
incubating with TNFα, LPS and IL-8 for 30 mins, as inflammatory stimuli are 
often used after a priming step in primary neutrophils, before attempting to 
activate PADI4 with calcium ionophore (personal communication, Dr David 
Dorward and Prof Adriano Rossi). Two out of three of these stimuli, LPS and 
TNFα, but not IL-8, increased the extent of activation of PADI4 by the 
ionophore A23187 (Figure 4.4A). From this preliminary result, I took the LPS 
priming treatment forward for validation given that it is known not to cause an 
intracellular calcium flux18 (Figure 4.4B). Incubating LPS for longer (up to 60 
minutes) increased the priming effect, causing a much greater extent of 
activation than without priming (Figure 4.4B, Lane 2 vs Lanes 4-6). It will be 
important to confirm that LPS was active by assessing rapid increase in 
levels of phospho-p38 after LPS stimulation (at ~30 min)54. These results are 
promising, as they indicate that there is more to activation of PADI4 than 
intracellular calcium flux provided by ionophore due to the priming effect by 
LPS, which is known not to mobilise intracellular calcium18,55 (see hypothesis 
outlined in Figure 4.3). 
 
4.2.2 Primary human neutrophils purified from peripheral blood 
Differentiated HL60s have been shown to produce low numbers of NETs 
when compared to neutrophils56, which may mean they are less relevant for 
the role of PADI4 activation. Given the difficulties encountered while 
attempting to reproduce the activation conditions in differentiated HL60s, it 
was decided to look at effects in primary human neutrophils purified from 
peripheral blood. Using a protocol developed in the Rossi lab (with initial 
instruction from Dr David Dorward, MRC Centre for Inflammation Research, 
Edinburgh), unstimulated primary human neutrophils were isolated from 
peripheral blood to greater than 95% purity, as measured by flow cytometric 
analysis and used for short term culture. Blood samples were drawn from 
healthy adult human volunteers and purified by the use of Dextran 
sedimentation and a discontinuous Percoll gradient (protocol in Chapter 
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2.2.4). The method results in the copurification of eosinophils, with distinctive 
orange granules under staining (Figure 4.5A, red arrow). Eosinophils, 
however, are typically at less than 1% abundance (but present at higher 
numbers in donors with hayfever).  
 
Cells were subsequently cultured in LPS and fMLF, lysed rapidly and 
analysed by Western Blot (Figure 4.5B) with cell numbers that will be 
sufficient in the future for mass spectrometry analysis. Western blotting in 
primary human neutrophils is not straightforward; a rapid and stringent lysis 
procedure was employed to prevent activity of proteases. In contrast to the 
results obtained with differentiated HL-60s, fMLF and LPS activated PADI4 
without the need for priming or treatment with Ionophore A23187 (Figure 
4.5B). LPS treatment requires presence of 1% autologous serum, which is 
known to provide LPS binding protein as a cofactor for TLR-4 receptor 
stimulation57. 
  
Figure 4.5: Purified primary human neutrophils treated with inflammatory stimuli show 
activation of PADI4. A: Cytospun image of purified granulocytes stained with DiffQuick. 
Neutrophils (black arrow, n) and eosinophils (red arrow, e) are purified, with neutrophils 
present at greater than 95% purity as determined by FACS. B: Immunoblot of whole cell 
extracts from primary human neutrophils elicited from healthy volunteers and purified by 
discontinuous Percoll gradient protocol (Chapter 2.2.4). After purification, cells were then 
cultured with fMLF (100 ng/mL) (Lane 1), vehicle (Lane 2), or LPS (1 µg/mL) in the presence 
of 1% autologous serum (Lane 3). Data shown are representative of n = 2. 
 
Given the requirement for blood donation from healthy volunteers, the 
numbers of cells obtained are limited but it is notable that numbers of cells 
would nonetheless be sufficient for analysis by MS/MS. LPS treatment of 
purified human neutrophils represents an ideal physiological activating 




involving endogenous levels of human PADI4. Secondly it is a rapid and 
physiologically relevant stimulus that models a real infectious situation. 
Thirdly, it is known not to cause an intracellular calcium flux18 so is likely to 
reveal mechanisms that are not confounded by local calcium availability. It 
was considered that this cellular system would therefore be useful for 
validating candidates in a physiological system when required. 
  
4.2.3 Mouse embryonic stem cells stably expressing human PADI4 
I then looked to find conditions for activating human PADI4 in a context 
relevant to their role in pluripotency32, but which was sufficiently controlled to 
be tractable for MS/MS analysis. To do this, I chose to make use of an E14 
mouse embryonic stem (ES) cell line, which stably expresses human PADI4 
(mES PADI4-stable). Pulldown of human PADI4 is achieved using an 
antibody to the endogenous human PADI4, but does not react with mouse 
PADI4 (personal communication, Dr Christophorou); no suitable antibody for 
pulling down mouse PADI4 was available commercially. 
 
The piggyBac transposon system was used to stably overexpress human 
PADI4. The piggyBac system makes use of a piggyBac transposase, which 
recognizes inverted terminal repeat sequences (ITRs) located at either end 
of the sequence to-be-introduced, cuts it out, and introduces it across the 
genome at TTAA sites with high stability and efficiency. This has the 
advantage of incorporating the stably expressed gene across the genome. 
Levels of ectopic expression will therefore not be specifically dependent on a 
single cellular stimulus. Expression of human PADI4, in the absence of a 
global change in transcription, would therefore be constant and controlled. 
The endogenous PADI4 locus by contrast is under endogenous 
transcriptional control and therefore may change under different activating 
conditions without affecting the activation status of PADI4 protein per se, but 
it will not be under examination after affinity pull-down followed by MS/MS. 
Comparing the effects on mES cells that stably express an empty vector 
(mES Control-stable cells) reveals the extent of activation caused by the 
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exogenous human protein. This system therefore enables experiments that 
can deconvolute the effect of an activating stimulus on PADI4 protein 
activation from additional effects that may affect PADI4 protein levels. At the 
same time, however, there are clear downsides to using this ectopic system 
in which human PADI4 is stably expressed in mouse cells. For example, this 
approach could potentially reveal interactions and relationships between 
proteins or pathways that would not occur when proteins are expressed in 
cells from their cognate species at the endogenous level. As a result, it will 
be important to return to a physiological system for validation. 
 
4.2.3.1 Treatment with calcium ionophore 
To identify activating conditions of the exogenous hPADI4 protein, I first 
explored the effect of ionophore in both mES Control-stable and PADI4-
stable cells. A low degree of background citrullination is observed in the 
untreated PADI4-stable cells over Control-stable cells (Figure 4.6A, 
comparing lane 1 and lane 7), implying some activity is observed in the 
resting state. This situation already contrasts with the observations in 
differentiated HL-60s (Figure 4.4). Mouse ES cells, despite having high and 
stable expression of exogenous hPADI4 were not activated by a 15-minute 
treatment of calcium ionophore (Figure 4.6A, lanes 7 and 8). By contrast, a 
robust increase in citrullination was observed at 6 hour and 24 hour time 
points after treatment with calcium ionophore in 10% serum (Figure 4.6A, 
lanes 10 and 12) suggesting activation of the exogenous human PADI4 was 
achieved. By comparing activation with the analogous treatment in control-
stable mES cells, increases in citrullination are inferred to be a result of the 
exogenous human PADI4. It is interesting that after a 24-hour treatment with 
ionophore, a small activation of the endogenous mouse PADI4 can 
additionally be observed (Figure 4.6A, lane 6). The predominant effect, 
however, of activation of PADI4 enzyme in the 24-hour ionophore condition 
as detected by histone 3 citrullination is still due to the exogenously 





Figure 4.6: Activation of PADI4 in mES cells using calcium ionophore. Immunoblot 
analysis of H3Cit and human PADI4 of whole cell extracts of mES Control-stable (Lanes 1-6) 
mES PADI4-stable (Lanes 7-12) cells. Lanes labelled “L” contain protein molecular weight 
ladder. Mouse ES cells were cultured A: for 2 days in serum or B: for 2 days in KSR2i. 
Subsequently cells were treated with vehicle or A23187 for 15 minutes, 6 hours or 24 hours. 
Data shown are from a single experiment representative of n = 2. 
 
The experiment was repeated in the presence of KSR2i (Figure 4.6B). KSR2i 
increases reprogramming efficiency when reprogramming somatic cells to 
iPS cells, but in mouse ES cells, this condition leads to the establishment of 
a ground state of pluripotency58. Control-stable and PADI4-stable mouse ES 
cells were treated in KSR/2i for two days, but 2 days in KSR2i did not 
activate PADI4 in contrast to reprogramming cells32 (Figure 4.6B, lanes 1 and 
7). As occurred in cells in serum, a 15-minute treatment of calcium ionophore 
did not activate mES PADI4-stable cells in KSR2i (Figure 4.6B, Lane 8). 
Surprisingly, the robust PADI4 activation after 6-hour ionophore which was 
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observed in 10% serum was completely abrogated in KSR2i (Figure 4.6B, 
lane 10 compared to Figure 4.6A, lane 10). By 24 hours, ionophore treatment 
did cause activation in KSR2i as it did for serum treated cells (Figure 4.6B, 
lane 12). A preliminary test to see if the activation of PADI4 in cells cultured 
in serum after 6 hours in ionophore (Figure 4.6A, lane 10) was dependent on 
transcription was performed by culturing cells in the presence of actinomycin 
D. This reduced the extent of PADI4 activation by calcium ionophore (Figure 
4.7). Further work to try to deconvolute the effects of serum, KSR and 2i was 
then undertaken at different time points, but the effects were very 
complicated and will not be discussed in detail here, except to note that 
activation by ionophore at 15 minutes could be observed if the treatment was 
made in unsupplemented media, but was suppressed in the presence of 
serum or knock out serum replacement as observed in Figure 4.6A and B, 
lane 8).  
 
Figure 4.7: Activation of PADI4 in mES cells using calcium ionophore is reduced in 
the presence of actinomycin D. Immunoblot analysis of H3Cit and human PADI4 of whole 
cell extracts of mES PADI4-stable cells. Mouse ES cells were cultured for 2 days and treated 
with vehicle or 4µM calcium ionophore A23187 for 6 hours in the presence of an increasing 
concentration of actinomycin D. Data shown are representative of n = 2. 
 
The complicated and interacting effects of calcium ionophore with serum or 
KSR on causing large changes in levels of citrullinated histone 3 were highly 
unexpected. For the purposes of choosing conditions for mass spectrometry, 
it was considered that further work would be useful to identify PADI4 
activation conditions reliant on less complicated cellular stimuli. It would also 
be advantageous to identify activating stimuli that did not involve calcium 




ionophore treatment and presence or absence of serum/ KSR would be 
consistent with complicated priming events occurring on PADI4 protein (as 
hypothesized in Figure 4.3).   
 
4.2.3.2 Treatment with KSR2i 
I then tested to see whether KSR2i, which activates PADI4 during the course 
of cellular reprogramming58,59, might activate human PADI4 during a shorter 
treatment than 2 days. The levels of human PADI4 expression in mES PADI4 
stable cells will not be affected by 2i treatment, unlike in the iPS cells where 
these effects cannot be separated. At 6 hours after switching into KSR/2i, 
PADI4 activity was robustly detected and was abrogated in the presence of 
the PADI inhibitor Cl-amidine (Figure 4.8A). Alpha-amanitin (α-amanitin) 
pretreatment (Figure 4.8B) and actinomycin D co-treatment (data not shown) 
were then tested with respect to KSR2i after a 6 hour treatment time point. 
Neither α-amanitin or actinomycin D abrograted PADI4 activation by KSR/2i 
in contrast to the effects on ionophore treatment. It will be important to 
confirm these effects occurred on transcription. However, this suggests that 
PADI4 activation by KSR2i at 6 hours is different in nature from the PADI4 
activation caused by ionophore in these cells (Figure 4.8B) and implies 
PADI4 activation by KSR2i did not take place as a result of any 
transcriptional changes brought about in KSR2i, which might for example 
have resulted in the expression of an unknown activating protein factor. It 
was lastly checked against identical treatment on control stable cells where 
no activation was observed, suggesting activation was derived from 
exogenous human PADI4; this important control will need to be confirmed in 





Figure 4.8: Activation of PADI4 in mES cells using KSR2i. A: Immunoblot analysis of 
H3CitR2 and Mod-Cit of whole cell extracts of mES PADI4-stable cells after six hour 
treatment with serum and vehicle (Lane 1), KSR 2i (Lane 2), and  KSR 2i in the presence of 
100µM Cl-amidine. 2i refers to the use of 1µM PD03250910 (inhibitor of MEK1/2) together 
with 3µM CHIR99021 (inhibitor of GSK3β)58. B: Immunoblot analysis of H3CitR2 of whole 
cell extracts of mES PADI4-stable cells after five hour treatment with vehicle (Lanes 1,3) or 
α-amanitin (Lanes 2, 4) followed by treatment for six hours of serum (Lanes 1-2) or KSR2i 
(Lanes 3-4) with α-amanitin added again for the second incubation. C: Immunoblot analysis 
of H3Cit and human PADI4 of whole cell extracts of mES PADI4-stable cells (Lanes 1-2) and 
mES Control-stable cells (Lanes 3-6) after 6 hour treatment in serum (Lanes 1, 3 and 4) or 
KSR with 2i (Lanes 2, 5 and 6). Dotted line indicates the removal of irrelevant lanes, from the 
same gel at the same exposure. In Panel A, data shown are representative of n = 3; in Panel 
B, data shown are representative of n = 2; in Panel C, data shown are from a single 
preliminary experiment. 
  
4.2.3.3 Treatment using GSK3β inhibitors 
Activation by KSR2i is likely to occur within the window of cell signalling, 
such as a signal transmitted by a kinase cascade. In the simplest instance 
this might be brought about by the action of the two kinase inhibitors that 




responsible for activation of PADI4 within short-term KSR2i culture, I made 
efforts to deconvolute the different elements of KSR2i. In the first instance, I 
tested the effect of 2i in serum media, KSR media alone and 2i in KSR media 
(KSR2i) (Figure 4.9A). This indicated KSR and 2i act together to give full 
PADI4 activation at 6 hours, as the degree of activation by Serum2i is less 
than the degree of citrullination induced in KSR2i (Figure 4.9A). The 
activation effect was also confirmed using the Mod-Cit antibody (which 
recognizes protein citrullination independently from sequence context), 
showing that particularly the combined effect of KSR2i was robust in 
activating citrullination of a wide range of cellular substrates of different 
molecular weights (Figure 4.9A).  
 
I then used the constituent inhibitors of 2i separately, culturing the cells in 
serum media. Treatment with the single kinase inhibitor CHIR99021 resulted 
in a small amount of rapid PADI4 activation (Figure 4.9B, C and D). This 
occurs as quickly as 15 minutes after inhibitor treatment and without 
changing media composition (in the presence of 10% serum throughout) 
(Figure 4.9B). Treatment with the MEK1/2 inhibitor alone did not result in any 
increase in citrullination by contrast, and the dual inhibition of 2i did not 
cause a greater activation than GSK3β inhibition alone (Figure 4.9B). This 
indicates that the effect can be ascribed to GSK3β inhibition (Figure 4.9B). In 
such a short time frame, it would be expected that effects of activation are 
occurring within the timeframe of cell signalling, but it will be useful to confirm 
this using α-amanitin and actinomycin D in future work. The effect of single 
GSK3β inhibition persisted at a 45 minute time-point (Figure 4.9 C and D). 
Structurally unrelated GSK3β inhibitors were then tested under the same 
conditions in mES PADI4-stable cells to validate the effect of CHIR99021 in 
acting on PADI4 was occurring via its published role of GSK3β inhibition and 
not through off-target action26-28. Short-term treatment using Li+ or SB216763 
after 45 minutes reproduced the effects of CHIR99021 suggesting inhibition 
of GSK3β is specifically responsible for PADI4 activation in this context 
(Figure 4.9C). This is consistent with the single digit nanomolar IC50 of 
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CHIR99021 for GSK3β inhibition in the literature (6.7 nM)60 and studies 
which show it is a highly selective and specific small molecule inhibitor when 
used at the concentrations employed here26-28.  
 
Figure 4.9: PADI4 is activated in mES cells after short-term GSK3β inhibition. 
A: Immunoblot analysis of H3CitR2 and Mod-Cit of whole cell extracts of mES PADI4-stable 
cells after six hour treatment in serum (Lane 1), serum with 2i (Lane 2), KSR (Lane 3) and 
KSR with 2i (Lane 4). Dr Christophorou helped perform Mod-Cit analysis. Data are 
representative of n = 3; Mod Cit analysis was performed once. B: Immunoblot analysis of 
H3CitR2 in whole cell extracts of mES PADI4-stable cells cultured in serum for 2 days before 
15 minute treatment in serum with vehicle (Lane 1), 1µM PD03250910 (Lane 2), 3µM 
CHIR99021 (Lane 3) or in 2i (Lane 4). Data are representative of n = 3. C: Immunoblot 
analysis of H3CitR2 in whole cells extracts from mES PADI4-stable cells cultured in serum 
for two days before treatment for 45 minutes with vehicle, 10µM SB216763, 10mM LiCl, or 
3µM CHIR99021. Data are representative of n = 2. D: Immunoblot analysis of H3CitR2 in 
whole cells extracts from mES PADI4-stable cells after treatment for 2 hours in vehicle (Lane 
1-2) or 100µM Cl-amidine (Lane 3) before 45 minutes with vehicle (Lane 1) or 3µM 
CHIR99021 (Lanes 2-3). The data shown are from the experiment performed in tandem with 
proteomic analysis from Chapter 6 and are representative of n = 3.  E: PADI4-stable mES 
cells were grown sparsely in serum before treatment. Treatments comprised 15 min with 
vehicle (Bar 1), 10µM CHIR99021 (Bar 2 and 4) or pre-treatment in 100µM Cl-amidine 




H3CitR2 as determined by immunofluorescence with detection by high content microscopy 
(Chapter 2.4). The average nuclear intensity across two identically treated runs is shown. 
The number of cells analysed under high content microscopy is given above each bar and 
error bars show standard deviation and significance assessed using an unpaired student t 
test (p<0.05). 
 
The effects of CHIR99021 in increasing H3Cit were then confirmed outside of 
Western blotting detection using immunofluorescence. To do this, I adapted 
a high-throughput immunofluorescence protocol from Dr Priya Hari and Dr 
Juan-Carlos Acosta61 where fluorescence signal is captured using automated 
high content microscopy. Cells were treated with 10µM CHIR9901 for 15 
mins or pretreated with Cl-amidine (200µM) before CHIR99021 treatment. 
Mouse ES cells form rounded 3D colonies in culture and do not grow easily 
in a single layer for high content microscopy detection so a protocol was 
established such that cells were seeded very sparsely before treatment 
(Chapter 2.4). At a 1:500 concentration of H3CitR2 antibody, signal was 
detected by immunofluorescence over background and over Cl-amidine 
treated cells (Figure 4.9E), reproducing the activation that is induced over 
background after 15 minute CHIR99021 treatment by Western blot (Figure 
4.9B). In the future, this set-up should enable high-throughput analysis of 
PADI4 activation (see Discussion).  
 
4.2.3.4 Note on PADI4 activation in mouse ES cells 
At this point, a note should be made about the reproducibility observed on 
PADI4 activation as detected by histone 3 citrullination. The most robust 
effects are those presented, and those conditions using KSR 2i and the 
CHIR99021 were used for ~2 years in ~30 biological repeats across the 
various experiments described in this thesis. Unfortunately, during April 
2018-June 2018 (at the end of my wet lab work), the behaviour of the mouse 
ES cells began to deviate from the results obtained previously. After the 
same treatment of KSR2i for 6 h or short term GSK3β inhibition, no increase 
in histone 3 citrullination was detected. During this period, I attempted to 
resolve this problem but could not provide a resolution in the time frame 
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available before stopping to finish the evolution work in Chapter 3 and to 
write the thesis. 
 
Other labs had also noticed problems with cells cultured in 2i at the same 
approximate time (personal communication Dr Andrew Wood and various 
members of the ES cell culture room). During this period, I replaced all 
reagents, attempted a biological repeat in a different cell culture room, and 
tested different cell confluency, but encountered the same problems. It was 
reported to me while I was writing that the CO2 levels in the building were 
increased in the three months after I finished and had been altered towards 
the end of the course of my work in the lab, so CO2 consistency could be 
critically important. It would appear to this author that it is a high priority for 
future work to re-derive the PADI4 cell line in early passage mouse ES cells 
to attempt to reproduce the activation condition. It is also possible that later 
cell passages of stably expressed human PADI4 may adapt in culture and 
restrain or suppress the background levels of citrullination and that this could 
affect attempts to activate PADI4. It is likely in addition to be important to test 
and control different bicarbonate concentrations in the media, especially in 
light of the paper suggesting regulation of PADI4 activity in cells by 
bicarbonate concentration29, given the knowledge that CO2 levels changed 
over the course of the experiments. I had already submitted MS/MS 
conditions by this stage for which the activation was shown to be successful 
by Western blot (Figure 4.9D). These problems will be therefore be 
something to address before attempting future work but did not affect the 
work described in the rest of this chapter or Chapter 6. Until this can be 
resolved, any conclusions taken from this chapter should reflect a degree of 





4.2.4 Exploring PADI4 activation upstream of GSK3β inhibition: Wnt 
signalling 
 
Figure 4.10: Simplified schematic of the canonical Wnt signalling pathway. The 
schematic is adapted from information in reviews of the Wnt signalling pathway62,63. 
    
To explore the signalling pathways activating PADI4 further, I then attempted 
to identify the upstream cause of GSK3β inhibition. GSK3β is a highly 
promiscuous kinase with a large number of possible cellular substrates. At 
least two different pools of GSK3β have been reported to act in the cell and 
act orthogonally in different signalling pathways64. Given that CHIR99021 is 
in part thought to mimic canonical Wnt signalling in the establishment of 
ground state pluripotency and in increasing the efficiency of 
reprogramming58,65-70, I hypothesized that canonical Wnt signalling may be a 
good first candidate for identifying the signalling upstream of the kinase 





Figure 4.11: PADI4 is activated by treatment with Wnt3a. Immunoblot analysis of 
H3CitR2 or Mod-Cit of whole cells extracts from mES PADI4-stable cells cultured in serum 
for two days (A-B: Lanes 1-3; C: Lanes 3-6) or cultured in serum for 24 hours before serum 
withdrawal in KSR for 24 hours (A-B: Lanes 4-5; C: Lanes 3-6). Cells were then treated with 
vehicle, CHIR99021 3µM or recombinant Wnt3a 10ng/mL for 30 minutes (A), 6 hours (B), or 
24 hours (C). In C Cl-amidine (100µM) added to cells 30 minutes prior to Wnt3a treatment 
(lane 5). Dr Christophorou performed Mod-Cit analysis. Data are representative of n = 2; 
Mod Cit analysis was performed once. 
  
To test this, I used recombinant Wnt3a (10ng/mL) in place of CHIR99021 
(3µM) on mES PADI4-stable cells. After 30 minutes, 6 hours and 24 hours of 
treatment, recombinant Wnt3a caused PADI4 activation, conditional on a 24 
h serum withdrawal prior to treatment (Figure 4.11A, B and C). This was 
repeated using detection by anti-ModCit, showing that a broad range of 
substrates as well as histone 3 were also citrullinated after Wnt3a treatment 
(Figure 4.11C). Wnt3a activation after serum withdrawal strongly activates 




determined by Mod-Cit detection. It is noticeable that this stronger extent of 
activation is not detected on H3CitR2 detection. We do not know whether 
histone 3 is the most important citrullinated substrate in this context and are 
merely using it as a useful proxy for PADI4 activation. These data therefore 
highlight the importance of validating PADI4 activity on other substrates in 
addition in future work. Optimizing an assay that can record activation of an 
alternative citrullinated substrate, in particular one that is less dynamically 
turned over than histone 3, such as using antibodies to citrullinated HP-1-
gamma, NPM1, or hnRNPA1 may be particularly useful to support the work 
in this chapter.  
 
Another small molecule Wnt agonist has been reported, BML284, which dose 
dependently induces β-catenin driven gene expression and is blocked in the 
presence of a dominant negative TCF471. It is not known exactly how Wnt 
agonism is achieved directly by the small-molecule BML284, but BML284 
does not inhibit GSK3β at these doses (IC50 > 60 µM)71. As further validation 
of the Wnt pathway, I therefore tested BML284 in PADI4-stable cells. 
BML284 activated PADI4 very robustly at 1µM and 10µM concentrations 
(Figure 4.12). No increase in H3Cit was observed on Control-stable cells. 
 
Figure 4.12: PADI4 is activated by BML284, a small molecule Wnt agonist. Immunoblot 
analysis of non-phosphorylated S45 of β-catenin, PADI4 and H3CitR2 of whole cells extracts 
from mES Control-stable cells (Lanes 1-3) or mES PADI4-stable cells (Lanes 4-6), cultured 
in serum for one day before 24 h in KSR media and treated with vehicle (Lanes 1, 4) or 
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BML284 (Lanes 2-3, 5-6) at final concentration of 1µM or 10µM. Dotted line indicates the 
removal of irrelevant lanes, from the same gel at the same exposure. Data are 
representative of n = 2. 
 
These data would appear to place PADI4 activation in the Wnt signalling 
pathway, but suggest it occurs independently of GSK3β inhibition71 (Figure 
4.12). This would suggest that GSK3β inhibition therefore activates PADI4 for 
its effects on activating canonical Wnt signalling and that a downstream Wnt 
signalling effector goes on to activate PADI4. The other surprising 
observation was observed on the stability of β-catenin. Work was begun to 
explore these effects but will have to be addressed in the future.  
 
4.2.5 Does PADI4 affect Wnt transcriptional output? 
Taken together, these data suggest a role for canonical Wnt signalling 
(recombinant Wnt3a, BML284 and GSK3β inhibition) in activating PADI4 in 
this cellular system. Given the role for Wnt signalling in activating PADI4, I 
hypothesized that PADI4 may in turn play a role in modulating canonical Wnt 
signalling. Wnt signalling is thought to play a complicated role in the 
establishment of ground state pluripotency and in increasing the efficiency of 
reprogramming62,63,72. It would be particularly interesting if this may in 
principle be modulated by PADI4 activation, given that PADI4 inhibition 
decreases the efficiency of reprogramming. To test whether PADI4 may play 
a role in regulating the Wnt transcriptional output, I made use of a 
transcriptional reporter of Wnt signalling. Mouse ES cells stably expressing 
hPADI4 were transfected with a TOPflash vector, which contains binding 
sites for TCF/LEF that drive transcription of GFP, acting as a reporter of Wnt-
mediated transcriptional activation. If Wnt signalling is activated, then the 
resulting stabilized β-catenin will drive GFP expression. A FOP vector is used 
as a control, which has mutations in the TCF/LEF binding site that render it 





Figure 4.13: Inhibition of PADI4 reduces canonical Wnt signalling. PADI4-stable mES 
cells were cultured in KSR2i media for 24 hours, transfected with FOP-GFP or TOP-GFP 
and media replenished after 5 hours. Cells were then treated with vehicle, 100 ng/mL Wnt3a, 
100 ng/mL Wnt3a and 100 µM Cl-amidine, or 100 ng/mL Wnt3a and 5 µM BB-Cl-amidine for 
24 hours. GFP signal was detected by flow cytometry and was normalized to a GFP 
transfection control. Mean was taken of 3 biological replicates, error bars show standard 
deviation, and significance was assessed using a two tailed t-test (* p < 0.05, ** p < 0.001). 
Data shown are from a single experiment representative of n = 3 
   
Treatment of mES PADI4-stable cells with Wnt3a caused an expected 
increase in Wnt-driven transcription as detected by the increase in GFP 
expression over untreated cells (Figure 4.13). This was not observed in the 
FOP control that was treated with Wnt3a (Figure 4.13). Inhibition of hPADI4 
using Cl-amidine or BB-Cl-amidine (a more cell permeable and effective 
variant of Cl-amidine in cells)73 caused a significant reduction in Wnt driven 
transcription (at least a two fold reduction by BB-Cl-amidine). These data 
show that Wnt driven transcription is reduced by PADI4 inhibition in this 
model system. This implies that PADI4 activity amplifies Wnt transcriptional 
output – such that Wnt signalling activates PADI4, which in turn amplifies the 
downstream gene expression. It will be very interesting to look at these 
effects using microarrays for Wnt target gene expression or by using RNA-
sequencing to identify whether specific Wnt targets may be affected by 
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PADI4 activity. It will also be important to confirm these effects occur in a 
physiologically relevant system for Wnt signalling where PADI4 is also 




In this chapter, I established stimuli for activating PADI4 in cells that are 
tractable for MS/MS analysis. In systems relevant both to innate immunity 
and pluripotency, this resulted in activation of PADI4 protein in cells where 
levels of PADI4 protein are carefully controlled and independent from the 
cellular stimulus. Mass spectrometry analysis of PADI4 activation using 
selected cellular conditions is then explored in Chapter 6 and this is 
discussed further there. In addition, work in this chapter looked at the 
signalling pathways upstream of PADI4 activation, which arose from the 
results obtained in this chapter. Excitingly, PADI4 was activated downstream 
of canonical Wnt signalling. This was confirmed using recombinant Wnt3a, 
the small molecule Wnt agonist BML284 and three distinct GSK3β inhibitors.  
 
It is interesting that PADI4 can be activated by GSK3β inhibition, given that 
PKC inhibitors have previously been shown to activate or inhibit PADI4 under 
different conditions15. As these PKC inhibitors have been shown to inhibit at 
the ATP binding pocket, they target multiple other kinases and have been 
shown to target GSK3β26-28. It may be the case that the described activation 
of PADI4 by PKC inhibitors may be in part due to inhibition of GSK3β. A 
chemical genetic approach to explore the signalling pathways upstream of 
PADI4 was devised in conversation with Dr Greg Findlay and Prof Philip 
Cohen (MRC Protein and Phosphorylation Unit (PPU), University of Dundee). 
A small molecule inhibitor library to a large panel of kinases, which was a 
kind gift from Dr Greg Findlay and Prof Nathanael Gray, was made available 
to us. This was the primary reason for developing the high-throughput assay 
to detect PADI4 activation by immunofluorescence as previously I had relied 




throughput set-up will allow for these upstream signalling networks to be 
interrogated more carefully. In the first instance it will be interesting to test if 
other inhibitors in the library may mimic the activation caused by GSK3β 
inhibition. Secondly, using the library in combination with GSK3β inhibition or 
Wnt agonism (as a form of negative screen) is also likely to help dissect the 
pathway by which GSK3β inhibition or Wnt signalling activates PADI4. 
Kinase inhibitors that can disrupt PADI4 activation would be particularly 
interesting therapeutically. 
 
In concert with the work looking at upstream signalling causing PADI4 
activation, PADI4 inhibition was shown to reduce Wnt-driven transcription in 
the model ES cell system used in this chapter. It will be important to confirm 
that these effects on Wnt driven transcription occur in a more physiologically 
relevant context for Wnt signalling where PADI4 is also present32,35,58,62,63,65-
70,74,75. That PADI4 inhibition can reduce Wnt-driven transcription is 
nonetheless an exciting finding as it could explain why inhibiting or knocking 
down PADI4 reduces reprogramming efficiency32 – as the effect of this could 
be to concurrently dampen down Wnt signalling. Contexts where PADI4 is 
highly expressed may therefore be those that make use of enhanced Wnt 
signalling output. It is therefore particularly interesting that PADI4 is highly 
expressed in haematopoetic stem cells and upregulated in various cancer 
contexts65,76,77, contexts which are well established to be reliant on increased 
Wnt signalling. Similarly this therefore provides a plausible hypothesis as to 
why PADI4 might be upregulated in certain cancer contexts. It will be 
interesting to know whether PADI4 activation may also play a role to redirect 
or tune Wnt signalling – gene expression microarray analysis or RNA 
sequencing experiments analogous to those in Figure 4.13 could test this 
hypothesis. 
 
Further experiments will also help tease out mechanistic details by which 
increased PADI4 activity might enhance Wnt transcriptional activity, 
especially to look investigate effects on β-catenin stability and citrullination. It 
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is of note that while undertaking the experiments described in the chapter, 
another study identified PADI2 as having an opposing role in Wnt 
signalling78. In this study, a small molecule screen found a new role for the 
anti-parasitic drug NTX in inhibiting Wnt signalling. Following a 
chemoproteomic screen, the authors identified that NTX binds to and 
stabilizes PADI2. They subsequently showed that PADI2 citrullinates β-
catenin directly and that this increases β-catenin turnover. In light of the 
results from the reprogramming system, possibly opposing roles of PADI2 
and PADI4 might be anticipated. 
 
This is interesting with respect to the data outlined here and also to a follow 
up experiment performed by Abigail Wilson, lab technician in the 
Christophorou lab. In the reprogramming system, two populations of cells 
were revealed (Figure 4.14). The reprogrammed population was enriched for 
PADI2, and the non-reprogrammed population enriched with PADI4. It is also 
notable that the non-reprogrammed population is enriched with PADI4 and 
could potentially show amplified Wnt signalling. This lends credence to the 
possibility that PADI2 and PADI4 might have opposing roles in Wnt 
signalling. If validated, this could imply a role for the non-reprogrammed cells 
as support cells that increase or drive reprogramming in the minority 
population. Given the role of Wnt in paracrine signalling, this is an attractive 
hypothesis. 
 
Figure 4.14: Contrasting expression of PADI4 and PADI2 in reprogramming cells. Pre-




factors, are cultured in neural stem cell media for 4 days, then in mouse ES cell media 
supplemented with recombinant LIF for 2 days and finally frozen following Christophorou et 
al.32,59. C: Immunoblot analysis of mouse PADI4, mouse PADI2, and H3Cit of whole cell 
extracts of pre-iPS cells (day 6 cells, Lane 1). Pre-iPS cells were then also cultured for 
seven additional days of KSR2i treatment (Lanes 2-4). These cells (lanes 2-4) were then 
sorted GFP by FACS. Since the endogenous mouse Oct4 locus is tagged with GFP, after 
reprogramming, successfully induced pluripotent stem cells can be distinguished from the 
non-reprgrammed population by GFP expression. Immunoblot analysis was then performed 
on a mixed GFP and non-GFP population (Lane 2), a purified majority (~95%) non-GFP 
population (Lane 3), and on the purified minority (~5%) GFP-positive population (Lane 4). 
Experiments shown in this figure were performed by Abigail Wilson. 
 
It will be important to consider the effects of both PADI2 and PADI4 in future 
experiments to explore in detail these effects. It would be interesting to 
repeat some of the experiments in this chapter using the analogous model 
system of PADI2-stable mouse ES cells such that the effects of Wnt 
signalling on PADI2 protein and the effect of PADI2 inhibition on Wnt 
signalling could be directly compared to the effects described for PADI4. 
Opposing effects for the two paralogues (PADI2 and PADI4) would be 
particularly important findings, especially in light of difficulties teasing apart 
their complementary roles in disease (discussed in Chapter 1). The data from 
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Chapter 5: Cyclic peptide reagents to target PADI4 for inhibition, 
activation and affinity purification 
 
5.1.1 Introduction  
The current toolkit for probing PADI4 activity is limited. PADI4 enzyme 
activity in cells is poorly understood and activation can be induced by 
pleiotropic stimuli. As there are no ways to activate the enzyme cleanly, this 
has hampered efforts to understand the biological functions of PADI4. 
Irreversible inhibitors have been developed1,2, and a reversible inhibitor had 
been recently published at the start of my PhD that targets the inactive 
conformation of PADI43.  An enzyme activator would be particularly useful for 
the purpose of elucidating more precise biological roles for PADI4. It would 
also be useful to have additional tools capable of isolating the protein from 
cells, as well as other reagents for specifically visualizing PADI4.  
 
This chapter describes the collaborative project that I initiated with Dr Louise 
Walport at the University of Tokyo to develop and characterise chemical 
biological tools for targeting PADI4. Dr Louise Walport was a colleague of 
mine during my Masters lab (Schofield lab, University of Oxford) and went to 
join the Suga lab (University of Tokyo) for a Marie Curie fellowship to study 
2-oxoglutarate-dependent oxygenases4 when I began my PhD. The Suga lab 
pioneered a method to screen a vast library of peptides for high binding 
affinity to a protein target5. Previously the RaPID method has been very 
successful in generating cyclic peptide displaying high affinity binding and 
potent inhibition of protein targets. We thought the RaPID method might be 
particularly appropriate for targeting PADI4 in order to generate potent 
reversible inhibitors. The RaPID system has not previously been used to find 
enzyme activators, but we considered that PADI4 may be an interesting test 
case for identifying PADI4 activators as well as potentially for finding 






5.1.2 Challenges and progress in developing PADI inhibitors 
One of the key challenges in discovering PADI inhibitors has been the 
development of high throughput assays for measuring protein citrullination. 
The colorimetric COLDER assay makes use of a Colour Developing Reagent 
(COLDER) (diacetyl monoxime and thiosemicarbazide in the presence of 
strong acids and Fe3+) to convert citrulline into a visible dye, but the reliance 
of the assay on strong acids and toxic reagents has limited its use6,7. 
Glutamate dehydrogenase (GLDH) was used to monitor PADI activity 
through detection of ammonia release8, but a significant problem is the need 
to deconvolute hits that target GLDH, which is not trivial given GLDH’s own 
complex allosteric regulation. A competition assay involved incubating 
enzyme with target compounds in the presence of rhodamine-conjugated F-
amidine, but relies on detection by gel electrophoresis (F-amidine and Cl-
amidine are irreversible inhibitors discussed in the introduction, Section 
1.9)1,9. This assay was used to identify various weak PADI inhibitors (such as 
streptomycin, chlortetracycline and minocycline as weak inhibitors). 
Additionally, an antibody based ELISA assay was developed but makes use 
of an antibody that is no longer commercially available10. Finally, a 264-
member peptide library was synthesized (comprising variants of Ac-Y-X-F-
amidine-cystamine) to adapt F-amidine for PADI paralogue selectivity and 
resulted in TDFA, which is an irreversible inhibitor that shows at least 15-fold 
preference for PADI411. More recently, Lewis et al. used a fluorescence 
polarization binding assay in combination with GlaxoSmithKline’s DNA-
encoded small-molecule libraries in the presence and absence of calcium3. 
This identified a first compound GSK121 that is a weak inhibitor of PADI43. 
After structure-activity relationship (SAR) development, this led to the 
optimized molecule GSK484, which targets the structure in the absence of 
Ca2+ and is a potent inhibitor at low concentrations of calcium (80nM), but 
shows five-fold reduced efficacy at higher concentrations of calcium3,12. 
Tejeda et al. subsequently used the COLDER assay to validate a set of 
compounds found through in silico binding approaches with selectivity for 
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PADI2, before SAR development led to an optimized lead13. This was tested 
for efficacy in a mouse model13. 
 
5.1.3 RaPID discovery system 
The elegant Random nonstandard Peptides Integrated Discovery (RaPID) 
system was developed in the Suga lab (University of Tokyo)5 and allows a 
huge library of peptides (containing ~1013 - 1015 peptides) to be screened for 
high binding affinity (low nanomolar KD) to a target protein (Figure 5.1). This 
bypasses the need for a high throughput assay to measure protein 
citrullination as the first pass is high affinity binding, from which a number of 
candidates may be tested in more low throughput assays.  
 
The RaPID system makes use firstly of flexizyme in vitro translation (FIT) 
using purified recombinant ribosomal components that can incorporate 
noncoded amino acids. Flexizymes are evolved ribozymes that are able to 
charge a variety of non-proteinogenic amino acids directly to the 3′-end of 
tRNA. In general, this is done simply by mixing the flexizyme, a matched 
acyl-donor, and tRNA in the presence of Mg2+ and incubating for 2 hours at 
4°C. If a codon set is removed from the purified in vitro translation mix, then 
this native codon can be substituted for the flexizyme charged amino acid. In 
particular, FIT is typically used to replace the initiation codon (methionine) 
with an amino acid that spontaneously cyclises after translation. A non-
proteinogenic chloroacetyl-amino acid (where the amino acid is typically Trp, 
Phe or Tyr) is charged to tRNAfMet and the machinery for methionine is 
removed from the in vitro translation mix. The produced peptide, with an N-
terminal chloroacetyl amino acid then spontaneously cyclises post-
translationally if a cysteine residue is present C-terminally in the peptide 
sequence. The cysteine attacks the chloroacetyl amino acid intramolecularly 
to form a macrocycle closed by a thioether bond. This reaction occurs 
spontaneously to form macrocycles of at least 20 amino acids long, 
independent of the peptide sequence composition. The constrained structure 




conformations, which aids the possibility of bioactive interactions. 
Macrocyclic peptides of this type are inspired by natural lantibiotics, which 
are similarly closed by a thioether linkage (such as that in lanthionine). 
Lantibiotics often also incorporate heavily post-translationally modified or 
otherwise non-proteinogenic amino acids (and may be the function of the 
cyanobacterial and other bacterial homologues identified in Chapter 3, 
Section 3.4). Using FIT, other amino acids can be similarly substituted as 
desired to replace another codon in the mixture enabling replacements such 
as non-proteinogenic amino acids, D-amino acids or backbone N-methylated 
amino acids. This additional variety, along with cyclisation, can confer on the 
polypeptide structural rigidity, very high target affinity, resistance to 
proteolysis, and occasionally membrane permeability. 
 
Flexizyme in vitro translation was ingeniously combined with an mRNA-
peptide display method originally developed in the Szostak lab14,15 to 
comprise the full RaPID system, whereby cyclic peptide drug targets can be 
screened in a time frame of less than a week5. Overall, the RaPID system 
makes use of the following approximate general protocol. A vast DNA library 
is synthesized (coding for ~1015 peptides in a single screen – as much as 
eight orders of magnitude larger than most large pharmaceutical company 
small molecule screens). By comparison, the peptide library used to develop 
peptide versions of Cl-amidine such as TDFA made use of a library of 264 
different peptides11. The vast DNA library is in vitro translated as described 
above to introduce the N-terminal chloroacetyl amino acid and a cysteine is 
always included C-terminally in the sequence, resulting in spontaneous 
peptide cyclisation. Crucially, this FIT step is also performed in the presence 
of the antibiotic puromycin, which is incorporated into the ribosome in the 
final step of translating messenger RNA for each peptide. Puromycin stalls 
the ribosome during translation such that each peptide is subsequently 
ligated to the mRNA that codes for its own sequence– thus acting as a 
barcode. Reverse transcription is then performed so that the barcodes are 
converted into mRNA-DNA hybrids. This vast library of barcoded cyclic 
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peptides is then presented to a target protein of interest (this process is 
referred to as a “round of selection”). Any peptide sequences that are 
retained (enriched in the selection) can therefore be amplified by polymerase 
chain reaction (PCR) and the process is repeated. After a number of rounds, 
certain peptides become heavily enriched and their barcodes can be 
amplified and sequenced. Any candidate peptides can then be synthesized 
by solid phase peptide synthesis (SPPS) and tested in downstream assays 
(Figure 5.1). 
 
Figure 5.1: Schematic showing the RaPID system method and the design for PADI4 
selections. A: RaPID overview. A DNA library (1013) coding for short peptide sequences all 
containing an N-terminal methionine and a cysteine located C-terminally, is synthesized and 
transcribed into mRNA. The mRNA library is ligated to puromycin and in vitro translated 
using flexizyme charged tRNA to replace methionines with a chloroacetyl tyrosine amino 
acid. This generates a library of cyclic peptides each covalently ligated to the mRNA that 
codes for it. After reverse transcription, the library is washed against the target protein 
(‘selection’). Tight binding peptides are retained and their sequences can be enriched by 
PCR. Further rounds of selection are performed which enriches sequences that bind with 
very high affinity. B: Schematic of the first selection to identify cyclic peptides that bind with 
high affinity to the active site of PADI4 in its active conformation. This was performed against 
biotinylated human PADI4 immobilised on streptavidin beads in the presence of 10 mM 
CaCl2. See Figure 5.2A for crystal structure representation. C: Schematic of the second 
selection to identify cyclic peptides that bind allosterically to PADI4 protein trapped in the 
active conformation. This was performed against biotinylated human PADI4 immobilised on 
streptavidin beads in the presence of 10mM CaCl2 but which was also incubated with Cl-
amidine (an irreversible inhibitor that reacts covalently in the PADI4 active site to cysteine 




calcium ions, the red oval represents the enzyme active site, and the blue square represents 
the irreversible small molecule inhibitor Cl-amidine. 
 
The RaPID system has been used for the discovery of many highly potent 
peptide inhibitors, typically with extremely high (low-to-sub nM) binding 
affinities (KD) and IC50s5. This has been used very successfully to develop 
potent inhibitors against a variety of protein targets. These include 
membrane proteins and extracellular enzymes including human α-amylase16, 
drug transporters and receptor tyrosine kinases17, but also inhibitors of some 
intracellular targets such as the AKT2 kinase18, the ubiquitin ligase E6AP19, 
the histone deacetylase SIRT220,21 and the lysine demethylase KDM4A22. 
Another peptide targeting a protein-protein interaction was discovered 
against Zaire Ebola virus protein 24 (VP24)23, and allosteric inhibitors have 
also been found using this system24. Although in general the process reliably 
identifies molecules with very high binding affinity, the main focal problem for 
the broad application of cyclic peptides as therapeutic intracellular drug leads 
is that these macrocyclic inhibitors are only occasionally cell permeable and 
bioavailable.  
 
It is not fully understood what elements of a peptide sequence, particularly in 
combination, may enable cell permeability, as there are a range of competing 
factors25. In some cases, cyclic peptides, such as cyclosporine A, are thought 
to be freely diffusible across cell membranes. In other examples, they are 
thought to hijack a cell’s active uptake mechanisms: α-amanitin is thought to 
use an organic anion transporting polypeptide transporter26, whereas 
cyanobacterial microcystins appear to hijack active uptake specific to 
mammalian liver cells (explaining their hepatoxicity)27. Other cell-penetrating 
peptides (or peptide transduction domains) appear to cross cell membranes 
directly. These short peptidic regions belong to diverse sequence classes 
ranging from arginine-rich polycationic sequences such as the HIV-1 TAT 
peptide (GRKKRRQRRRPQ)28, through to amphipathic sequences such as 
the Drosophila spp. antennapedia peptide sequence 
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(RQIKIWFQNRRMKWKK)29, and even to a rarer class of predominantly 
hydrophobic sequences30-32.  
 
The secondary structure of the peptide, such as the presence of alpha helical 
structure, is also likely to be involved in permeability, as is polarity, size and 
lipophilicity. Other peptidic molecules may traverse membranes by forming 
pores, through endocytosis mechanisms, such as macropinocytosis, or 
through hijacking the endoplasmic reticulum associated protein degradation 
(ERAD) machinery. Because of the multiple methods by which cyclic 
peptides might attain cellular access and although certain peptides can be 
engineered to ameliorate their intrinsic cell permeability, a general and 
predictive approach has not yet been elucidated and adopted. Multiple 
strategies can nonetheless be employed to improve intrinsic cell permeability 
including backbone N-methylation, single point substitutions, D-amino acid 
incorporation, myristoylation, tagging to a cell targeting peptide, or 
conjugating to a scaffold with intrinsically permeable properties33. In 
individual cases, it is difficult to predict in advance which may be the most 
valuable. An alternative and likely promising approach would be a cargo 
approach for therapeutic delivery25,34. 
 
5.1.4 Previous RaPID targeting of PADI4 in the Suga lab 
As it happens, several years before the start of my PhD project, a C-terminal 
His-tagged-PADI4 had already been screened for inhibitors in the Suga lab 
against a newly designed library that had been created to optimize cell 
permeability (personal communication, Prof Hiroaki Suga and Dr Louise 
Walport). The selection was carried out without calcium in the buffers and 
with ethylenediaminetetraacetic acid (EDTA, a calcium ion chelator) present. 
Several 30-80 nM KD binders were found as determined by surface plasmon 
resonance (SPR) in the absence of Ca2+ and in the presence of EDTA. 
However, in vitro IC50s by the COLDER assay were only ~5 µM and only 
slightly more potent than Cl-amidine. COLDER activity assays were carried 




most potent peptides all included an arginine residue; it was not tested 
whether this was converted to citrulline. A second-generation peptide was 
made where the arginine was replaced by Cl-amidine, but which did not 
increase the potency greatly. Activity assays were subsequently performed in 
cells, using western blot to detect citrullination, but inhibition was not 
observed using the peptides from the selection. 
 
Dr Louise Walport and I hoped to try to improve on the results obtained 
previously and in particular to design selections that might result in a greater 
correlation between binding affinity and potency. It was therefore decided to 
subclone the PADI4 gene into a 6xHis-Avi-tagged expression vector and co-
express the protein with the biotin ligase BirA. The 6xHis tag allows for high 
yield and efficient purification. The Avi tag is site-specifically biotinylated by 
BirA at a Lys residue contained within the tag, such that the protein can be 
coordinated to streptavidin-coated magnetic beads during the selection step. 
The strong affinity of biotin for streptavidin enables robust protein 
immobilization during the RaPID system process and in general is found to 
give better results (such as by allowing for more stringent washing steps). 
We also opted to design modified selection strategies to try to improve the 
correlation between binding affinity and potency of inhibition. 
 
5.1.5 Objectives 
• Design and perform cyclic peptide selections to target PADI4 
• Screen candidate cyclic peptides targeting PADI4 for inhibition, 
activation and pulldown 
• Characterise peptides for activity in vitro and in cells and optimise 
peptides for cellular permeability 
 
5.2 Designing selections to target PADI4  
Dr Louise Walport and I designed two modified selection strategies for the 
identification of PADI4-binding peptides. Firstly, it was decided to preincubate 
the immobilized beads bound to PADI4 protein in a high calcium ion 
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concentration (10 mM Ca2+) before performing the selection (Figure 5.2A). 
The high calcium concentration would be maintained in all buffers during the 
selection steps. It was reasoned that this would force the PADI4 enzyme into 
an active conformation for the selection rounds, such that high affinity binding 
peptides might be found against the fully structured active site cleft35. It was 
hoped that selecting against the active enzyme conformation, provided that 
calcium did not interfere with the RaPID steps, would be likely to give an 
improved correlation between binding affinity and inhibition. 
 
We then designed a second selection. PADI4 would be preincubated in 
calcium containing a saturating concentration of Cl-amidine prior to selection. 
Cl-amidine is an irreversible small molecule pan-PADI inhibitor that reacts 
covalently with the active site cysteine of PADI4 and therefore blocks access 
to the active site (Figure 5.2B). This inhibited form of PADI4, maintained in 
high calcium and trapped in an active conformation, would then be used in 
the rounds of selection. It was hoped therefore that this strategy might enrich 
for high affinity binding peptides that bind PADI4 allosterically. Within such a 
pool of peptides, we hoped that we might identify ones that might act to 
stabilize the active conformation of the enzyme and act as activators of the 
enzyme. This would in theory provide proof of concept that the allosteric 
binding of an interacting partner can activate PADI4, which has been 
hypothesized to occur within the cell.  
 
Finally, candidate peptide sequences that bind strongly and independently of 
the calcium concentration are likely to be enriched in either selection. These 
would be potentially useful for developing into affinity reagents or a chemical 
biological probe for visualizing PADI4 by, for example, conjugating it to biotin 





Figure 5.2: Crystal structures showing PADI4 selection designs for inhibitors and 
activators.  A: Crystal structure of PADI4 soaked in 10mM CaCl2 (pdb: 1wd9) to maintain it 
in the active conformation visualized in Chimera with protein surface displayed. Active site 
triad (Asp, His, Cys) residues are coloured in red showing the structured active site cleft. B: 
Crystal structure of PADI4 soaked in 10mM CaCl2 to maintain it in the active conformation, 
with the active site blocked by the irreversible inhibitor Cl-amidine (pdb: 3b1t) visualized in 
Chimera with protein surface displayed. Active site triad (Asp, His, Cys) residues are 
coloured in red showing the structured active site cleft. The active site cysteine is covalently 
ligated to Cl-amidine (coloured in dark blue). Figures were prepared in Chimera using PDB 
structures 1wd9 and 3b1t. 
 
The selections were performed by Dr Louise Walport in the lab of Prof 
Hiroaki Suga at the University of Tokyo. Candidate peptides were sequenced 
and synthesized by SPPS and sent in lyophilized form for me to test in 
downstream assays at the MRC Human Genetics Unit, Edinburgh.  
 
5.3 Inhibitor peptides 
5.3.1 Design for an in vitro screening assay for PADI4 inhibition 
A citrullination assay was required to screen the candidate peptides in vitro 
as well as for other uses described elsewhere in this PhD thesis. Given that 
PADI activity has been shown to be robust to the presence of detergent in 
previously published assays3,37, a citrullination assay using cell lysates was 
173 
 
developed. In Darrah et al., undifferentiated HL60s were lysed in 1% NP-40, 
sonicated and cleared by centrifugation before incubation with recombinant 
PADI enzymes, providing the enzymes with a wide range of substrates37. 
These were detected using western blotting with a protocol and antibody that 
detects chemically modified citrullinated products (Mod-Cit). This implied that 
PADI enzymatic activity might be sustained in the presence of as much as 
1% NP-40 detergent. In Lewis et al.3, a similar type of assay was used to test 
the selectivity of different PADI orthologues. Stable HEK293 cell pools 
expressing FLAG-PAD1, FLAG-PAD2, FLAG-PAD3 or FLAG-PAD4 were 
engineered and lysed in 0.4% NP-40 with the same detection method by 
Western blotting against anti-modified citrulline. 
 
Based on these two approaches, I set up a lysate assay using the human 
PADI4 expressing mES cell line described in Chapter 4 (PADI4-stable mES 
cells)38. A control mES cell line that contains the empty vector was also 
included in the assays (Control-stable mES cells). Cells were washed in PBS 
with 0.5 mM EDTA and lysed by adding a lysis buffer containing 1% NP-40 
directly to the plate and scraping the cells (Chapter 2.2.6.1). A relatively high 
concentration of NP-40 was selected to disrupt the nuclear membrane more 
efficiently. Benzonase was added and the lysate passed through a 25 G 
needle to shear and digest genomic DNA, disrupt the chromatin, and release 
histone substrates and chromatin-bound PADI4. The lysate was cleared by 
centrifugation, pooled and separated in equal volumes into different tubes 
preincubated on ice. Additional components such as calcium chloride or the 
cyclic peptide candidates may be added at this point to the lid of the tube 
made up to an identical total volume, and the assay initiated by a quick 
bench top centrifuge spin. Boiling the tubes at 95˚C quenches the assay. The 
activity of PADI4 can then be tested under a carefully controlled calcium 
concentration; other recombinant factors, inhibitors or cofactors can be 





The lysate assay design provides several advantages. As the protein 
components are all produced by the cultured cells, there is no need to 
express, produce, and purify batches of recombinant enzyme or substrate. 
Since both enzyme and substrate are produced in the same starting cell 
lysate mixture, the relative concentrations of each will be exactly the same 
between each assay condition such that differences in total amounts of 
substrate/enzyme are kept to within a single pipetting error measurement 
and the ratio between the two will be identical. This assists in ensuring 
consistency in medium-throughput format when many samples are run for 
detection by Western blotting. Similarly, all the sample preparation for 
running by Western blotting occurs prior to the start of the assay such that no 
variability is introduced between conditions after the assay. 
 
Figure 5.3 shows the results of the assay set-up. No activity is detected from 
the control cells in any condition showing that all activity under these 
experimental conditions is due to the exogenous human PADI4 enzyme. In 
PADI4-stable mES cells, a small amount of histone 3 substrate is 
endogenously citrullinated by human PADI4 in the resting cell state prior to 
assay incubation (Lane 12), but no additional citrullination can be detected 
after incubation in the absence of calcium during the course of the assay 
(Lane 7). Human PADI4 enzyme therefore shows the expected absolute 
requirement for calcium in this assay. In 5 mM Ca2+, a large extent of H3Cit 
can be detected after the assay incubation showing a wide maximum 
detection range for inhibition. This level of citrullination is clearly reduced in 
conditions where Cl-amidine and GSK484 have been added. In neither Lane 
10 (Cl-amidine) nor Lane 11 (GSK484) is H3Cit totally inhibited to 
background levels (Lane 7), showing that these inhibitors are not saturating 
in this assay even at their respective recommended concentrations. Full 
inhibition in this assay is a stringent test for candidate inhibitors (Figure 5.3). 
At their recommended concentrations, Cl-amidine (at 200 µM) can be seen to 
be more effective than GSK484 (5 µM). This indicates that the lysate assay is 
sensitive to differently effective inhibitors, which gives plenty of scope to 
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compare the efficacy of inhibition by any potential peptide candidates. A 
couple of additional observations were interesting: NPM1 appears to shift to 
higher apparent molecular weight in the activated conditions, most likely as a 
result of citrullination and autocitrullination respectively. As the mass change 
resulting from citrullination is small (0.98Da), the concomitant loss of charge 
is likely to result in the differing behavior under electrophoresis conditions in 
affecting protein motility. The reported citrullination site of NPM1 (R197) is 
not contained within the N-terminal epitope of the antibody to NPM1 (the 
epitope is an 14-22 amino acid region within a synthetic peptide 
corresponding to N-terminal amino acids 6-55 of human NPM1) and does not 
appear to affect antibody binding as the loading appears to be equal between 
conditions. A similar effect appears to be occurring to human PADI4. 
 
Figure 5.3: Initial set-up of the lysate citrullination assay to detect PADI4 activity. 
Immunoblot analysis of H3CitR2 and PADI4 of a lysate citrullination assay using Control-
stable mES cells (Lanes 1-6) or PADI4-stable mES cells (Lanes 7-12). Lysates were 
incubated in the absence (Lanes 1 and 7) or presence of Ca2+ (5mM) (Lanes 2-5, 8-11) for 
30 mins. Cl-amidine (200µM), GSK484 (100µM) or EDTA (10mM) were added at the start of 
the assay. Lanes 6 and 12 show cells lysed before the start of the assay incubation. Data 






5.3.2 Screening for PADI4 peptide inhibitor candidates 
Candidate peptides (1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 11b, and 14) at three 
different concentrations (200 µM, 20 µM, 2 µM) were then screened for 
PADI4 inhibition in vitro. Peptides were reconstituted from solid in pure 
DMSO at a high stock concentration (Chapter 2.1.18) such that DMSO 
concentrations were kept below 1% per assay condition. Control conditions 
always contained the same amount of DMSO as the peptide treated samples 
(labelled as “vehicle”). Spectrophotometry was used to measure the peptide 
concentrations using the predicted extinction coefficients and concentrations 
calculated using the Beer Lambert law (A = ε.c.l). This is likely to be more 
accurate than accurate mass measurements as different peptides in 
lyophilised salt form after SPPS will have unpredictably different counter ions 
that will affect their relative masses. Peptides or previously published 
inhibitors were added to the lid with calcium chloride, and assays begun by 
quick centrifugation. The peptide names in the screen were blinded both to 
the peptide sequence and to which method of selection (for inhibitors or 
activators) they had been enriched in. Although the majority of peptides 
(peptides 4, 5, 6, 7, 8, 9, 10, 11, 11b, and 14) did not show inhibition (Figure 
5.4), two candidates (peptides 2 and 3) showed a clear inhibitory effect in the 
assay (Figure 5.4A) at 200 µM and 20 µM concentrations. Peptide 3 showed 
full inhibition to background levels even at 2 µM concentration (Figure 5.4A, 




Figure 5.4: Screen of candidate cyclic peptide inhibitors. Immunoblot analysis of 
H3CitR2 of a lysate citrullination assay supplemented with vehicle, Cl-amidine (200µM), 
GSK484 (200µM) and serially diluted peptide # (200µM, 20µM, 2µM) in the presence of 
5mM Ca2+ for 30 minutes. Data shown are from a single preliminary screening experiment; 
candidate peptides 2 and 3 from Panel A were taken forward for validation. 
  
The assay was repeated at ten-fold serial dilutions of peptide 3 from 20 µM 
down to 2 nM (Figure 5.5). This experiment showed that Peptide 3 resulted in 
partial inhibition down to a concentration of at least 20 nM. Peptide 3 showed 
comparable inhibition to the best previously published reversible PADI4 
inhibitor (GSK484) at a thousand-fold lower concentration (Figure 5.5). 
 
Figure 5.5: Peptide 3 potently inhibits PADI4 in vitro. Immunoblot analysis of H3CitR2 of 
a lysate citrullination assay supplemented with Cl-amidine (200µM), GSK484 (200µM) and 
serially diluted peptide 3 (20µM, 2µM, 200nM, 20nM, 2nM) in the presence of 5mM Ca2+ for 
30 minutes. Data are representative of n = 2. 
 
GSK484 has been previously published to have much a higher efficacy in 
vitro than observed in these assays3, but is also reported to be five times less 
potent in a 2 mM calcium buffer than in the low calcium buffer for which its 
IC50s were measured12. Given that GSK484 binds to a loop in the inactive 
calcium unbound form of PADI4, I hypothesized that a pre-incubation step 
with the enzyme might therefore increase the potency of GSK484 to more 




repeated such that the peptide or other inhibitors were added for 20 minutes 
prior to the addition of calcium chloride. This showed a marked increase in 
the efficacy of GSK484 at 100 µM (Figure 5.6). These data are consistent 
with the reported mode of action of GSK484 in targeting only the inactive 
form of PADI4. In addition, these data show that already activated PADI4 will 
continue to be active even in the presence of a very high concentration of 
GSK484 (Figure 5.6). The irreversible inhibitor Cl-amidine at 200 µM (Figure 
5.6: Lane 3 versus Lane 10) as well as peptides 2 and 3 at 50 µM (Figure 
5.6: Lanes 5 and 6 versus Lanes 12 and 13) were equally effective with or 
without pre-incubation steps, showing they can also inhibit the activated 
enzyme. 
 
Figure 5.6: Comparison of peptides 2 and 3 for inhibition of PADI4 with GSK484. 
Immunoblot analysis of H3CitR2 of a lysate citrullination assay. In Lanes 1-7 lysates were 
preincubated on ice with vehicle, EDTA (10 mM), Cl-amidine, GSK484, peptide 2, peptide 3 
or peptide 7 for 20 minutes, before CaCl2 was added to begin the assay and the lysates 
incubated at 37˚C for 30 minutes. In Lanes 8-14, no preincubation step was performed and 
inhibitors or peptides were added concurrent to the addition of CaCl2 and incubated for 30 
minutes at 37˚C. Data are representative of n = 2. 
 
5.3.3 Testing peptides on cells: inhibitors 
The inhibitor peptides were then tested for their effect on cellular PADI4 
(peptides 2 and 3) using conditions established in the previous chapter. 
Firstly, the activation condition of PADI4-stable mES cells treated for 6 hours 
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in KSR2i, was used to test the effect of the peptide inhibitors on cells (Figure 
4.8A). As discussed in Chapter 4 (Section 4.2.5), this activation condition 
makes use of serum withdrawal and culture in knockout serum replacement 
(KSR), in combination with two specific small molecule inhibitors of the 
kinases GSK3β and MEK1/2 respectively (abbreviated as KSR2i) during a 6-
hour treatment. KSR2i has precedent in the literature in increasing the 
efficiency of reprogramming somatic cells into induced pluripotent stem cells 
and in the establishment of ground state pluripotency39,40. Peptide 2 and 3 
both reduced levels of H3Cit (Figure 5.7). H3Cit is taken as a proxy for 
PADI4 inhibition in this system. Cells were treated with this activation 
condition concurrently with four different peptide concentrations (75 µM, 15 
µM, 3 µM, 0.6 µM) for 6 hours, with total DMSO concentrations kept constant 
across all treatments at 1% (Figure 4.8B and C). Peptide 3 showed efficacy 
at 75 µM with some efficacy at 15 µM and was observed to be more potent 
than peptide 2. It was concluded therefore that although both peptide 2 and 3 
appear to be somewhat cell permeable, peptide 3 was more potent in all 
tested cases, both in vitro and in cells. To streamline efforts, peptide 3 was 
taken forward for validation and sequence optimization. 
 
Figure 5.7: Peptide 2 and 3 inhibit PADI4 in cells activated by KSR2i. A: Immunoblot 
analysis of H3CitR2 of whole cell extracts of mES PADI4-stable cells after six hour treatment 
with serum and vehicle (Lane 1), KSR2i (Lane 2-6) in the presence of vehicle (lane 2), Cl-




refers to the use of 1µM PD03250910 (inhibitor of MEK1/2) together with 3µM CHIR99021 
(inhibitor of GSK3β)58. Dotted line indicates the removal of irrelevant lanes, from the same 
gel at the same exposure. Panels B and C show immunoblot of H3CitR2 of whole cell 
lysates extracted from PADI4-stable mES cells cultured in KSR2i for 6 hours in the presence 
of an increasing concentration of B: peptide 2 and C: peptide 3. In Panel A, data shown are 
representative of n = 3; in Panel B, data shown are from a single preliminary experiment; in 
Panel C, data shown are representative of n = 3. 
 
Peptide 3 was then tested in a second activation condition identified in 
Chapter 4 (Section 4.2.6). In this second activation condition, activation of 
PADI4 was observed after use of the GSK3beta inhibitor (CHIR99021) after 
45 minutes (without serum withdrawal or MEK1/2 inhibition) (Figure 4.9). 
Peptide 3 was pre-incubated with the cells for 2 hours and then CHIR99021 
applied for 45 minutes (Figure 5.8). Full PADI4 inhibition occurred in the 
presence of 30 µM peptide 3 to the same level as control. Inhibition occurred 
dose dependently with some inhibition at 10 µM peptide, but no inhibition 
observed at 3 µM (Figure 5.8).  
 
Figure 5.8: Peptide 3 inhibits PADI4 in cells activated by GSK3 inhibition. Immunoblot 
of H3CitR2 of whole cell lysates extracted from PADI4-stable mES cells pre-treated for 2 
hours in the presence of an increasing concentration of peptide 3 (30µM, 10µM, or 3µM) 





5.3.4 Optimising the peptide 3 sequence for cellular potency 
We reasoned that it might be possible to optimize the peptide 3 sequence 
further for cellular potency. To do this, Dr Louise Walport performed a 
mutational scanning experiment with the RaPID selection methodology, 
using a strategy recently developed in the Suga lab41. Briefly, a new DNA 
library was prepared, using the parent peptide 3 sequence as a template, in 
which every residue was individually mutated to every other amino acid. 
Multiple members of each alternative sequence were included. The original 
library was then sequenced to identify what the original make-up of the 
library is at the start and then a single selection was performed with this 
library against the protein target, with long washes (3 x 12 hour washes) to 
ensure equilibrium binding is reached with the target protein41. The input and 
output libraries were then sequenced and compared to produce log2 ratios of 
enrichment for every mutated residue in the parent sequence. This in theory 
should be proportional to the KD of the new sequences (provided equilibrium 
binding is achieved during selection). In addition, a codon for backbone N-
methylated alanine was used, so the log2 ratio was obtained for N-methyl 
alanine over alanine for each residue in the parent sequence is included in 
addition. From the comparison of enrichment of N-methyl alanine against 
alanine, Dr Walport hypothesized that it may be possible to deduce which 
residues may be well-tolerated for backbone methylation.  
 
Dr Walport then synthesized a first round of peptide variants for me to test in 
citrullination assays on cells. After this first set of results, a second round of 
optimization was undertaken, including a myristoylated variant of peptide 3 
and both Arg-Cit mutants of the parent sequence. The latter variants were 
selected based on the results of the Arg->N and Arg-W mutants from the first 
round (which at these positions revealed enrichment) and from the results of 
the SPR data (Figure 5.15) where peptide 3 mutation from arginine to 
citrulline still maintained nanomolar binding affinity. A handful of double 
mutants were also prepared. Citrullination assays were then performed on 





All assays were performed blinded to the sequence name or identity 
(Peptides 3.2, 3.3, 3.4, 3.5, 3.6, 3.7, 3.8, 3.9). Figure 5.9A-B shows the 
efficacy of two of the synthesized peptide 3 variants used in cell assays (right 
panels, Figure 5.9A-B) alongside the panel of log2 ratio of enrichment 
obtained from mutational scanning for that residue (left panels, Figure 5.9A-
B). As before, Dr Walport then obtained SPR data for the new variants. The 
efficacy of all tested peptide 3 variants is summarized in a table (Figure 5.9C) 
together with the SPR data obtained by Dr Walport. 
 
 
Figure 5.9: Optimising inhibitor peptide sequences. A RaPID selection against human 
PADI4 was performed with a DNA library containing a known number of copies of variants of 
the initial peptide 3 sequence (YRDHHYRHPKYCG) where every amino acid was singly 
permuted to all other possible amino acids along with a known number of copies of the 
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original sequence. Several rounds of selection were performed with long washes after which 
all barcodes were sequenced. The log2(ratio) for variant sequence enrichment over the 
original sequence was plotted (y-axis) for each mutated residue (x-axis) in a separate graph 
for every residue in the original peptide 3 (one graph of log2(ratio) enrichments per residue in 
the original sequence). A plot for all possible single substitutions are shown in the middle 
panel for B: the 4th residue (His) of peptide 3 and C: the 10th residue (Lys) of peptide 3. The 
right hand panels show immunoblot analysis of whole cell lysates extracted from PADI4-
stable cells cultured in KSR2i for 6h, in the presence of an increasing concentration of A: the 
original peptide 3 sequence, as well as two synthesized peptide variants B:  peptide 3.5 
(variant His4 to Arg) and C: peptide 3.3 (variant Lys10 to Ile). Data are representative of n = 
2. D: Table showing sequences of the peptides tested including all variants of the original 
peptide 3 tested with results of tests in cells (column 4) and SPR binding data obtained from 
experiments by Dr Walport (column 5). Dr Walport performed RaPID screen and synthesized 
all cyclic peptides. 
 
5.4 Activators 
5.4.1 Screening for PADI4 peptide activator candidates 
The citrullination lysate assay to screen for candidate inhibitors was then 
adapted to screen for putative PADI4 peptide activators. To do this, the 
citrullination lysate assay was performed at a single concentration of peptide 
(100 µM) at three different calcium concentrations (100 µM, 500 µM, 1 mM) 
for 45 minutes. This Ca2+ range spans the absolute requirement for calcium 
of human PADI4 on the histone 3 substrate (Figure 4.2A)7,42. I hypothesized 
that a candidate activator might act to lower the calcium dependence of 
PADI4 (in other words increase the calcium sensitivity) in this assay as 
compared to a vehicle treated condition. 
 
The assay was then performed to screen all of the peptide candidates for 
their ability to activate PADI4 in vitro (peptides 1, 4, 5, 6, 7, 8, 9, 10, 11, 11b 
and 14). The peptide names were blinded both to the peptide sequence and 
to the method of selection (for inhibitors or activators) from which they were 
discovered. Peptide 2 and 3 were not included, as they had already showed 
efficacy as inhibitors. Although the majority of peptides (peptides 1, 4, 5, 6, 7, 
8, 9, 10 and 11b) did not show any clear activating effect at the lower calcium 




vehicle was also performed (Figure 5.11A). Using control Peptide 9 or 
vehicle, no activity could be detected at 500 µM Ca2+ or lower during the 30-
minute incubation, but robust activity was detected in the presence of a 
minimum of 1 mM Ca2+ (Figure 5.11 A and B, left hand panels).  By contrast, 
the addition of either peptide 11 or peptide 14 results in activity of PADI4 at 
the lower 500 µM concentration of calcium ions (Figure 5.11 A and B, right 
hand panels). This shows that the presence of peptide 11 or 14 lowers the 
calcium dependence of human PADI4 and thereby drives enzyme activation 
in vitro. The control peptide ensures that an unknown artefactual cofactor 
introduced in the synthesis of the peptides (such as in the SPPS steps) was 
not responsible for the observed activation effect. This indicates that the 
specific sequences of Peptides 11 and 14 are responsible for the effect, 
although it is possible that the activation effect could be mediated indirectly 
through binding to a different component in the lysate.  
 
Figure 5.11: Peptides 11 and 14 activate PADI4 in vitro. Immunoblot analysis of H3CitR2 
of a lysate citrullination assay. A: Vehicle (Lanes 1-8, left hand side of panel) or 100µM 
peptide 11 (Lanes 9-16, right hand side of panel) were added with serially diluted CaCl2 and 
incubated with the lysate for 30 minutes. B: Control peptide 9 (Lanes 1-8, left hand side of 
panel) or 100µM peptide 14 (Lanes 9-16, right hand side of panel) were added with serially 





A further preliminary assay was also performed at a longer incubation of 90 
minutes. During the 90 minute incubation, activity could be detected in as low 
as 250 µM Calcium (Figure 5.12B). Additionally, in each case, peptide 14 
elicited a greater activating effect than peptide 11 (Figure 5.12B). At this long 
incubation, activity in vitro appeared to be saturated at 500µM CaCl2. Further 
experiments will be need to explore further the limiting concentration of 
activating peptides and optimal in vitro incubation time. 
 
Figure 5.12: Characterising peptides 11 and 14 in vitro.  Immunoblot analysis of H3CitR2 
of a lysate citrullination assay. Vehicle (Lanes 1-4), 50µM peptide 11 (Lanes 5-8), or 50µM 
peptide 14 (Lanes 9-12) were added with serially diluted CaCl2 (500µM, 250µM, 125µM, 
62.5µM) and incubated with the lysate for 90 minutes. Data shown for these additional 
conditions are from a single preliminary experiment. 
 
5.4.3 In vitro experiments to analyse the activating peptides on 
recombinant proteins 
These experiments so far have shown the capacity for these peptides to 
activate endogenous protein from a lysate. We firstly wanted to test whether 
the peptides bound at the enzyme active site. Dr Walport therefore 
performed an assay using a biotin conjugated F-amidine molecule developed 
in the Thompson group43 (Figure 5.13A). F-amidine, unlike Cl-amidine, reacts 
only with the activated calcium-bound conformation of PADI443. Peptides 1, 
2, 3, 7, 11, and 14 were first incubated with PADI4 in the presence of 
calcium, subsequently incubated with the biotin conjugated F-amidine 
compound, and then run on an SDS PAGE gel with detection by 
Streptavidin-HRP. Preincubation with peptides 2 and 3, but not 1, 7, 11, or 
14, abrogated Streptavidin-HRP signal. This confirms that the inhibitor 
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peptides 2 and _3 clearly bind at the active site of PADI4 as they prevent 
biotin-conjugated F-amidine reacting with the active site of active PADI4 
(Figure 5.13B). The experiment lastly suggests that peptide 11 and 14 
activate by binding allosterically as suggested by their discovery from the 
second selection method, as their binding does not block access to the active 
site. 
 
We also considered that the calcium sensitivity of PADI4 may be increased 
further from the tests performed using lysates if recombinantly purified 
proteins only were used. Dr Walport therefore repeated the assay for 
peptides 11 and _14 at different calcium concentrations (0, 50 µM, 75 µM, 
100 µM, 125 µM, 150 µM, 250 µM Ca2+). We hypothesized that the activating 
peptides might enable an active conformation at lower concentrations of 
calcium. Streptavidin-HRP signal was observed down to 50 µM Calcium in 
the presence of peptides 11 and 14, where no signal could be detected in the 
absence of peptide. The intensity of Streptavidin-HRP signal was increased 
in the peptide 11 and 14 conditions over calcium only up to 150 µM, and at 
250 µM the Streptavidin-HRP was saturating with equal signal in presence 
and absence of peptide. This shows that peptides 11 and 14 allow 
stabilization of the active PADI4 conformation down to 50 µM Ca2+ when 
using recombinantly purified protein. Discrepancies in calcium dependencies 
between real substrates such as histone 3 and BAEE (on which F-amidine is 
based) have been published and may explain the higher absolute calcium 
requirement on calcium which was observed in the in vitro cell lysate assays. 
This also helps rationalize how longer incubations of peptide with enzyme 
and substrate in vitro may nonetheless enable activity on histone substrate at 
a lower calcium dependency of PADI4 (Figure 5.13C). This is strong 
additional support that Peptides 11 and 14 activate PADI4 by allosteric 
binding; their presence increases reaction of the probe at the active site. 
Presence of peptides 11 and 14 thereby mediate formation of the active 
conformation of PADI4 with the active site available for chemical reaction 






Figure 5.13: Testing peptides for active site binding and generating the active PADI4 
conformation. A: A biotinylated_F-amidine reagent developed by the Thompson group1,43. 
The probe reagent (Bio-F-amidine) reacts irreversibly with the active site cysteine (Cys645) 
only if human PADI4 is in the active conformation, but is not reactive with the inactive 
conformation43. This reagent can be subsequently visualized by western blot using 
streptavidin conjugated to horseradish peroxidase (Streptavidin-HRP) and used to detect the 
presence of active PADI4. It was synthesized and used here with a PEG linker between 
biotin and F-amidine. B: Peptide 2 and 3, but not peptides 1, 7, 11, or 14, directly bind at the 
active site. Vehicle or peptide 1, 2, 3, 7, 11, 14 were preincubated with human PADI4 in the 
presence of Ca2+ before incubating with Bio-F-amidine. Detection was then performed with 
Streptavidin-HRP by western blotting at the molecular weight of PADI4. The lack of signal in 
lanes preincubated with either peptide 2 or peptide 3 indicate active site protection from Bio-
F-amidine. C: Peptide 11 and 14 lower the calcium requirement to form active conformation 
of PADI4. Vehicle (–) or peptide 11 (+) (top panel), or vehicle (–) or peptide 14 (+) (bottom 
panel), were incubated with PADI4 at increasing concentrations of calcium before incubating 
with Bio-F-amidine and detection by western blot with Streptavidin-HRP. Experiments in this 
figure were performed by Dr Walport. 
 
5.5 Testing activating peptides on cells 
Given the promise shown by the inhibitor peptides on cells, I then decided to 
test the peptide activators directly on mouse embryonic stem cells 
expressing human PADI4 cultured in serum (Figure 5.14). Treatment with 
peptide 11 or peptide 14 activated PADI4 in these mouse ES cells without 
any additional activating stimulus. In serum, clear activation could be 
observed at 75 µM peptide 11 and as low as 30 µM peptide 14 (Figure 5.14). 
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Preliminarily, I then employed the peptides in combination with the KSR2i 
activation condition developed in Chapter 4 (Section 4.2.5, Figure 4.8). In 
combination with KSR2i the peptides appeared to activate at a concentration 
as low as 15 µM, suggesting that the modes of activation may work in 
tandem (Figure 5.14C) and clearly merits further repeats. It will be 
particularly exciting to test these activating peptide reagents in biological 
contexts and this is returned to in the discussion.  
 
Figure 5.14: Peptides 11 and 14 activate PADI4 in cells. A and B: Immunoblot of 
H3CitR2 and PADI4 of whole cell lysates extracted from PADI4-stable mES cells treated 
with an increasing concentration (0 µM, 10µM, 30µM, 90 µM) of A: peptide 11 or B: peptide 
14. C: Immunoblot of H3CitR2 and PADI4 of whole cell lysates extracted from PADI4-stable 
mES cells treated in serum (Lanes 1-3 and Lanes 7-9) or in KSR2i (Lanes 4-6 and 10-12) for 




tested for binding to human PADI4 in a no calcium buffer (column 1), high calcium buffer 
(column 2), or in a high calcium buffer in the presence of Cl-amidine (column 3). Peptides 1, 
2 and 3 all contain an arginine residue within the cyclic lariat sequence, which was 
substituted for citrulline. SPR data were also obtained for these substituted peptides (column 
4). Experiments in this figure were performed by Dr Louise Walport. 
 
5.7 Developing an affinity molecule: Peptide 7 
Peptide 7 showed comparable high affinity binding to PADI4 in buffers 
containing no calcium, in buffers containing calcium and to PADI4 that had 
been preincubated with Cl-amidine (Figure 5.14). In addition, after incubating 
peptide 7 with PADI4, biotinylated-F-amidine was still able to react at the 
active site showing peptide 7 does not bind the active site. Taken together, 
these data clearly demonstrate that peptide 7 binds away from the active 
site, at a location of the enzyme that is unaffected by calcium binding and 
therefore that is likely to be structured at all concentrations of Ca2+ (Figure 
5.1, regions in white). Dr Walport and I reasoned that it therefore might make 
a very good candidate to explore as a reagent for affinity pulldown 
experiments. A major advantage of having the biotinylated peptide 7, in 
addition to the commercial antibody, is that it is likely to bind to PADI4 and 
pull it down in a different conformation from the antibody binding. It therefore 
may enable a more complete set of interacting partners to be identified and 
was a particularly useful reagent for the mass spectrometry experiments 
undertaken in Chapter 6. 
 
I then elected to test whether this peptide might be suitable for use as an 
affinity molecule with Dr Christophorou. A biotinylated peptide 7 was 
synthesized by SPPS by Dr Louise Walport at the University of Tokyo. The 
identified peptide 7 sequence DYYPKGSWGYKLFCG (underlined residues 
are those included in the cyclic lariat sequence) was synthesized with the 
inclusion of an additional serine, β-alanine, and biotinylated lysine. Two 
further variants were synthesized with even longer linkers: the first with an 
11-carbon length chain (“Undec”) to replace the β-alanine residue, and a 




synthesized as lyophilized powders by Dr Walport. Based on lysis conditions 
I had established from antibody pull down (Chapter 6), Dr Christophorou and 
I then tested all three molecules with lysates from PADI4-stable mES cells 
according to two different protocols: 1) incubate the peptide overnight with 
the cell lysate, followed by a 2 hour incubation with streptavidin magnetic 
beads (as the pulldown step) or 2) pre-incubate the peptide with the 
streptavidin beads for 2 hours first, followed by overnight incubation with the 
cell lysate (Figure 5.16A). The second protocol produced a much higher 
efficiency pulldown for all three peptides (as had also been observed for my 
antibody pulldowns, Section 6.2). The original biotinylated peptide 7 was at 
least as effective as (and in fact somewhat more effective than) either of the 
longer linker peptides as detected by western blotting for PADI4 (Figure 
5.16A, Lane 2 shows stronger signal than Lanes 3 or 4, and Lane 6 over 
Lanes 7 or 9). The second protocol additionally reduced the extent of 
background binding of PADI4 to the beads. The second protocol and original 
biotinylated peptide 7 were therefore taken forward (Lane 6) and showed 




Figure 5.16: Biotinylated Peptide 7 isolates PADI4 from cells and is suitable for MS/MS 
analysis. A: PADI4-stable mES cells were lysed and incubated with biotinylated peptide 7, 
with no linker (Lanes 2 and 6), with a 5x beta-alanine linker (Lanes 3 and 7), with an 11au 
linker (Lanes 4 and 9) or with vehicle (Lanes 5 and 8). In Method 1, peptide and lysates were 
incubated overnight at 4˚C and then pulled down with streptavidin beads (Lanes 2-5). In 
Method 2, peptides were incubated with streptavidin beads first for 2 hours and then 
incubated with lysates overnight at 4˚C (Lanes 6-9). Detection was by western blot using an 
antibody to human PADI4. Data are representative of n = 2. B: Affinity pulldown followed by 
mass spectrometry analysis showing LFQ intensity of human PADI4 from analysis of 
proteomic data in MaxQuant. Pulldown was performed with beads alone or biotinylated 
peptide 7 from Control-stable mES cells or PADI4-stable mES cells. This experiment was 
performed with Dr Christophorou. 
 
A preliminary experiment was then performed with Dr Christophorou to pull 
down PADI4 using biotinylated peptide 7 for analysis by quantitative mass 
spectrometry. Control cells and PADI4 stably expressing embryonic stem 




and streptavidin coated magnetic beads. Four conditions were assessed: 1) 
control cells pulled down with beads alone, 2) PADI4 cells pulled down with 
beads alone, 3) control cells pulled down with peptide 7, and 4) PADI4 cells 
pulled down with peptide 7. Beads were washed in 50 mM Ammonium 
bicarbonate and submitted for analysis by the IGMM Mass spectrometry 
facility. Briefly, dry beads were digested with trypsin and peptides purified by 
Liquid chromatography using C18 STop And Go Extraction (STAGE) tips. 
MSMS analysis was performed on a Thermo Q-Exactive Plus machine and 
data analysis was performed using MaxQuant.  LFQ intensity for PADI4 
protein across the four conditions is presented in Figure 16B. 27 different 
PADI4 tryptic peptides were identified and PADI4 was the second highest 
intensity protein identified in the peptide 7 pulldown from PADI4-stable cells 
(second to Actin). Actin was 20-fold enriched in peptide 7 pulldowns over 
beads in both PADI4-stable and control conditions implying it may 
additionally be pulled down by the peptide and not pulled down together with 
PADI4. Enrichment for PADI4 peptides was found only in the PADI4-stable 
condition pulled down using peptide 7: an 8000 fold increase in LFQ intensity 
was observed over beads alone and a 20 000 fold increase in LFQ intensity 
was observed over a peptide 7 pulldown from mES Control-stable cells. ~50 
proteins were additionally highly enriched (>50 fold enrichment in LFQ 
intensity) in the peptide7 pulldown from PADI4-stable cells, including an 
identified interactor of PADI4 from BioGrid (ANXA4) suggesting other 
proteins could be co-pulled down.  
 
5.8 Development of control peptides 
It would be very desirable to have negative control peptides that are inactive 
for future use of these reagents in biological contexts as a control for the 
addition of cyclic peptides to cells (such as peptide 9, Figure 5.11A). With Dr 
Walport, a series of scrambled control peptides were therefore designed for 
peptide 3, 7, 11 and 14; these have the same amino acid content but with a 
disrupted sequence that in theory ought to render them inactive with respect 




I started by testing the scramble inhibitor peptide 3, while I was testing the 
optimized peptide 3 sequences. Very unfortunately in preliminary 
experiments to test this on cells, the scrambled peptide also appeared to 
inhibit PADI4 in cells (Figure 5.17B). I therefore tested it in the in vitro 
citrullination lysate assay where it did not inhibit. These data on their own are 
hard to reconcile, and need to be repeated carefully. Given the data derive 
from a single preliminary experiment, technical problems with the experiment 
cannot be ruled out. If the effects, however, are validated then a possible, if 
very unfortunate, hypothesis is that the scramble peptide 3 is similarly cell 
permeable (it has the same amino acid composition) and affects the 
activation pathway in an unpredictable way, but without inhibiting PADI4 
directly. It will be useful to test the inhibitors for efficacy in a different mode of 
activation such as that caused by the calcium ionophore A23187.  
 
Scramble peptides may not be the best negative control for the active 
peptides. As an alternative, several variant peptides were already tested that 
showed little effects on inhibition and therefore act already as good negative 
controls. For example, the 3.7 variant of peptide 3 is backbone N-methylated 
with no change to the sequence. This variant does not inhibit PADI4 in cells 
(shown in Figure 5.17C) suggesting it can be a good negative control for 
peptide inhibition. Dr Walport had also confirmed that this variant bound 






Figure 5.17: Initial testing of control peptides. A randomly shuffled peptide 3 variant was 
synthesized and tested A: in vitro in a citrullination lysate assay, compared to Peptide 3 with 
a single Glycine absent from the sequence (see Figure 5.9D) and B: in cells which had been 
activated using KSR2i treatment for 6 hours. C: An alternative peptide 3 variant with a 
sequence that differs only by backbone N-methylation showed no inhibitory effects in cells. 
Data in this figure are shown from a single preliminary experiment. 
 
I was unable to finish this work before ending in the lab so this will have to be 
continued in future work. Nonetheless this quick final experiment emphasizes 
the need for robust peptide controls. Scrambled versions of activator 
peptides 11 and 14 as well the pulldown peptide 7 were prepared for this 
purpose and will be the first place to start. Peptide 3.7 already should provide 
a good alternative negative control for the inhibitory peptide 3 and peptide 9 
provides a control for the activator peptides in the meantime. These 
experiments will be important for the validation of the reagents described in 
this chapter and I hope this work will be followed up in the future. 
 
5.9 Discussion  
This chapter presents work to develop and characterize a toolkit of cyclic 
peptide reagents that were shown to inhibit, activate and pull down human 
PADI4 with efficacy in vitro and in cells. As my work in the lab finished 
somewhat abruptly, some obvious follow-up experiments and repeats are left 
to future work. Obtaining formal IC50s and EC50s of the inhibitors and 
activators respectively will clearly be useful. The method developed for a 
high content microscopy chemical genetic screen is set up and ready to be 
used to obtain cellular IC50s and EC50s for the inhibitors and activators 
(Figure 4.9E) and will also assist cellular toxicity profiling. This work should 
include selectivity profiling against the different human and mouse PADI 
paralogues. Preliminary data suggest the inhibitor peptides at least are likely 
to be specific to human PADI4, as they are not active on mouse PADI4 
(personal communication, Dr Walport) and from the precedent of previous 
peptides identified using the RaPID system{Passioura:2017cc, Suga:2018ii}. 
197 
 
It will also be an interesting curiosity to test these peptides on the newly 
identified cyanobacterial homologue from Chapter 3. 
 
More exciting follow-up will include demonstrating target engagement of the 
peptides in cells. This can be done using a cellular thermal shift assay 
(CETSA). Work on this was initiated and CETSA temperatures for PADI4 are 
provided with the protocol in the Appendix. Coupling a CETSA experiment 
with MS/MS would help to identify any off-target effects. From a structural 
biology perspective, future experiments such as co-crystalisation of the 
enzyme with peptide could be used to identify where the activator peptides 
bind allosterically. Identification of an activating binding region by a cyclic 
peptide would aid mechanistic understanding of PADI4 activation such as by 
an endogenous protein (such as the candidate calmodulin that was identified 
from MS/MS data in Chapter 6). Similarly testing whether activators act in 
tandem with a candidate regulator to activate PADI4 would give an indication 
of whether they may operate using the same mechanism. 
 
The real advantage of these tools will be realized by the biological 
experiments they enable. Having potent reversible inhibitors will clearly be 
very useful, including the first reversible inhibitors to target the active 
conformation of PADI4. These can be used and characterized in the other 
cellular systems set up in Chapter 4 (such as to inhibit NET formation in 
HL60s or primary human neutrophils). The inhibitory peptides clearly also 
offer potential given the promise shown by PADI4 inhibition in 
disease44{Lewis:2016ul}. Other derivatives of the peptides (other than biotin) 
would also be worth investigating such as FAM-conjugated peptides for 
fluorescent detection, since the biotinylated peptide 7 worked very efficiently 
for pulldown. The real biological novelty is likely to be derived from the 
activators. This might firstly include experiments to dissect the precise effects 
of PADI4 from the pleiotropic NET-inducing inflammatory stimuli used at the 
moment. In the first instance, it will be possible to interrogate whether PADI4 




will be interesting for the role of PADI4 in pluripotency context. Use of 
activating peptides could ascertain whether activating PADI4 increases 
reprogramming efficiency. An immediate biological follow-up would to test 
whether activating peptides might be able to directly increase Wnt 
transcriptional output in mouse ES cells (a repeat of Figure 4.13). In 
summary, the ability to activate PADI4 directly will allow a precise dissection 
of its role and therefore facilitate exploration of the precise role of PADI4 
activation in cells. These reagents therefore present exciting possibilities for 
future work as a wide range of exciting experiments should now be possible. 
 
A final point for discussion is that several variant selections were also 
designed for future work depending on the success of these first selections. 
The first involved a variant of the second ‘activator’ version of the RaPID 
selection where a histone substrate, with the substrate arginine residue 
replaced with Cl-amidine, could be used to more comprehensively block the 
active site. A second idea was to perform the selection against enzyme that 
had been preincubated in limiting calcium concentrations, where only half of 
the calcium sites are occupied, as has been similarly shown in crystal 
structures of PADI236. This could conceivably trap a stabilised intermediate 
PADI conformation and also act to activate the enzyme. It was additionally 
hoped that, if we could develop a method to isolate the endogenously 
activated PADI4 from studies in vivo (such as a post-translationally modified 
variant of PADI4 or a PADI4 linked to an activating partner), selections (both 
for inhibitors or activators) could be performed either on the endogenously 
modified enzyme or endogenously activated conformation. This might enable 
inhibitors that could specifically tune down the deregulated enzyme activation 
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Chapter 6: Towards the Physiological Activation of PADI4 
 
6.1 Introduction 
In Chapter 4, cellular systems were set-up in which PADI4 could be 
physiologically activated. The aim for Chapter 6 was to use proteomic 
analysis (affinity purification tandem mass spectrometry, AP-MS/MS) to look 
firstly for any PTMs on PADI4 protein and secondly for any interacting 
proteins that differ between resting and activated PADI4. This would be used 
to collate a list of putative regulatory candidates for the endogenous 
activation of PADI4 protein. Finally one potential regulatory candidate, 
calmodulin, was taken forward for validation and explored in biochemical 
assays where it activated PADI4 in vitro.  
 
6.1.1 Past attempts to do MS/MS on PADI4 
Approaches to analyze the PADI4 interactome and PTMs on PADI4 have 
been attempted elsewhere, including to look for regulatory events1-6. The 
hope for this work was that the new tractable activation conditions in cellular 
systems and a carefully optimized MS/MS approach established in this 
Chapter might result in an improved chance of finding regulatory molecular 
events from previous attempts in the literature. Any candidates that differ 
across cellular treatments from the MS/MS analyses would need to be 
carefully validated for their capacity to activate PADI4 in vitro and in cells. 
 
6.1.2 Objectives 
• Perform proteomic analysis of PADI4 to identify candidates for the 
physiological regulation of the enzyme in cells. 
• Validate a chosen candidate for the potential to activate PADI4. 
  
6.2 Establishing methods for isolation and MS/MS analysis of PADI4  
Section 6.2 describes the optimization of conditions to isolate human PADI4 
from cells and the set-up of computational pipelines to process and interpret 




6.2.1 Optimizing lysis conditions 
I started by setting up lysis conditions to efficiently extract PADI4 from cells. 
The best conditions for preserving intracellular protein-protein interactions 
are clearly very different from those required to preserve and detect direct 
PTMs to the bait protein. In the first instance, it is desirable to preserve 
interactions using a gentle lysis. In the second instance, provided that both 
the pulldown is still efficient and the desired PTMs are not labile after 
stringent lysis, there is an advantage to aggressive lysis procedures as more 
protein can be isolated and enzymes present in the cell can be rapidly 
inactivated prior to isolation. 
 
Two different lysis protocols were established for isolating PADI4 from cells 
for these purposes. The first was designed as a compromise between being 
able to disrupt the nuclear membrane (and release nuclear PADI4) while at 
the same time minimizing the disruption of intracellular protein-protein 
interactions (0.5% NP-40 and benzonase, Chapter 2.3). A second protocol 
was established to rapidly lyse the cell and also rapidly denature any 
kinases, phosphatases or other enzymes present in the lysate (1% SDS, with 
boiling). The lysate is diluted tenfold to reduce the SDS concentration for 
efficient pulldown. It was hoped this second protocol would stabilize the state 
of direct PTMs present on PADI4. In both instances a cocktail of kinase and 
phosphatase inhibitors was added to preserve the endogenous 
phosphorylation state of proteins in the lysates. 
 
6.2.2 Isolation of PADI4 from cells 
Following a series of optimization steps, I was able to isolate PADI4 from HL-
60 cells and PADI4-stable mES cells using immunoprecipitation with a 
commercially available antibody (Chapter 2.3, Figure 6.1).  Importantly, this 
was done while disrupting and retaining the chromatin fraction of the cell, as 
a portion of PADI4 is expected to be bound to chromatin4. In order to reduce 
the extensive signal from the heavy chain of the antibody observed in 
Western blotting (that runs close to the molecular weight of human PADI4), 
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the crosslinking agent BS3 was used to conjugate the primary antibody to the 
Protein A/Protein G beads. Pulldown of PADI4 using peptide 7 was also 
achieved and is covered in the previous chapter (Section 5.7). 
 
Figure 6.1: Immunoprecipitation using anti-human PADI4 antibody ab50332. A: 
Immunoblot analysis of PADI4 immunoprecipitated from undifferentiated HL-60 cells where 
human PADI4 is not expressed (Lanes 1-5) and from terminally differentiated HL-60 cells, 
where human PADI4 is expressed, using anti-PADI4 and an isotype control anti-CTCF 
antibody (Lanes 6-10). The lower molecular weight band corresponds to the denatured 
heavy chain of the PADI4 antibody. The band labeled as PADI4 appears at the expected 
molecular weight for PADI4, which can be detected in the input (Lane 6). B: Immunoblot 
analysis of PADI4 immunoprecipitated from control-stable cells (Lanes 1-5) and from PADI4-
stable cells, using anti-human PADI4 and an isotype control anti-CTCF antibody (Lanes 6-
10). The lower molecular weight band corresponds to the denatured heavy chain of the 
PADI4 antibody. The band labeled as PADI4 appears at the expected molecular weight for 
PADI4, which can be detected in the input (Lane 6). Abbreviations IP = contents of 








6.2.3 Mass spectrometry data analysis approaches 
Two different software approaches were used for raw mass spectrometry 
data analysis. Although MaxQuant is used widely by the MRC IGMM Institute 
Mass Spectrometry service, it presents a number of challenges for the 
purposes in this Chapter. The sophisticated label free protein quantification 
(LFQ) employed in MaxQuant firstly assumes broad proteome coverage and 
secondly that most proteins will be unchanging across different samples. 
This is less applicable, however, to affinity pulldowns where the proteins 
detected after isolation will be inherently biased by design: the point of the 
experiment is specifically to identify those proteins enriched by the bait, and 
not to obtain broad proteome coverage. The second major problem is that 
searching for variable post-translational modifications is hugely 
computationally expensive, particularly for multiple modifications as 
additional variable PTM searches scale exponentially in computational time. 
In this case, we had hoped to map as comprehensive a list of PTMs as 
possible to PADI4 protein. MaxQuant was therefore only used for generating 
initial interactome datasets. It performs very effective feature matching and 
identification across different runs. Where presented in this Chapter, the 
MaxQuant LFQ intensity for a given protein was normalized to the LFQ 
intensity for trypsin. Samples were then averaged and the log2(ratio) 
calculated for a given condition. 
 
I undertook a second approach to MS/MS analysis using a computational 
pipeline with PEAKS7.0. PEAKS software performs complete de novo 
peptide sequencing of the data in silico before doing database searches. 
This involves label free quantification and statistical analysis but does so 
across replicates that are assigned to be within a single group of the same 
treatment. This is a particularly useful way to handle exploration of the 
differential interactome under different cellular stimuli. Our hypothesis is that 
a limited number of proteins will change significantly across samples treated 
differently in this instance, but that replicates by contrast ought to be 
relatively unchanged. The data were then presented as heat maps of 
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log2ratio of enrichment and depletion as well as assigning and ranking any 
proteins that significantly differ between cellular treatments. These are 
provided in the order of their -10log10(p-value) where a value >20 
corresponds to a p-value < 0.01.  
 
A more detailed account of the calculation of significance is given below. 
Briefly, the LFQ analysis by PEAKS is based on having multiple samples per 
group (biological condition). Feature detection is performed separately on 
each sample and LFQ is then based on the relative intensities of peptide 
features detected across multiple samples. Features are aligned based on 
retention time alignment and an Expectation-Maximization algorithm means 
that more overlapped features can be detected. Normalization was 
performed against the total ion count of the samples. Peptide feature 
significance is based on a two-tailed p-value with respect to deviation of the 
feature vector from a lognormal distribution corresponding to both the largest 
group ratio (features which change most across different conditions) and the 
peptide quantification quality (best detected peptides). Protein significance is 
then inferred from the supporting peptide feature significances. These are 
weighted by the intensity rank of each peptide feature corresponding to that 
protein as well as the correlation between the relative abundance of the 
protein and the relative abundance of its supporting peptides (further details 
can be found in the PEAKS documentation). 
 
The second significant advantage of the PEAKS computational pipeline is the 
de novo peptide sequencing approach. This means all modified peptides are 
sequenced and identified a priori which allows any combination of post-
translational modifications to be identified afterwards. This bypasses the 
prohibitively computationally expensive problems associated with combined 







6.2.4 Coverage of protein for PTMs 
One of the major challenges in obtaining comprehensive PTM analysis of a 
single target protein is protein coverage. MS/MS still relies on proteolytic 
enzymatic digestion to produce peptide fragments of a certain size that can 
be readily detected by MS/MS (this is generally taken to be a limit of 6-30 
amino acids). For the most part, the MS/MS workhorse enzyme is trypsin, 
which cuts at lysine and arginine residues. If these residues are either too 
frequently or too sparsely distributed in the protein sequence of interest, 
detectable tryptic fragments will not be generated within the appropriate 
window, which almost invariably results in incomplete protein coverage. I 
performed multiple digestions using various enzymes in silico. Assuming 
100% digestion efficiency, I found that the theoretical coverage of PADI4 was 
61.1% with single digestion using Trypsin, but could be improved up to 
97.9% with the use of four enzymes for digestion (Trypsin, Chymotrypsin, 
AspN, and GluC)7. The computational pipeline in PEAKS is designed for use 
in experiments that include multiple digestions in the future.  
 
6.3 Overview of experiments to analyze PADI4 by MS/MS 
The MS/MS experiments to analyze PADI4 that were performed are outlined 
in table below (Figure 6.2) and referred to throughout in the text by the name 
given in the first column, but are introduced again in each section for clarity 
of reading. Section 6.4 summarizes the MS/MS attempts to analyze PADI4 
for regulatory PTMs. Section 6.5 summarizes experiments to identify the 
differential interactome of PADI4 between resting and activated cells. Section 
6.6 then describes experimental validation of one of the candidates derived 
from Section 6.5 (calmodulin) and biochemical assays to validate its effects 










PTMs to PADI4 in EXP1 were analyzed using the computational pipeline in 
PEAKS7.0 (Section 6.2.3). The coverage obtained for the PADI4 sequence 
after this initial experiment was 49% after tryptic digestion with the 
distribution of coverage across the PADI4 sequence shown in Figure 6.3 
(compared to theoretical maximum coverage of 61.1%). No putative 
regulatory PTMs were detected on PADI4 from EXP1. One surprising finding, 
however, was that two peptides containing the active site cysteine in PADI4 
were found to specifically modified in the resting condition, with evidence of 
this modification specifically depleted from the activated condition (Figure 6.3, 
log2ratio < –3.5). The modification detected, carbamidomethylation, is an 
artificial modification introduced during the mass spectrometry workflow in 
which cysteine residues are converted to carbamidomethylated cysteines 
prior to MS/MS. Interestingly, if a modification were endogenously present at 
cysteine, then the efficiency of introduced carbamidomethylation in the mass 
spectrometry workup would differ. This serendipitous observation is a similar 
approach to the method specifically designed to detect cysteine nitrosylation 
in the literature. Cys S-nitrosylation modifications are otherwise labile under 
typical mass spectrometry conditions and so cannot usually be detected. If 
the active site were differentially protected by an endogenous PTM such as 





Figure 6.3: PTM analysis of PADI4 analyzed from EXP1. A: Output of all PTMs detected 
to PADI4 in EXP1. Four replicates were performed per condition. 49% of the protein was 
covered. Blue lines below the PADI sequence correspond to identified peptide features.  B: 
Differential carbamidomethylation state of active site cysteine 645 of PADI. Modified peptide 
is enriched in the condition where PADI4 was isolated from differentiated HL60s (resting), 
but depleted from differentiated HL60s that had been treated with calcium ionophore 
(activated). C: Schematic showing possible hypothesis that the active cysteine may be in a 
different endogenous state in the inactive form. This could be due to a different redox state 
and could be endogenously nitrosylated. 
 
PTMs on other proteins were then used as an estimate of the success of 
PTM detection in this experiment overall given the lack of PTMs identified on 
the target protein, PADI4. To do this, I analyzed the known PADI4 substrate 
Histone 1.24. Citrullination of Arginine 54, located within the DNA binding 
domain of H1, is particularly interesting as it was shown to result in its 
displacement from chromatin and in global chromatin decondensation4. This 
protein was co-enriched in both resting and activated PADI4 conditions, but 
not in the control condition where PADI4 is absent (Figure 6.4) suggesting it 




multiple modified peptides could be detected including 17 phosphorylated, 33 
acetylated, 21 hydroxylated and 14 citrullinated features. This included 
detection of phosphorylations to Thr4, Ser36, Tyr71 and Ser78; acetylation to 
Lys17, Lys21, Lys27, Lys75 and Lys90 and citrullinations to Arg33 and Arg54 
(Figure 6.4). Citrullinated peptides (with a 0.98Da mass shift) containing 
Histone 1 Arginine 54 (a known target of PADI4) were identified as being 
enriched specifically in the activated PADI4 condition, but were depleted from 
the resting condition (Figure 6.4). 
 
It is therefore pleasing from this experiment that, in the binary case of 
citrullination of Arg 54 of histone 1.2, a known PTM could be differentially 
identified from the PEAKS computational pipeline. In addition, 
phosphorylations were detectable such as those to histone H1.2. For less 
binary modifications, however, observing different levels of a modified 
peptide against the unmodified form will be challenging as these peptides will 
behave differently (and non-quantitatively with respect to each other) in the 
mass spectrometer. 
 
Figure 6.4: PTM analysis of Histone H1.2 (P16403) that was identified by co-IP of 
human PADI4 from EXP1. Blue lines below the PADI sequence correspond to identified 
peptide features. 73% of the protein was covered. Four replicates were performed per 
condition. A: Output of all PTMs detected to the H1.2 detected in EXP1. Multiple modified 
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peptide features could be detected including 17 phosphorylated, 33 acetylated, 21 
hydroxylated and 14 citrullinated peptide features. This included phosphorylated Thr4, 
Ser36, Tyr71, Ser78; acetylated Lys17, Lys21, Lys27, Lys75, Lys90 and citrullinated Arg33 
and Arg54. B: The differential citrullination state of known modified arginine 54 is evidenced 
by two different modified peptide features that were found to be enriched only in the sample 
isolated from differentiated HL60s treated with calcium ionophore (with activated PADI4).  
 
6.4.2 Analysis of PTMs identified on PADI4 in EXP5 
MS/MS was then conducted on the new PADI4 activating stimuli identified in 
Chapter 4 to look for any PTMs (Section 4.2.3.3). In this experiment (EXP5), 
human PADI4 was isolated from 1) PADI4-stable cells (treated for 45 
minutes with DMSO) and 2) PADI4-stable cells that were treated with 3µM 
CHIR99021 (GSK3β inhibitor) for 45 minutes. Samples were taken to confirm 
successful activation of human PADI4 occurred only in the treated samples 
by immunoblotting (Figure 4.9D). Samples were prepared for isolation by 
immunoprecipitation with a commercial antibody to human PADI4 (3 
replicates per treatment), and by pulldown using biotinylated peptide 7 
(Chapter 5) (3 replicates per treatment) for a total of 6 replicates per 
treatment. Analysis was performed using the PEAKS computational pipeline 
and the data from the peptide pulldown and antibody were pooled and all 
identified PTMs were collected (Figure 6.5). 
  
The PTM data are presented on the sequence of PADI4 with blue bars 
beneath showing the peptide features identified (Figure 6.5). The observed 
coverage was increased to 63% of the protein (417/663 amino acids), which 
is slightly higher than the theoretical maximum coverage assuming 100% 
digestion efficiency (61.1%). This is possible since incomplete tryptic 
digestion can increase the MS/MS coverage of smaller peptides. 25 PTMs 
were identified including a phosphorylation at Ser433 and a ubiquitination at 
Lys525 (Figure 6.5). As the cellular activation of PADI4 occurs downstream 
of single kinase inhibition (GSK3β), the direct phosphorylation to PADI4 is 
particularly interesting. Both unphosphorylated and phosphorylated peptide 




potentially regulatory as it may differ between different conditions. GSK3β 
typically has a priming phosphorylation site located three amino acid 
residues away from the target Serine/Threonine and is a Proline-directed 
kinase. Intriguingly this phosphoSer433 has a second Ser site located three 
residues C-terminally. In addition this downstream Ser436 is adjacent to a 
Pro residue so this site could be a direct target of GSK3β. These serines are 
conserved in PADI2 and the loop containing these two Serines is located 





noting that calcium binding site 6 is not conserved in PADI4. Red boxes denote the location 
of the catalytic triad with residues given by a black asterisk. An orange asterisk is included 
above other active site resides. A cyan blue box denotes the location of the phosphorylated 
motif identified by MS/MS experiments in this chapter. Data were collated from 12 replicates; 
six replicates were used per condition. Bottom panel: Crystal structure of calcium bound 
PADI4 (1wd9). The PAD_N domain is coloured in cornflower blue, the PAD_M domain in 
orange and the PAD_C domain in green. Calcium ions are coloured in magenta, active site 
residues in red, and the phosphorylated motif is shown in blue: DSCYPSNDS.  
 
6.5 Identifying PADI4 interacting proteins differing between resting and 
activated conditions 
 
Experiments were then undertaken to identify any proteins that interact 
differently with resting or activated PADI4 and may thereby modulate enzyme 
activation. 
 
6.5.1 Differential interactome analysis of EXP1 
Similarly to the PTM analysis, the first attempt (EXP1) was conducted on the 
promyeloblast HL-60 cancer cell line using an established PADI4 activation 
condition (Figure 6.6). Group 1 refers to the first condition where human 
PADI4 was immunoprecipitated from undifferentiated HL-60 cells (where 
PADI4 is not expressed), Group 2 to differentiated HL60 cells (where PADI4 
expression is induced, but no activity can be detected) and Group 3 to 
differentiated HL-60 cells treated with calcium ionophore (where PADI4 is 
present and has been activated) (Figure 4.2B and 4.4). 
 
After processing the raw data, the top proteins that were identified in PEAKS 
analysis were clustered and log2ratio enrichment or depletion was visualized 
across the three conditions in EXP1 (Figure 6.6). As expected, PADI4 protein 
(Q9UM07) is enriched in the two conditions using differentiated HL-60 cells, 
and absent from undifferentiated HL-60s, where it is not expressed and is a 





Figure 6.6: Mass spectrometry dataset from EXP1 with clustering analysis performed 
using Peaks7.0 software. Group numbers correspond to treatment numbers in Figure 6.2 –
group 1 are undifferentiated HL60 cells (no PADI4 expression), group 2 are differentiated 
HL60 cells (inactive PADI4), and Group 3 are differentiated HL60 cells treated with calcium 
ionophore (activated PADI4). Four replicates were performed per condition. 
 
Many of the top interacting proteins that differ between samples and are 
enriched in the two PADI4-containing conditions are known substrates of 
PADI4 (Figure 6.6). The list includes Histone 1 variants, H3 variants, Protein 
SON and HNRNPs (Figure 6.6). This is good validation that the method is 
identifying real interactors. To analyze this systematically, I then compared 
the top proteins from this MS/MS experiment to an unpublished mass 
spectrometry dataset obtained by Maria Christophorou and Prof Nielsen that 
represents an extensive list of citrullinated proteins under the same activating 
conditions used in my experiment. A majority of the top identified interacting 
proteins were also found to be substrates in this so-called ‘citrullinome’ 




the proportion of citrullinated proteins identified) is much greater than is 
expected by chance – given the citrullinome dataset contains 3266 out of an 
assumed total of ~20000 proteins (the representation factor = 3.8, p < 4.3 x 
10-10, modelled using the hypergeometric probability distribution). The 
expected number of expected substrates is six (total in set 1 x total in set 2 
divided by the overall number of proteins), and the greatest expected by 
chance is an overlap of 10 substrates (greatest number giving a p value > 
0.05 under the hypergeometric probability distribution). 
 
Figure 6.7: Mass spectrometry data from EXP1 with analysis performed using 
Peaks7.0 software. PADI4 was immunoprecipitated from non-differentiated HL-60 cells as a 
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control (no PADI4 expression), from differentiated HL-60 cells in a resting condition (where 
PADI4 protein has been induced), and in activated HL-60 cells after A23187 treatment. 
Group numbers correspond to the treatment numbers in Figure 6.2.The top proteins with 
differential detection between control and PADI4 containing conditions are shown in the 
table. These proteins were compared to a dataset obtained by Maria Christophorou (labelled 
MAC set in the table), which identified citrullination substrates in the same cell-types and 
with the same activation condition. Many of the candidates identified as PADI4 interacting 
proteins are also citrullinated in the other dataset. The number of independently identified 
citrullination sites identified for these proteins is given in column 3. Log2 enrichment of the 
protein in each condition is displayed as a heatmap in column 4. Data were collated from 
four replicates per condition. 
 
Given the data from Chapter 5 that showed peptides activating allosterically, 
it is probable, but by no means conclusively true, that bona fide PADI4 
substrates are a less likely source of candidate regulators. By this logic, two 
possibly interesting non-substrate proteins appeared to be exclusively 
enriched in the activating conditions: PGK2 and AURKAIP. PGK2 is a testis-
specific enzyme found in mitochondrial metabolism and, at least in the 
opinion of this author, therefore unlikely to be interesting with respect to 
PADI4 regulation; but AURKAIP, although partly pulled down in the 
undifferentiated HL60 cells, may be an interesting candidate to validate 
further. On the other hand, it is of course also possible that proteins that 
interact may also be modified if in close proximity to the enzyme. Ruling out 
substrates a priori therefore does not seem to be a good idea with respect to 
this particular dataset. Candidates identified here are not discussed further 
for reasons of space, but the list of candidates with enrichments is provided 
(Figure 6.7). It is notable that the full list of proteins identified as interacting 
with PADI4 that was obtained with MaxQuant is extensive, showing very 
efficient AP-MS/MS but also in some ways shows the inherent difficulty in 
prioritizing candidates without stringent criteria as it is not possible to know 






6.5.2 Differential interactome analysis of EXP2 and EXP3: transient 
PADI4 interactors 
Primarily to see if it was possible to identify more transient interactors, a 
crosslinking Mass spectrometry approach was then attempted on cell 
conditions established in Chapter 4. The Rapid immunoprecipitation mass 
spectrometry of endogenous proteins (RIME) protocol was used, which 
makes use of a formaldehyde crosslinking step before lysis, similar to a 
chromatin immunoprecipitation (ChIP) protocol9. The RIME protocol was 
performed on two sets of cell treatments (EXP2 from HL-60 cells and EXP3 
from mouse ES cells) and datasets were analyzed (Figure 6.8). In EXP2, 
human PADI4 was immunoprecipitated from undifferentiated HL-60 cells 
(where PADI4 is not expressed), from differentiated HL60 cells (where PADI4 
expression is induced, but no activity can be detected), from differentiated 
HL60 cells primed with LPS, and from differentiated HL60 cells primed with 
LPS and treated with calcium ionophore (as in Figure 4.4B). In EXP3, human 
PADI4 was immunoprecipitated from control-stable cells (mouse ES cells 
from which no human PADI4 should be isolated), PADI4-stable cells, and 
from PADI4-stable cells treated with calcium ionophore for six hours (as in 
Figure 4.6A). In these experiments, cells were crosslinked with formaldehyde 





Figure 6.8: Comparison of LFQ intensities for PADI4 across different trial MS/MS 
experiments. A: The LFQ intensity for PADI4 is presented on the y-axis. For EXP1, there 
are duplicate conditions for Protein G (Lanes 1-6), and Protein A (Lanes 7-12) to capture the 
antibody. B: Table of human proteins that were at least threefold co-enriched across all 
PADI4-isolated conditions in EXP2 after normalization against trypsin (from HL-60 cells). C: 
Table of proteins that were at least threefold co-enriched across all PADI4-isolated 
conditions in EXP3 after normalization against trypsin (from mouse ES cells). In EXP1, 
PADI4 was immunoprecipitated from 1) non-differentiated HL-60 cells as a control (no 
PADI4 expression) (Bars 1-2 and 7-8), 2) from differentiated HL-60 cells in a resting 
condition (where PADI4 protein has been induced) (Bars 3-4 and 9-10), and 3) from 
activated HL-60 cells after A23187 treatment (Bars 5-6 and 11-12). In EXP2, PADI4 was 
immunoprecipitated from 1) undifferentiated HL60s (Bars 1-2), 2) differentiated HL60s (Bars 
3-4), 3) differentiated HL60s primed with LPS (Bars 5-6), and 4) differentiated HL60s primed 
with LPS and treated with Calcium ionophore (4µM). In EXP3, PADI4 was 
immunoprecipitated from 1) mES Control-stable cells (Bars 1-2), 2) mES PADI4-stable cells 
(Bars 3-4), and 3) mES PADI4-stable cells treated with Calcium ionophore (4µM) for 6 hours. 
(Bars 5-6). Each condition was performed in duplicate. Treatments are also summarized in 
Figure 6.2.  
 
In both cases, PADI4 was identified as one of the top proteins in both 
datasets and depleted from the control. For EXP2, a total of 169 proteins, 
and for EXP3 a total of 255 proteins were co-enriched with a number of 




conditions (enriched in the activated conditions) (Figure 6.8). Of these 16 
proteins were at least threefold co-enriched across all PADI4-isolated 
conditions in EXP2, and 23 proteins were at least threefold co-enriched 
across all PADI4-isolated conditions in EXP3 (Figure 6.8). In general MS/MS 
experiments generate very long lists of potential candidates, which pose 
problems for validation. Many fewer proteins were identified using the RIME 
methodology, which may therefore be an advantage. The significant problem 
is that no MS/MS experiment is saturating and there is no current way to 
quantify missing data. The formaldehyde step appears to decrease quality of 
the MS/MS data obtained overall seen both from lower LFQ intensity values 
(two orders of magnitude lower) and given that fewer peptides contribute to 
protein groups across the analysis (Figure 6.8). Another better approach for 
transient interaction identification, which was published towards the end of 
my PhD might be the improved BioID method10 called TurboID11 and might 
retain the MS/MS data quality. The latest paper showed much faster 
enzymatic modification of the conjugated biotin-ligase enabling proximity 
ligation within 10 minutes. This would suit the fast timescales of the cell 
treatment required in this instance. 
 
6.5.3 Differential interactome analysis of EXP5 identifying allosteric 
PADI4 interactors 
 
MS/MS was then conducted on the new PADI4 activating stimuli identified in 
Chapter 4 to look for protein interactions that may activate PADI4. I selected 
the activation condition that made use of GSK3 inhibition in mouse ES cells 
for detailed MS/MS analysis (CHIR99021 treatment for 45 minutes in serum) 
(Figure 4.9). Although this activation condition resulted in lower levels of 
PADI4 activation than after six hours in KSR2i (Figure 4.8), the advantages 
appeared to me to be that 1) the cell type and environment are as 
comparable as possible between treatments, 2) the treatment of 45 minutes 
is rapid and within the framework of cell signalling, 3) there are no 
confounding effects of serum withdrawal or changes in growth medium, and 
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4) the levels of PADI4 are both carefully controlled and independent of the 
stimulus. CHIR99012 is one of the most specific and potent kinase inhibitors 
available for any kinase target12-15. The simplicity of the system therefore 
ought to give the best chance of observing real physiological regulators. 
Successful activation of PADI4 protein was confirmed by Western blotting in 
parallel samples to those prepared for mass spectrometry (Figure 4.9D).  
 
Pulldown using biotinylated Peptide 7 from Chapter 5 was performed 
alongside immunoprecipitation with PADI4 antibody. Since the antibody and 
peptide_7 are unlikely to bind to the same face of PADI4, this should allow as 
comprehensive a set of interacting proteins as possible to be identified. True 
regulatory proteins pulled down by peptide 7 may not be visible in the 
antibody pulldown and vice versa, depending on where they bind.  
 
In order to identify allosteric interactors, I decided to include conditions where 
PADI4 was pre-incubated with saturating quantities of the irreversible 
inhibitor Cl-amidine to block the active site. Specific enrichment in this 
condition ought to enrich for proteins that bind allosterically and this condition 
therefore provides a way to exclude proteins that bind merely at the active 
site. Cl-amidine pre-treatment was included for both resting and activated cell 
treatments. If a candidate drives formation of the activated conformation, 
blocking the active site ought not to prevent this (given the data with Cl-
amidine, and the active site probe specific to the active conformation of 
PADI4 used in Chapter 5, Figure 5.13).  
  
Four conditions were included using three technical replicates each resulting 
in four treatment groups using PADI4-stable mES cells cultured 1) in serum, 
2) in serum + 3µM CHIR99021, 3) in serum + 200µM Cl-amidine, and 4) in 
serum + 200µM Cl-amidine + 3µM CHIR99021. The experiment was 
performed in full once with the antibody, and once with the biotinylated 
peptide 7 to pulldown human PADI4. Dr Christophorou assisted with some 




MS/MS pulldowns. The data for the antibody and peptide 7 were analyzed 
separately. Significant differentially interacting proteins across the four 
conditions were tabulated according to their rank separately for antibody and 
for peptide_7 (Figure 6.10 and 6.13). 
 
6.5.4 Differential interactome analysis of PADI4 in EXP5 
 
 
Figure 6.9: Venn diagram of proteins identified between the two pulldowns and with 
proteins from RIME mES control-stable cells. 
 
The data for the differential interactome of PADI4 are presented separately 
for the antibody (34 candidates) and for peptide 7 (35 candidates) in order of 
significance (10log10(p) > 20 corresponds to a p-value < 0.01, and > 40 to a 
p-value < 0.0001) (Figure 6.10 and 6.13). Significance corresponds both to 
greatest differences across cell treatments and high confidence detection of 
its peptide features (Section 6.2.3). One protein (Actin B) was in common 
between both pulldowns, giving a list of 88 significant candidate regulatory 
proteins and 29 candidates with a significance of >40 (Figure 6.9 and 6.10). 
The data for the antibody and the Peptide 7 are presented with the coverage 
of each protein, the number of peptide features contributing to its detection, 
and the enrichment or depletion across the different cellular treatments 





treatments in the profile of enrichment and depletion is Group 1: vehicle treatment for 45 
minutes. Group 2: activation with GSK3 inhibitor treatment for 45 minutes. Group 3: inhibited 
with Cl-amidine then vehicle treatment for 45 minutes. Group 4: inhibited with Cl-amidine 
and then activated with GSK3 inhibitor treatment for 45 minutes. Data used 3 replicates per 
condition. Full treatments are in Figure 6.2. Green shows depletion, red shows enrichment 
as for Figure 6.5 as a representation of the log2(ratio) from -4 to +4. Top panel: Antibody 
pull down. Bottom panel: Peptide 7 pulldown.  
 
6.5.5 Background set analysis of EXP5: the CRAP-ome 
To validate the candidates, I then sought to analyze the likelihood these 
proteins might derive from artefactual non-specific binding. A standard use of 
MS/MS negative controls might be to use beads only or an isotype control to 
attempt to capture a background set of non-specific interactors. The logic of 
this approach is somewhat flawed - the true background set that we are most 
interested in obtaining is anything that is not regulatory (doesn’t differ 
between cellular treatments) rather than anything that can be enriched by 
non-specific binding. A sticky protein might bind beads alone more intensely 
than PADI4 isolated on beads, but still be differentially bound to the PADI4 in 
resting versus activated cells. Clearly it should not be excluded as a non-
specific interaction merely because it interacts strongly with beads. 
Considering background binding is of course nonetheless important, so to 
avoid these problems, I considered that tempering possibly significant 
differential regulatory candidates with reference to the Contaminant 
Repository for Affinity Purification–Mass Spectrometry (CRAP-ome) would be 
a more useful method, alongside retrospective comparison with a separate 
negative set obtained in these cell lines16 (Figure 6.11 and 6.12). This 
approach avoids excluding data de facto from inappropriate prediction of the 




Figure 6.11: List of proteins identified from the Peptide 7 pulldown, with homologues 
in Homo sapiens, were queried against the CRAP-ome database. The average spectral 
counts across all 400 background experiments is plotted. 
 
To do this, I took a list of the candidate mouse proteins and generated a list 
of their human homologues that I queried against the CRAP-ome database 
(this database does not have data for Mus musculus yet). I then plotted the 
average spectral counts for each of the candidates across the 400 
background experiments contained within the CRAP-ome dataset (Figure 
6.11). For several promising candidates, I have in addition presented the 
distribution of spectral counts across the background set experiments (Figure 
6.12) as well as presenting two candidates that you might ordinarily expect to 
be from the background set for comparison (Krt1 and Actin B). Given that 
PADI4 is known to take keratins and actins as substrates, the classic 
background set profiles of spectral counts for Krt1 and Actin B may or may 
not indicate that they are true false positives. Some of the most promising 
high confidence candidates do not have this profile, however, which is a fair 




6.5.6 Candidate interacting proteins for the regulation of PADI4  
The dataset provides some very interesting protein candidates that bind to a 
different extent between cellular treatments. From the peptide 7 data in 
particular several of the top candidates leapt out as being potential regulators 
for their previously known calcium binding functions. Eight proteins showed a 
similar pattern of differential enrichment and these are highlighted in orange 
in Figure 6.13 (detail of Figure 6.9, bottom panel). Three of these were small 
proteins with multiple EF-hand domains (a prototypical calcum-binding 
domain) including calmodulin, MYL6 and MYL6B. In addition to these EF-
hand containing proteins, a number of calmodulin-binding proteins were 
identified with a similar profile of enrichment and depletion across the 
different cellular treatments (each of which possess at least one calmodulin-
binding IQ-motif: Myosin 10, Myosin 12a, Myosin 1C, Tropomyosin 3 and 
Myosin 11). Most interesting was that this group of proteins was significantly 
enriched in conditions where PADI4 was at a resting state and where the 
PADI4 active site had been blocked by preincubation with Cl-amidine (Figure 
6.13, Group 3). In the activated conditions, these proteins were found to be 
depleted (Figure 6.13, Group 4).  
 
These data evoke a possible hypothesis where EF-hand containing proteins 
interact with PADI4 in the resting condition. As these proteins appear to be 
enriched in conditions where the PADI4 active site is blocked in the resting 
state, they are therefore likely to be interacting allosterically, which is 
consistent with other activating molecules such as the peptides in Chapter 5 
and the cross reactive antibodies from Darrah et al.17. What is less clear is 
the explanation of the reduced intensity of calcium binding protein interactors 
to activated PADI4 – one possibility is that an activating stimulus could 
disrupt the interaction between these calcium-binding proteins and PADI4, 




of enrichment (specifically enriched in the Cl-amidine treated resting condition) are 
highlighted in orange. These proteins are particularly interesting as they are either calcium or 
calmodulin binding proteins. A further nine nuclear-located proteins are highlighted in green. 
 
A second set of candidates were highlighted (Figure 6.13 in green) as they 
are known to be located in the nucleus (such as on UniProtKB) or specifically 
involved in nuclear transport (RAN, NUP205, NUP43, Protein ELYS, 
LAMA5). This is interesting with respect to PADI4 as it has a nuclear 
localization signal and has been well characterized for functions in the 
nucleus (such as in histone modification)4,18-20. A recently published paper 
analyzing PADI2 using proximity ligation with BioID2 identified RAN as a 
PADI2 interactor6. This study showed RAN binding was involved in calcium 
dependent nuclear localization. These nuclear candidates therefore offer 
further avenues for future work.  
 
Another notable candidate appeared from the antibody dataset, which was 
RACK1 (Receptor of activated protein C kinase 1) (Figure 6.10, top panel). 
This is particularly promising in light of a previous paper which showed 
regulation of PADI4 after use of small molecule PKC inhibitors21. From my 
MS/MS data, RACK1 interacts allosterically (in the Cl-amidine treated 
conditions), but not differentially between activated and resting treatments. It 
is conceivable that RACK1 could act as a scaffold for regulation of PADI4 by 
activated PKC isoforms and this would be interesting to explore further. 
  
6.6 Validating calmodulin as a candidate regulator of PADI4 
6.6.1 Choosing a candidate activator from MS/MS data 
From literature searches at the beginning of the project, the calcium 
regulatory protein calmodulin (CaM) had stood out as a possible activating 
candidate for calcium regulated activation. Calmodulin responds to 
physiological calcium increases by changing its conformation dramatically on 
calcium binding (Figure 6.14A and B). Interestingly, it has been shown 
previously to regulate kinase and phosphatase catalytic activity by calcium-




proteins and is a key transducer of calcium-dependent cellular signalling. 
After it was identified as one of the most significant novel interacting 
candidates from EXP5, it was the first protein that I decided to validate from 
the MS/MS dataset. 
 
Figure 6.14: Crystal structures of calmodulin in A: the apocalmodulin structure, 
shown coloured in white, in the absence of calcium binding (pdb: 1qx5) B: the 
calmodulin structure in the presence of full calcium occupancy shown coloured in 
red (pdb: 3cln) C: the inhibited calmodulin structure, shown coloured in orange, with 
full calcium occupancy and bound to the small molecule TFP (coloured in cyan) 
(pdb: 1ctr). Calcium ions are represented as dark blue spheres. 
 
In EXP5, calmodulin was identified as the third most significant differentially 
interacting protein with PADI4, and was enriched in conditions where the 
active site had been blocked with Cl-amidine, suggesting the interaction may 
be allosteric. I then retrospectively looked more closely at the other 
experiments to see if calmodulin could be identified in the full MaxQuant data 
analysis. EXP1 also contained calmodulin in the full list of interacting proteins 
where it was identified as enriched in the resting condition but depleted from 
the activated condition. This adds further some support to the MS/MS data 
from EXP5 as calmodulin could be identified in both HL-60s and in mES cells 
and therefore across two different cell types, two different species and two 
different PADI4 activating stimuli.  
 
6.6.2 PADI4 binds calmodulin by reciprocal pull-down 
It was therefore attempted to confirm the interaction identified by MS/MS by 
performing the reciprocal pull-down of calmodulin and assessing if PADI4 
could be co-enriched. This work was done with Emma Clarke (a PhD rotation 
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student in the lab) and Dr Christophorou performed the repeat of the 
experiment (Figure 6.15). PADI4-stable mES cells, alongside PADI4-null 
mES cells, were transfected with CaM-GFP. GFP-trap beads were then used 
to isolate the exogenous calmodulin from the lysate, eluted and run for 
Western blot with detection by anti-human PADI4 antibody. Given the 
MS/MS data indicated a difference between resting and active conditions, the 
pulldown was performed firstly in the presence of Ca2+ and secondly in the 
presence of the calcium chelator EDTA. Results showed that human PADI4 
is enriched by pull-down of CaM-GFP with more efficient co-enrichment in 
the absence of Ca2+ (Figure 6.15). These data are consistent with the results 
from the mass spectrometry data and suggests the biochemical interaction of 
calmodulin with PADI4 can be recapitulated from reciprocal pulldown of 
calmodulin. 
 
Figure 6.15: Reciprocal pulldown with calmodulin confirms PADI4 interaction. 
Immunoblot analysis of human PADI4 and GFP after CaM-GFP trap pull-down performed in 
the presence of 5mM EDTA (Lanes 2, 4, 6, 8, 10, 12) or 5 mM CaCl2 (Lanes 1, 3, 5, 7, 9, 
11). PADI4-stable mES cells (Lanes 1-2, 5-6, 9-10) or PADI4-null mES cells (Lanes 3-4, 7-8, 
11-12) were transfected with GFP-CaM before pull-down. This experiment was undertaken 
with the help of Emma Clarke; this figure is from a repeat of the experiment, which was 
performed by Dr Christophorou. Data are representative of n = 2. 
 
A couple of future experiments will be very interesting to develop these data. 




transfected with GFP-CaM will be a useful additional control. Secondly, 
performing the reciprocal pull-down in the presence of Cl-amidine would be 
useful to confirm that the interaction with calmodulin is not mediated through 
the active site of the enzyme. Additionally, performing this pull-down after 
treatment with activating peptides 11 and 14 would show whether calmodulin 
and the peptides bind at the same location in the enzyme, if for example, the 
peptides were to prevent the interaction with calmodulin.  
 
6.6.3 Recombinant CaM activates PADI4 in vitro 
Given these data and the previous roles for calmodulin in calcium dependent 
enzyme regulation, I then performed a citrullination lysate assay to test if 
recombinant bovine calmodulin might increase PADI4 activity at limiting 
calcium concentrations, analogously to the activating peptides (Chapter 5). 
To do this, 98 µL clarified PADI4-stable cell lysate was added to different 
assay tubes. Recombinant calmodulin (rCaM) or vehicle was added to the lid 
of treated tubes. A serially diluted Ca2+ concentration was added to the lid of 
each tube to cover the range of limiting calcium dependence shown by 
PADI4 in vitro (up to 100 µL total assay volume). The tubes were spun 
quickly to start the assay and incubated at 37˚C with detection by Western 
blot to citrullinated H3 for exactly 30 mins. This enabled a tightly controlled 
comparison of activation with and without the addition of rCaM. 
 
Addition of rCaM did not elicit a PADI4 activation response (Figure 6.15A). In 
the presence of Ca2+, therefore, rCaM does not appear to activate PADI4 in 
vitro. In addition, these data suggest that rCaM, activated by Ca2+, does not 
activate a component in the lysate that acts on PADI4 either. Then, given 
that calmodulin bound more strongly in the inactive condition (by MS/MS and 
by reciprocal pull-down), I tested the possibility that rCaM may only activate 
PADI4 if it can first interact with the inactive conformation of PADI4. I 
therefore repeated the assay, but preincubated rCaM in the lysate with 
PADI4 in the presence of EDTA to quench any calcium already present in the 
cell lysate. After 20 mins of preincubation, CaCl2 was then added to the tube 
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lids as before to a concentration that accounts for the added EDTA (EDTA 
chelates calcium in a 1:1 ratio) but which then surpasses this level to give the 
same limiting concentrations of Ca2+ as in the previous assay (500µM + 
100/250µM CaCl2). In principle, this would allow calmodulin to bind to the 
inactive conformation of PADI4 before the citrullination assay was initiated 
with calcium. Excitingly, PADI4 was now activated to a greater extent in the 
conditions where rCaM had been added (Figure 6.15B-C). The assay was 
repeated in the presence of trifluoperazine (TFP) during the pre-incubation 
step, an irreversible small molecule inhibitor of CaM (crystal structure of 
inhibition is shown in Figure 6.13C). TFP attenuated the CaM-mediated 
PADI4 activation, without inhibiting PADI4 activation in the other conditions. 
This suggests a specific interaction of apocalmodulin with PADI4, which acts 
to activate PADI4 at a reduced Ca2+ concentration and is consistent with the 
MS/MS data. 
 
Figure 6.16: Recombinant Calmodulin activates PADI4 in vitro. A: Immunoblot analysis 
of H3CitR2 and CaM of a lysate citrullination assay using PADI4-stable mES cells. Human 




1-4) or recombinant bovine Calmodulin (Lanes 5-8) in the presence of serially diluted CaCl2 
and incubated for 30 mins at 37˚C before blotting. B: Lysates were pre-incubated with 
vehicle (Lanes 1-4) or recombinant bovine Calmodulin (Lanes 5-8) in the presence of EDTA 
and incubated for 20 mins at 37˚C. Lysates were then supplemented with serially diluted 
CaCl2 and incubated for a further 30 mins at 37˚C before blotting. C: Densitometry analysis 
of conditions shown in panel B normalized to PADI4 levels performed in ImageJ. D: 
Immunoblot analysis of H3CitR2 and CaM of a lysate citrullination assay using PADI4-stable 
mES cells. Human PADI4 is presented as a loading control. Lysates were supplemented 
with vehicle (Lanes 1-3, 7-9) or recombinant bovine Calmodulin (Lanes 4-6, 10-12) in the 
presence of EDTA, treated with vehicle (Lanes 1-6) or TFP (Lanes 7-12), and incubated for 
20 mins at 37˚C. Lysates were then supplemented with serially diluted CaCl2 and incubated 
for a further 30 mins at 37˚C before blotting. For Panels A and B, data are representative of 
n = 2; for the additional controls in Panel D, data are shown from a single preliminary 
experiment. 
   
Similar experiments to those performed in Chapter 5 (Figure 5.13) using 
biotinylated F-amidine, a reagent that reacts only with the activated PADI4 
conformation would be good as a follow-up. Incubating recombinant 
calmodulin and recombinant PADI4 in the presence of an increasing 
concentration of calcium, before treatment with biotinylated F-amidine would 
reveal whether the presence of calmodulin could drive formation of an 
activated conformation of PADI4 at lower calcium concentrations. 
 
6.6.4 Putative CaM binding site on PADI4 
Given the broad roles of calmodulin in regulating calcium signalling in the 
cell, I therefore considered that disruption of calmodulin and PADI4 through 
targeted perturbations made to PADI4 would be most amenable in deducing 
a cellular role for calmodulin activation of PADI4. To explore this line of 
enquiry more closely, bioinformatic approaches were used to identify 
possible calmodulin binding sites on PADI4 (using the Calmodulin target 
database, CaMELs and Calmodulation tools)22-25. Multiple putative 
calmodulin binding site motifs on PADI4 were identified with one particularly 
good candidate that arose from multiple computational methods (with a 1-8-
14 motif) and was consistent in sequence composition with CaM binding 
sites that have previously been identified in proteins that bind the calcium-
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unbound conformation of CaM (in charge and secondary structure: with +3 
overall net charge)26. These regions were compared against sequences in 
other species to assess conservation (Figure 6.16). The region is conserved 
in PADI4 paralogues. Interestingly the region is also conserved in 
mammalian PADI2, but is deleted in cyanobacterial protein. In addition, point 
mutants of this putative CaM binding region in PADI2 allow full calcium 
activation in the crystal structure (F220A and F221A)27. This is suggested to 
allow full calcium occupancy in the crystal structure by disrupting the dimer 
interface. A recent paper analyzing interactions of PADI2 found this region 
bound to RAN and modulated nuclear transport6. It is notable that RAN was 
also identified as one of my most significant differential interacting proteins to 
PADI4 (Figure 6.12). Lastly, a paper identified that auto-antibodies to PADI4 
are found to specifically bind at this region28, not far from where activating 
antibodies were hypothesized to bind17. 
 
Figure 6.17: Putative Calmodulin binding motif on PADI4. A: The top candidate region 
from the calmodulin target database is also identified from the calmodulation as the following 
overlapping target motifs: 1-8-14, FQATRGKLSSKCSV, 214-227, 1-16, 
FQATRGKLSSKCSVVL, 214-229 and 1-14, FQATRGKLSSKCSV, 214-227. B: PADIs from 
three cyanobacteria and from human and mouse PADI4 and PADI2 were aligned using Mafft 
L-ins-I and the putative calmodulin binding motif region was extracted and viewed in AliView. 
Cyanobacterial proteins show a truncation in this region. C and D: The region is unstructured 




ordered (pdb: 4n2c) and changes conformation between inactive and active conformations. 
Inactive and active conformations (white, 4n20 and red, 4n2c) of PADI2 were superimposed 
using Chimera using MatchMaker (Section 2.5.3.4). The region highlighted in cyan (4n20) or 
blue (4n2c) is the location of the putative CaM motif. 
 
This motif is located adjacent to the Ca3-5 binding switch and is an 
unstructured region in the protein crystal structure in PADI4. In the 
holoenzyme of PADI2 is the fully active conformation generated, in which this 
CaM binding region is shown to be ordered (Figure 6.16B)27. This is shown in 
Figure 6.18. In PADI4 the region remains disordered in both structures so it 
is currently unknown how this region affects activation and may explain how 
this has evaded previous understanding elicited from published crystal 
structures.  
 
As other good calmodulin binding motifs also exist on PADI4, it will be 
important to obtain more data as to calmodulin regulation of other paralogues 
in vitro. In particular, it is important to test whether recombinant calmodulin 
activates PADI4, PADI2, and cyanoPADI proteins. This will help determine 
whether the calmodulin binding region is expected to be evolutionarily 
conserved across the three isozymes and narrow down which CaM binding 
motifs are most promising for the design of point mutants (Discussed in the 
section below). 
 
6.6.5 Discussion of immediate follow-up work on calmodulin 
The data showing calmodulin activation in vitro point to immediate follow-up 
experiments. independently from cell lysates. One important test will be 
whether recombinant calmodulin activates recombinant PADI4, PADI2, and 
cyanoPADI proteins outside of a cell lysate context. This would provide 
further support for a role of calmodulin in activating PADI4 by direct binding 
(as implied by the MS/MS data and the reciprocal pull-down) rather than for 
example by acting on an unknown component of the lysate that might 
subsequently act on PADI4. The data are interesting in either model but it will 




From this work, point mutants of PADI4 that are unable to bind calmodulin 
can be readily introduced into cells by site directed mutagenesis of the 
PiggyBac PADI4-stable vector construct to make calmodulin-binding dead 
mutants. PADI4 point mutants can then be introduced into mouse embryonic 
stem cells to generate mutant PADI4 stables (in as little as a week or two) 
and activity can then be tested both in the lysate assay and using the cellular 
activation conditions established in Chapter 4. These experiments will 
provide much stronger evidence in confirming a role for calmodulin in PADI4 
activation than perturbing calmodulin globally. This nods to the wider 
consideration that studying effects of calmodulin in general is not always 
easy given the many roles CaM plays in regulating calcium fluxes in the cell 
and the likelihood for toxicity. Mutating the effect at the point of PADI4 protein 
will allow much stronger and more specific mechanistic conclusions to be 
drawn with respect to regulation of PADI4 by calmodulin binding. This is 
especially true given the possibility for cell death to activate PADI4 
artefactually such as from the provision of high calcium ion concentrations 
that would be available in the extracellular space after the cell membrane is 
compromised. 
 
Given the data showing that the cyanobacterial protein has a more stringent 
calcium requirement than mammalian PADI4 (Figure 3.11), it will be 
particularly interesting if rCaM only activates the mammalian isoenzymes and 
not cyanoPADI. This would be consistent with the calmodulin-binding motif 
on PADI4 being regulatory for calmodulin dependent binding. While it is fully 
conserved in PADI4 orthologues and most likely maintained in PADI2 
sequences, it is truncated in cyanoPADI. Additionally if calmodulin does not 
activate cyanoPADI, then the truncation found in the cyanobacterial 
sequence can be introduced into the mammalian homologue as a model for 
a calmodulin-dead mammalian PADI mutant by producing the hybrid mutant 





6.6.6 Calmodulin Discussion 
These data, taken together, are consistent with a hypothesis where 
calmodulin binds to PADI4 in the inactive calcium-unbound state, such that 
only once calcium is added, calmodulin is released from binding to PADI4. 
This release event then generates active PADI4, but it is unknown exactly by 
what mechanism. It is possible this is achieved through elevation of the local 
calcium concentration either as a result merely of the calmodulin interaction 
or potentially mediated through additional interacting proteins. From the 
MS/MS data, it is very interesting that other candidates including a variety of 
Myosin proteins also bound PADI4 in the inactive resting state and also 
showed decreased binding in the activated condition. These calcium-binding 
myosins could also be responsible for activating PADI4 in a similar manner to 
Calmodulin. As these myosin proteins possess calmodulin-binding motifs (IQ 
motifs) they may also interact in combination with calmodulin. IQ motifs in 
particular are known to bind calmodulin in the absence of calcium 
(apocalmodulin). It is a possible hypothesis, therefore, that if an interaction 
between calcium-binding myosin proteins is mediated by apocalmodulin, that 
an increase in calcium could disrupt and change the conformation of 
apocalmodulin and release calcium bound by myosins to elevate the local 
concentration.  
 
Also interesting is that many IQ motifs are protein kinase C (PKC) 
phosphorylation sites; there is extensive calmodulin and PKC crosstalk in the 
literature29-35. This could in principle connect the published roles found for 
opposing PKC isozymes in regulating PADI4 derived from relatively 
unspecific small molecule inhibitors21 and develop the observations of effects 
from small molecule inhibitors to a clearly defined mechanism at the level of 
PADI4 protein. Furthermore this could connect to the identification of RACK1 
(Receptor of Activated PKC 1) as a PADI4 interacting protein from the 
MS/MS data (Figure 6.10). These possibilities remain very interesting 
avenues to explore in future work to elucidate the precise mechanism 




Another interesting consideration is that calmodulin is a well-established 
myelin basic protein (MBP) interacting protein36-39. MBP is the major 
component of myelin. This points to a connection to the role of PADI2 or 
PADI4 in MBP citrullination and also to PADI overexpression and 
hypercitrullination in multiple sclerosis. This may also be interesting with 
respect to evolutionary conservation especially given the complicated 
evolutionary origin identified for PADIs in Chapter 3. The modes of binding of 
myosins and calmodulin have been found to be well-conserved across 
different species40 41 42 43. As PADIs appear to have been acquired 
horizontally in the animal lineage, co-evolution with specific calcium binding 
proteins in the vertebrate lineage may have enabled intracellular roles to 
have evolved. Testing recombinant proteins from various species for their 
capacity to be activated by recombinant calmodulin is likely to make 
identifying the CaM binding motif easier, but will also provide exciting 
avenues towards understanding how physiological PADI regulation may have 
evolved in the vertebrate lineage.  
 
6.7 Discussion of future MS/MS approaches for PTM identification 
6.7.1 Future work to identify S-nitrosylation 
Given the indications of possible active site modification, experiments to test 
the hypothesis that it may be S-nitrosylated would be interesting. 
Diethylammonium (Z)-1-(N,N- diethylamino)diazen-1-ium-1,2-diolate (DEA 
NONOate) is a crystalline solid that when dissolved spontaneously 
dissociates into the free amine and nitric oxide (NO). It therefore acts as a 
NO donor in solution with a half-life of 2 minutes at 37°C and 16 minutes at 
22-25°C to liberate 1.5 moles of NO per mole. NO is highly reactive and will 
spontaneously nitrosylate cysteine residues in vitro that can be modified in 
an endogenous protein context. Treatment with DEA NONOate may be used 
to test on recombinant PADI4 to see if citrullination may be disrupted or 
enhanced. Equally, this approach may be employed on cells to test whether 




whether the physiological activation conditions identified in Chapter 4 may be 
disrupted or enhanced by DEA NONOate pre-treatment. 
 
A complementary approach using the ‘biotin switch’ method could also be 
used to detect cysteine S-nitrosylation modifications directly either by 
Western blot or MS/MS44,45. Briefly, PADI4 protein is treated with methyl-
methane thiosulfonate (MMTS) such that any free cysteines will be 
methylated and protected, but which leaves nitrosylated cysteines intact. 
Then, ascorbic acid is used to reduce the S-nitrosylated cysteines, but which 
is not able to reduce the methylated cysteines. Finally the protein is treated 
with HPDP-Biotin or an iodo-tandem mass tag (iodoTMT) reagent, that 
covalently conjugates endogenously S-nitrosylated cysteines (that were 
subsequently converted to free cysteines) to either biotin, or the TMT group. 
Detection can then be performed using either Streptavidin-HRP or anti-TMT 
by Western blot or by using mass spectrometry with the TMT.  
 
The biotin switch method mirrors the speculative inference made in the 
observation of differential carbamidomethylation efficacy, which had been 
suggested by the initial mass spectrometry (Figure 6.3). It is hoped these 
plans, as they could not be undertaken within the timeframe of the PhD, 
might be undertaken in the near future as all the reagents are ready. That 
PADI catalysis uses a cysteine in the active site means S-nitrosylation is a 
particularly interesting possibility. In addition, other members of the pentein-
containing fold that PADIs possess (described in detail in Chapter 5) have 
previously been shown to be regulated by endogenous nitrosylation: in fact 
DDAH, Argininosuccinate synthetase and ornithine decarboxylase enzymes 
are all regulated by Cysteine-S-nitrosylation46-52. 
 
6.7.2 Future work to analyze phosphorylations 
Another important avenue to explore in the future is mapping 
phosphorylations to PADI4. One major difficulty in mapping comprehensive 
phosphorylations is their stability. Phosphorylations are generally sub-
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stoichiometric and labile in a cellular lysate environment where they are 
subject to enzymatic removal. As an approach to look for phosphorlyations 
will be particularly interesting for PADI4, it is likely to be profitable to perform 
phosphopeptide enrichment strategies such as by TiO2 column enrichment or 
by using phos-tag reagent enrichment. Discussions with Dr Greg Findlay at 
the MRC PPU suggested that may be possible through collaboration. A 
recent approach to identify non-canonical phosphorylation by strong anion 
exchange chromatography may also be useful53. 
 
6.8 Concluding Discussion 
In this chapter, work was progressed towards understand how PADI4 may be 
physiologically regulated in cells. Cellular activating conditions from Chapter 
4 were subjected to proteomic analysis to produce a list of candidate 
regulatory events. This included the phosphorylation of Ser433 as part of a 
putative phosphorylated motif, and a list of interacting proteins that include a 
number of EF hand containing calcium binding proteins, RACK1 and a 
number of nuclear proteins. One of the candidates, calmodulin, was validated 
further by reciprocal pulldown and was shown to activate PADI4 in vitro. 
 
The similarity between S100 proteins and calmodulin is provocative 
especially with reference to the possible regulation of PADI3/PADI154 by 
S100A3. S100 proteins are thought to have evolved from a calmodulin 
duplication in the animal lineage and over 21 different proteins exist in 
humans. This could explain the tissue specific regulation of PADIs. For 
example, S100A8/A9 proteins are among the most abundant proteins in 
neutrophils, whereas calmodulin itself is a major interacting protein with MBP 
at the myelin. It is therefore conceivable that different calcium binding 
proteins may regulate different PADI paralogues in different cell type specific 
contexts. It is clear that targeted exploration of EF-hand type calcium binding 





The final consideration relates to possible connections of calmodulin to other 
candidate regulators evidence within the Chapter. Firstly calmodulin 
regulation may relate to S-nitrosylation. Several papers have identified cross 
talk between calmodulin and S-nitrosylation such as with nitric oxide 
synthases and enzymes structurally related to the PADIs (containing the 
same pentein catalytic fold)46-52. Secondly there are extensive connections 
between calmodulin and PKCs that have been documented in the literature. 
Given the body of evidence suggesting that PADI4 regulation is complicated, 
explorations of the possibly multi-faceted regulation of PADI4 will be required 
for a full understanding of their physiological regulation. Requirements for 
different levels of activation in cells are likely and mechanisms to carefully 
restrict the drastic consequences caused by hypercitrullination may be 
different from those required in transcriptional fine-tuning. 
 
As such the work in Chapter 4 and this Chapter 6 provides a platform for the 
discovery of the precise biological regulation of PADI4 and other PADI 
paralogues. It remains in particular to identify how the activation signal may 
be transmitted via calmodulin, given the reduction in binding to PADI4 after 
activation. This is perhaps most likely to be mediated through 
phosphorylation given the evidence provided of kinase inhibition regulating 
PADI4 activation in cells, downstream of canonical Wnt signalling. In 
addition, it will be particularly interesting to consider further how PADI 
regulation evolved over evolutionary time and as such to elucidate how the 
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Chapter 7: Thesis Summary 
The five human Peptidyl arginine deiminases (PADIs) catalyse the PTM 
citrullination and have particular biomedical interest for their deregulation in 
diseases such as Rheumatoid Arthritis, Multiple Sclerosis and cancer. 
Chemical inhibition and genetic ablation have been shown to mitigate against 
these pathologies, making PADIs important therapeutic targets. Little 
however, is understood about how PADI activity is switched on in 
physiological contexts or how that becomes disrupted or overactive in 
disease. Work described in this thesis focused firstly on the evolutionary 
origin of the enzyme family in the human lineage showing the family of five 
mammalian PADI enzymes were acquired by a single ancient horizontal 
gene transfer event from cyanobacteria. I then looked at one of the human 
paralogues, PADI4, to address the critical open question as to how the 
enzyme may be regulated in cells. This identified calcium binding proteins 
which differentially interact with PADI4 protein before and after activation. 
One of these proteins, calmodulin, was shown to activate PADI4 in vitro. 
Lastly, the thesis focused on targeting PADI4 for inhibition, pulldown and 
activation with novel cyclic peptide reagents, performed in collaboration. 
Several cyclic peptides were shown to bind with high affinity to the human 
protein, and showed efficacy separately as enzyme inhibitors and as enzyme 
activators both in vitro and in cells. 
 
Experiments in the first results chapter (Chapter 3) focused on the 
evolutionary origin of the PADI family. This work revealed there are a number 
of cyanobacterial, actinobacterial and fungal homologues in addition to the 
mammalian enzymes, but that, following phylogenetic analysis, the 
eukaryotic homologues separate into two distinct clades – one of 
actinobacterial and fungal homologues and one of cyanobacterial and animal 
homologues. Phylogenetic testing, analysis of synapomorphic protein 
features and domains, and Bayesian analysis of evolutionary rates and 
accumulated protein sequence changes show that the three domain animal 




gene transfer. The mammalian proteins derive from a late diverging clade of 
cyanobacteria that possess the closest degenerate three domain PADI 
ancestor and retain conservation of all six calcium binding sites in PADI2. 
Experiments showed the cyanobacterial protein is calcium dependent and 
catalytically active on mammalian substrates, targeting human histone 3, but 
possesses a different, even more stringent, calcium dependency than the 
mammalian enzyme. This points to exciting possibilities for future work to 
uncover how mechanisms for PADI regulation in the human lineage evolved. 
   
Experiments in Chapter 4 and Chapter 6 looked at the activation of the 
human enzyme PADI4 in cells. In Chapter 4, cellular conditions were set up 
to activate human PADI4 in terminally differentiated HL-60 cells, in purified 
human neutrophils and in a stringently controlled model system related to the 
role of PADI4 in pluripotency. Cellular conditions were identified where 
PADI4 could be activated within a rapid time window under conditions that 
would be tractable for differential proteomic analysis. As part of this work, 
PADI4 was shown to be activated by canonical Wnt signalling using 
recombinant Wnt3a, different small molecule inhibitors of GSK3β and a 
chemical agonist of the Wnt pathway. Furthermore, inhibiting PADI4 reduced 
Wnt driven transcription in this system suggesting a new role for PADI4 in 
amplifying Wnt signalling. Future work will be required to verify this exciting 
signalling pathway is implicated in activating PADI4 in a physiologically 
relevant context such as in haematopoetic stem cells, or in cancer contexts. 
 
In Chapter 6, proteomic experiments were undertaken to analyse PADI4 to 
identify differences between the inactive and activated enzyme. A number of 
novel PTMs were identified on PADI4 including a phosphorylation site close 
to the active site. Excitingly, a list of interacting proteins were also identified 
that differed in binding between the resting and active enzyme conditions – 
including a set of known calcium-binding proteins, which were revealed to 
preferentially bind PADI4 allosterically in the resting condition. For one of 
these proteins, calmodulin, the mode of binding was verified by reciprocal 
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pulldown and recombinant calmodulin was shown to activate human PADI4 
in vitro by reducing the calcium dependency of the enzyme. This represents 
the first endogenous protein shown to activate PADI4 and provides a 
potential endogenous mechanism for the physiological activation of PADI4. 
Work in this chapter concluded with bioinformatic analysis to identify a 
putative calmodulin binding motif on human PADI4. A series of follow-up 
experiments to validate these effects in cells are left for future work. 
 
Experiments in Chapter 5 complement the work in the thesis and describe a 
collaboration to target human PADI4 by screening a large library of cyclic 
peptides (>1013) for tight binding affinity with human PADI4 with Dr Walport 
and Prof Suga. This was done using the Random Non-Standard Peptide 
Integrated Discovery (RaPID) system that was developed in the lab of Prof 
Suga with the hope to identify candidates that can inhibit, activate and 
pulldown human PADI4 from cells. Two screens were undertaken on the 
calcium-soaked active human enzyme conformation to enrich candidates 
firstly that bind at the active site and secondly that bind allosterically, by 
covalently blocking the active site prior to the screen. Biochemical and 
cellular experiments were undertaken and showed that separate cyclic 
peptides were able to inhibit as well as to activate PADI4. After sequence 
optimization, the PADI4 inhibitors and PADI4 activators show efficacy both in 
vitro and in cells. These represent novel reversible and potent PADI4 
inhibitors, and the first to target the active enzyme conformation. The peptide 
activators represent the first such epigenetic activators. These reagents 
provide new tools for the citrullination field with use already demonstrated in 
the proteomic experiments in Chapter 6. In addition, they should enable 
specific questions to tease out the precise role for PADI4 activation in cellular 
contexts such as in innate immunity (in NET formation) and in the 
establishment of pluripotency. 
 
This body of work presents progress towards the understanding of PADIs in 




gene transfer was identified as providing the evolutionary origin of the 
enzyme family. Work was undertaken to identify the precise events that 
modulate PADI4 activation implicating PADI4 activation as occurring 
downstream of the important Wnt signalling pathway and involving regulatory 
calcium-binding proteins, including calmodulin, in mediating enzyme 
activation. Finally, new chemical reagents for PADI4 were created to inhibit, 
activate and isolate the enzyme from cells, with efficacy in vitro and in cells. 
This PhD thesis presents progress towards understanding the critical 
question as to how PADI4 activation is achieved in cellular physiology and 
disease. Teasing out the complete mechanism for PADI4 activation will 




A.1 Size exclusion chromatography methods 
Lysis and methods for analyzing interacting complexes by native protein 
interaction size exclusion chromatography were devised in conversation with 
Dr Martin Wear, Edinburgh Protein Production Facility, University of 
Edinburgh. This was optimized for two 15 cm3 dishes of mouse ES cells 
(approximately 20x106 cells) per condition. 1mL of ice cold PBSGF (PBS, 5% 
glycerol, 0.5 mM DTT, 0.05% Tween-20, with protease inhibitors and 
PhosSTOP) were added (in total) directly to the two dishes and cells scraped 
with a silicon cell scraper. The two dishes were combined into a single 
Eppendorf, 2 µL benzonase and 2 mM MgCl2 were added and the tube 
incubated at 4˚C for 40 minutes. Pellets were sheared by passing 10 times 
through a 25G needle and then centrifuged for 30 min at 25,000 x g at 4˚C. 
The lysate was analysed by immunoblot and revealed that sufficient hPADI4 
protein was released under these lysis conditions. Proteins are then ready for 
loading onto a Superdex size exclusion column such that either 250 µL 
sample is loaded in a 500 µL loop (optimally), or 500 µL in a 1 mL loop. 
Columns are run at 0.5 mL/min with equilibration with at least 2CVs of buffer. 
Either 0.25 mL or 0.5 mL fractions can be collected across the elution profile. 
The first third of the elution will yield nothing, between 7 - 8 mL there is the 
void volume containing material that is too large to partition in the matrix 
before the range of dynamic separation from approximately 8 mL to 18 mL. 
Up to three wavelengths from 190 nm - 750 nm can be monitored, usually 
including 258 nm and 280 nm for protein and nucleotide and either a 
wavelength between 214 - 220 nm to analyse total peptide composition or 
600 nm to assess the general turbidity of the sample. Fractions can be 
analysed by immunoblot, alongside a control protein, to see whether hPADI4 
appears in a protein complex. 
 
A.2 EMSA method 
This electrophoretic mobility shift assay (EMSA) protocol was adapted from a 




instruction. Three 20-24-mer oligo DNA probes are required, one forward 
strand (F), one reverse strand (R) and a third of either the forward or reverse 
which has been biotin labelled at the 3’ end (either F* or R*). The third oligo 
can be biotin labelled using the Biotin 3’ End labeling DNA kit (Thermo 
Scientifics, Prod no 89818) or synthesized with the label already attached 
(Sigma). Oligos were reconstituted to 100 µM in ddH2O. Probes were 
generated by incubating 10 µL of 1:500 diluted F* (biotin tagged), 1:500 
diluted 10 µL R oligo, 10 µL H salt buffer (Roche/SureCut restriction enzyme 
buffer) in 70 µL H2O at 95˚C for 5 min before allowing the reaction to 
equilibrate back to RT so that the oligos anneal. Competitor DNA was 
generated by incubating 20 µL of stock F, 20 µL of stock R oligo, 10 µL H salt 
buffer (Roche/SureCut restriction enzyme buffer) in 50 µL H2O at 95˚C for 5 
min before allowing the reaction to equilibrate back to RT so that the oligos 
anneal. This is diluted 1:5, such that 2 µL gives a 100 fold molar excess over 
probe DNA. Cellular nuclear extracts were prepared using NE-PER Nuclear 
and Cytoplasmic Extraction Reagents kit (Thermo Scientific 78833) with 
protease inhibitors added to yield a final approximate concentration of 2-4 
mg/mL. 10X Binding buffer was prepared at 10mM Tris-HCl pH7.9, 50 mM 
KCl and 1 mM DTT and poly dI/dC (1mg/mL) was obtained from Sigma. 
Binding reactions without competitor DNA were performed by incubating 1.5 
µL Binding Buffer, 1 µL poly dI/dC, 2 µL (4 µg) of nuclear extract, in 10.5 µL 
H2O at 4˚C for 5 min. Then 2 µL probe DNA (20 fmol) was added and the 
reaction incubated at RT for 20 min. Competitor binding reactions were 
performed by incubating 1.5 µL Binding Buffer, 1 µL poly dI/dC, 2 µL (4 µg) of 
nuclear extract, 2 µL annealed competitor DNA in 8.5 µL H2O at 4˚C for 5 
min. Then 2 µL probe DNA (20 fmol) was added and the reaction incubated 
at RT for 20 min. A control of nuclear extract without oligo, and a control of 
oligo without nuclear extract were always included. Sometimes the nuclear 
extract can exhibit non-specific banding so it can be useful see the quantity 
of unbound oligo appearing at the bottom of the gel.  After incubation, 4 µL of 




Acrylamide gels (6%) were prepared with 4.5 mL 40% Acrylamide/Bis 
Acrylamide (19:1), 750 µL 20 x TBE, 90 µL 25% Ammonium persulfate, 35 
µL TEMED up to 30 mL in H2O (Sigma). The BioRad Mini-PROTEAN® 3 Cell 
(Catalog Numbers165-3301 165-3302) system was used. The 19 µL samples 
are loaded onto the gel. Rainbow marker (GE healthcare) is used to give an 
approximate indicator of band size. Gels were run at 100 V at 4˚C until the 
dye front reached the bottom of the gel without running off. The dye front is 
not discrete but runs broadly with trailing edges that correspond to the lanes. 
Gels were transferred to a positively charged nylon membrane (Roche) 
between 2 sheets of 3 M chromatography paper at 100 V for 25 min in a 
Biorad transfer apparatus using 0.5xTBE buffer with ice packs at 4˚C. 
Membranes were crossed linked before being processed using the Thermo 
Scientific Chemiluminescent Nucleic Acid detection Module (Product no. 
89880). Membranes were blocked and then incubated with the Streptavidin-
Horseradish Peroxidase Conjugate in heat-sealed polythene bags to reduce 
the quantity of reagents used. Membranes were washed in 0.5 x wash buffer 
(gives a cleaner result) and what follows is a recipe for homemade 
Equilibration buffer. The following equilibration buffer was used (10X buffer 
uses 1.2 g     Tris, 0.58 g   NaCl, 0.2 g     MgCl2, pH to 9.5 in 100 mL H2O). 
Membranes were probed with the developer from the kit and exposed to 
Amersham Hyperfilm ECL. Blots took approximately 1-2 min to give sufficient 
signal. 
 
A.3 PhosTag gel electrophoresis method 
A protocol for Phos-tag gel electrophoresis adapted from Ito et al. and 
Kinosita et al. is presented1,2. Phosphorylated proteins visualised in the gel 
appear to migrate more slowly than corresponding dephosphorylated protein 
bands due to binding between phosphorylated amino acids with the Phos-tag 
reagent that is incorporated in the gel (obtained from Dr Hilary McLauchlan 
and Prof Dario Alessi at the MRC PPU). Following treatment, cells were 
washed with TBS (20 mM Tris-HCl, pH 7.5, and 150 mM NaCl) on ice and 




Triton X-100 (NP-40), 1 mM EGTA, 1 mM sodium orthovanadate, 50 mM 
NaF, 0.1% (v/v) 2-mercaptoethanol, 10 mM 2-glycerophosphate, 5 mM 
sodium pyrophosphate, 0.1 µg/mL mycrocystin-LR (Enzo Life Sciences), 
270 mM sucrose and protease inhibitors. Lysates were centrifuged at 17 
000 x g for 20 min at 4°C and supernatants mixed with Loading buffer before 
being used for immunoblot analysis. Samples were supplemented with 
10 mM MnCl2 prior to loading gels. 
 
Phos-tag gels were constructed with a 4% stacking gel (4% (w/v) acrylamide, 
125 mM Tris-HCl, pH 6.8, 0.1% (w/v) SDS, 0.2% 
(v/v) N,N,N′,N′_tetramethylethylenediamine (TEMED), 0.08% (w/v) 
ammonium persulfate (APS)) layered above a 12% resolving gel (12% (w/v) 
acrylamide, 375mM Tris-HCl, pH 8.8, 0.1% (w/v) SDS, 75 µM Phos-tag 
acrylamide, 150 µM MnCl2, 0.1% (v/v) N,N,N′,N′_tetramethylethylenediamine 
(TEMED), 0.05% (w/v) ammonium persulfate (APS)). The gel mixture was 
degassed for 10 min before adding TEMED and APS (Sigma). After 
centrifugation at 17000 x g for 1 min, 30 µg of total protein were loaded per 
well and electrophoresed at 70 V for the stacking gel and at 150 V for the 
resolving gel using Phostag running buffer (25 mM Tris-HCl, 192 mM glycine, 
0.1% (w/v) SDS). Gels were washed three times for 10 min in Phostag wash 
buffer (48 mM Tris-HCl, 39 mM glycine, 10 mM EDTA , 0.05% (w/v) SDS, 
20% (v/v) methanol), followed by washing once for 10 min in Phostag 
transfer buffer (48 mM Tris-HCl, 39 mM glycine, 20% (v/v) methanol) 
supplemented with 0.05% SDS, but not with EDTA. Proteins were 
electrophoretically transferred onto nitrocellulose membranes at 100 V for 
180 min on ice using Phostag transfer buffer (48 mM Tris-HCl, 39 mM 
glycine, 20% (v/v) methanol, without SDS or EDTA). Transferred membranes 
were blocked with 5% (w/v) BSA in TBS-T (20 mM Tris-HCl, pH 7.5, 150 mM 
NaCl, 0.1% (v/v) Tween 20) at room temperature for 30 min. Membranes 
were incubated with primary antibodies diluted in 5% BSA in TBS-T overnight 
at 4°C. Membranes were washed in TBS-T and then incubated with 
secondary antibodies (anti-rabbit-HRP abcam) diluted in 5% BSA in TBS-T at 
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room temperature for 1 h. Membranes were washed again in TBS-T and 
detection carried out by exposing films (Amersham Hyperfilm ECL (GE 
Healthcare) to the membranes using an ECL solution (SuperSignal West 
Dura Extended Duration (Thermo Fisher Scientific) or by imaging directly 
with the GE ImageQuant LAS 4000. 
 
A.4 Cellular Thermal Shift Assay (CETSA) method 
Per treatment condition, a T75 flask of cells was used –a treated condition 
was always compared to a vehicle only treatment. 10 mL of full serum media 
containing vehicle or inhibitor was added to the cells and incubated for 30 
min or 1 hour. Following treatment, cells were washed in 6 mL PBS before 
incubate in 3 mL Accutase. After 3 min, 6 mL of full serum media was added 
and detached cells washed twice in PBS, before resuspension in PBS 
containing protease inhibitors. 100 µL of resuspended cells were added to 7 
different tubes in a PCR strip. In a trial experiment PADI4 was found to be 
thermally unstable above approximately 56-59˚C. A PCR machine was used 
to heat the tube at a gradient between 46˚C and 70˚C. The PCR strip was 
heated in the middle lanes of a PCR block for 3 min with temperature thereby 
covering discontinuous steps from 50, 53, 56, 59, 62, 65, and 68 ˚C. The 
PCR strip was allowed to equilibrate back to RT for 5 min. Cell lysis was 
conducted by freezing in liquid nitrogen for 60 seconds and then thawing in a 
25˚C water bath for 60 secs, with vortexing in between. This was repeated 
three times. After lysis, the contents of each PCR tube was transferred to a 
fresh Eppendorf and centrifuged at 17 000 x g for 20 min at 4˚C. 60 µL of 
supernatant was added to 20 µL 4X reducing loading buffer and identical 
quantities loaded for SDS PAGE gel running and Western blotting for human 
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